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ABSTRACT 
Colorectal cancer is a common malignancy, characterized by high incidence and 
mortality rates. Hypoxia induces angiogenesis, metastasis and aggressive tumour 
phenotype and hence promotes cancer progression. Similarly, dysfunctions in 
mitochondria have been shown to contribute to cancer progression. Therefore, in this 
thesis, genetic markers in both the hypoxia pathway genes and the mitochondrial DNA 
are hypothesized to be candidate genetic prognostic markers in colorectal cancer. 
The aim of this study is to test genetic markers that can predict outcome in 
colorectal cancer patients. This study consists of two projects: 1) the mitochondrial DNA 
variations project and 2) the hypoxia pathway Single Nucleotide Polymorphisms (SNPs) 
project. In the mitochondrial DNA (mtDNA) variations project, six mtDNA 
polymorphisms and the mtDNA copy number change were tested for their prognostic 
associations. However, none of the mtDNA markers selected was found to be associated 
with outcome. The hypoxia pathway SNPs project was done in two phases. In the first 
phase, 49 tagging SNPs from six hypoxia genes (HIFJA , HIFJB, HIF2A, LOX, MIF and 
CXCL12) were genotyped in a cohort of 272 colorectal cancer patients (cohort I). In the 
second phase, 77 tagging SNPs from seven hypoxia genes (HIFJA , HJFJB, HIF2A , 
HIF2B, HIFJA, LOX and CXCL12) were genotyped in a separate cohort of 536 colorectal 
cancer patients (cohort II). 
In phase I, the TT and AT genotypes of the HIF2A rs11125070 polymorphism 
was associated with increased disease free survival (DFS) in the multivariable model 
18 I Page 
(p=0.004; HR=0.619; 95% CI: 0.446-0.859). In phase II, patients with TC and CC 
genotypes for the HIF2A rs4953352 polymorphism and patients with the GG genotype for 
the HIF2B rs12593988 polymorphism were associated with both reduced overall survival 
(OS) and DFS in multivariate models. However, the association ofthe HIF2A rs11125070 
polymorphism with DFS detected in the phase I cohort was not replicated in the phase II 
patient cohort, suggesting this association was possibly a false-positive association. 
Similarly, association of the HIF2A rs4953352 polymorphism with OS and DFS detected 
in the phase II cohort failed to be detected in the phase I patient cohort, which may be due 
to the small sample size of cohort I. Association of the HIF2B rs12593988 polymorphism 
remains to be tested in another colorectal cancer cohort. 
In conclusion, this study shows no evidence of associations between majority of 
genetic markers in hypoxia pathway genes and mtDNA with prognosis in colorectal 
cancer. However, whether or not the HIF2B rs12593988 polymorphism is associated with 
prognosis needs to be confirmed by investigating other patient cohorts. 
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CHAPTER 1: INTRODUCTION 
1.1) Cancer 
Cancer is characterized by uncontrolled proliferation of abnormal cells. It is a 
multifactorial disease caused by an individual's genetic factors in combination with 
several environmental factors. According to the World Health Organization (WHO), in 
2008, cancer accounted for 7.06 million deaths and was the leading cause of death 
worldwide (2). WHO estimates that the number of cancer related deaths will continue to 
rise and 13.1 million people will die because of cancer in 2030 (2). According to the 
Canadian Cancer Statistics 2012, it is estimated that twenty one Canadians will be 
diagnosed with some type of cancer and nine Canadians will die due to cancer every hour 
(3). Despite several significant advances in science and technology, survival rates for the 
majority of cancer types have not improved substantially. Therefore, cancer remains as a 
major public health concern in Canada and worldwide. 
The transformation of a normal cell to malignant cancer is a multi-step process 
that involves accumulation of mutations to form pre-cancerous cells which are then 
subjected to additional mutations to transform into malignant cancer cells ( 4). Genes that 
control and suppress cancer formation and proliferation are termed tumour suppressors, 
while other genes that contribute to cancer formation are referred to as proto-oncogenes 
( 4). In brief, in cancer cells, a group of tumour suppressor genes are deactivated and a 
group of oncogenes are activated (4). 
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Cancer cells have distinct characteristics when compared to normal cells. For 
example, cancer cells are characterized by abnormal metabolism and energy production to 
meet the energy needs of rapidly dividing cancer cells. In order to be metabolically active, 
normal cells derive energy produced through the Oxidative Phosphorylation Pathway 
(OXPHOS) (5). However, cancer cells undergo a metabolic shift to produce energy 
through aerobic glycolysis instead of OXPHOS (5,6). In addition, certain pathways that 
control cell proliferation such as programmed cell death (apoptosis) are deactivated, while 
signalling pathways that facilitate cell proliferation are activated. Hence, cancer cells 
have certain distinct characteristics when compared to normal cells. 
1.2) Colorectal cancer 
Colorectal cancer is a form of cancer occurring in either the colon or the rectum. 
The incidence and mortality rates of colorectal cancer are increasing worldwide due to 
lifestyle changes and dietary factors (7). According to the International Agency for 
Research on Cancer, colorectal cancer is the third most frequent cancer and the fourth 
leading cause of death worldwide (8). In particular, the western world is at an increased 
risk of colorectal cancer which is attributed to diet and sedentary lifestyle (7). According 
to the Canadian Cancer Statistics 2012, colo rectal cancer is the third most common cancer 
type and is the second leading cause of cancer related deaths in Canada (3). It has been 
projected that one in every 13 Canadians will develop colorectal cancer and one in every 
28 Canadians will die from it (9). 
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According to the American Joint Committee on Cancer (AJCC), the survival rates 
of colorectal cancer range from 1 0-90%, depending on the stage at which patients are 
diagnosed (1 0). For patients diagnosed with colorectal cancer at stage I, the 5 year 
survival rate is 93 .2%, whereas it is only 8.1% for the stage IV patients. In Canada, 
overall, the five year relative survival rate for colorectal cancer is 63% (9). Thus, 
colorectal cancer has a significant impact on the mortality rates of Canadians. 
In Newfoundland and Labrador (NL) the incidence and mortality rates of 
colorectal cancer are higher when compared to western provinces in Canada. Colorectal 
cancer rates in NL are two times higher when compared to those in British Columbia (9). 
Therefore, effective management of this disease requires serious attention especially in 
NL. 
Classification of colorectal cancer 
Colorectal cancer can be classified into inherited and sporadic forms based on 
familial clustering of this disease. 
Previous findings suggest that genetic factors contribute to 35% of the risk of 
colorectal cancer formation and only 6% of the patients characterised with colorectal 
cancer can be attributed to inherited mutations in specific genes (11 ). This shows that 
only a small portion of patients diagnosed with colorectal cancer have inherited 
components identified so far (12). Thus, for the majority of the colorectal cancer cases, 
the genetic basis of this disease is unknown. 
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Inherited colorectal cancer 
In inherited colorectal cancer cases, the disease is inherited through mutations in 
genes and can be sub-classified as 1) Lynch syndrome, 2) Familial colorectal cancer type 
X (FCCTX), 3) Familial adenomatous polyposis (FAP), 4) MUTYH associated polyposis 
(MAP) and 5) Attenuated familial adenomatous polyposis (AF AP). Lynch syndrome is an 
autosomal dominant disease caused by mutations in DNA repair genes MLHJ, MSH2, 
MSH6, and PMS2. In FCCTX, there is no recognizable pattern of Mendelian inheritance-
although it is believed that FCCTX predominantly follows an autosomal dominant mode 
of inheritance. Moreover, the disease pathogenesis seems to be distinct from other types 
of cancer (13,14). Nevertheless, it is believed that there are specific genes and 
mechanisms which are responsible for this disease which are yet to be identified (15). 
Hereditary non-polyposis colorectal cancer (HNPCC) comprises both Lynch syndrome 
and FCCTX (16). 
FAP is an autosomal dominant inherited disease (17) characterised by inherited 
mutations in the adenomatous polyposis coli (APC) gene (18). This gene is involved in 
normal cellular functions such as cellular adhesion, communication and microtubule 
assembly (17). Mutant APC is linked to high expression of cyclooxygenase (COX) gene 
which in tum increases the adhesion of extracellular matrix and inhibits apoptosis (19,20). 
MUTYH associated polyposis (MAP) is caused by mutations in the MUTYH gene and is 
inherited as an autosomal recessive condition (21 ). AF AP is also caused by mutations in 
the APC gene and is similar to F AP; however patients with AF AP have very few polyps 
when compared to patients with F AP (22). 
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Sporadic colorectal cancer 
Sporadic cancers account for the majority of the colorectal cancer cases (12). 
Sporadic colorectal cancers do not show specific inheritance patterns, but they may be 
associated with a genetic component (17). It is assumed that sporadic colorectal cancer is 
caused by low susceptibility alleles with small effect sizes whose effect is modified by 
interaction with environmental factors or other genetic and epigenetic factors (11 ,23). So 
far, several low susceptibility alleles have been identified in colorectal cancer through 
genome wide association studies (24-26). Sporadic colorectal cancer patients are also 
characterised by one or a combination of somatic mutations in APC, DCC, K-RAS, N-RAS 
and TP 53 genes as well as the deletion of chromosome 18q (17). 
1.2.1) Colorectal cancer tumourigenesis and progression pathways 
Vogelstein initially proposed that colorectal cancer tumourigenesis is a multistep 
process that involves sequential mutations for progression from adenoma to malignant 
carcinoma (27). The steps involved in this process are depicted in Figure 1. 
There are biological pathways that have been elucidated through molecular 
research, which have added more evidence to the adenoma-carcinoma model by 
Vogelstein as illustrated in Figure 2. 
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Figure 1: Vogelstein's genetic model for tumourigenesis 
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This figure shows the steps involved in the process of carcinogenesis starting from the early 
stages to the later stages as proposed by Vogelstein. (Adapted from the genetic model proposed 
by Vogelstein) (27). 5q mutation or allelic loss ref ers to mutations or allelic loss in APC gene. 
12p mutations refers to the mutations that occur in the RAS gene (predominantly K-RAS gene), 
18q LOH (loss of DCC) ref ers to the loss of heterozygosity on chromosome 18q which is 
predominantly characterized by allelic loss of the DCC locus. Order of these alterations might 
vary; however, what is more important is that the accumulation of these mutations is required 
for cancer initiation. Combined with other alterations they also facilitate cancer progression. 
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Figure 2: Colorectal cancer tumourigenesis 
Normal 
Tissue 
APC ~-catenin 
deactivation 
BRAF 
mutations 
CIN 
Adenoma J MSI 
Promoter 
methylation MLH 1 
.....---...~ 
CIMP 
. Hyperplastic J ---... ·~ 
CIMP+ 
MSI+ 
CIMJ? + 
MSI+ 
CIMP+ 
MSI+ 
r M . etastasts 
A recent model of carcinogenesis with additional pathways included into the Vogelstein 's model (adapted from (29)). 
APC: Adenomatous polyposis coli; CJN: Chromosomal instability; MSI: Microsatellite instability (MSJ+); CIMP+: CpG 
island methylator phenotype; LOH: Loss of heterozygosity. These pathways are explained in detail in Section 1.2.1. 
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Chromosomal Instability (CIN) pathway 
The gain or loss of chromosomal fragments or chromosomal rearrangements is 
referred to as chromosomal instability (CIN). Nearly 75-85% colorectal tumours are 
characterised by CIN (28). Usually, the events that lead to CIN are aneuploidy, 
chromosomal translocations, gene amplification, allelic loss and mutations in specific 
genes such as K-RAS, TP53, APC and SMAD4 (28). In addition, CIN tumours are 
characterized by the loss of either the paternal or the maternal allele which is referred to 
as Loss of Heterozygosity (LOH) (30). Furthermore, mutations of genes involved in 
mitotic spindle checkpoint, such as MAD2, BUBJ and BUBRI, and the genes involved in 
the DNA damage control check point, such as ATM, ATR, BRCA I , BRCA2, and TP53, 
can also lead to CIN (30). Telomere length and telomerase enzyme also can play a crucial 
role in preventing chromosomal instability (30). 
Microsatellite Instability (MSI) pathway 
Microsatellite instability (MSI) 1s caused by length changes in repetitive 
microsatellite sequences. Up to 15-20% of the colorectal cancer tumours are characterised 
by MSI-High (MSI-H) phenotype (31). It occurs by inactivation of the mismatch repair 
system (MMR). MLHI, MSH2, MSH3, MSH6, PMSJ, PMS2 and MLH3 genes encode 
proteins that are essential for an effective MMR system (30). Inactivation of MMR occurs 
by either mutations or by epigenetic alterations in either one, or more than one, MMR 
gene (31). 
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The MSI phenotype is categorized into three groups based on the instability in 
markers recommended by the National Institute of Health (NIH) such as BAT-25, BAT-
26, NR-21, NR-24 and MON0-27 (32). Tumours with instability in one or two markers 
are categorized as microsatellite instability-low (MSI-L), and tumours with no instability 
in these markers are categorized as microsatellite stable (MSS) (32). If tumours are 
characterised with instability in more than two markers, then they are categorized as MSI-
H. Lynch syndrome patients are characterised by MSI-H tumours and this occurs by 
inherited mutations in the mismatch repair genes (mainly MSH2 and MLHJ) (33). In the 
case of sporadic colorectal cancer, up to 15% of the tumours are categorized as MSI-H 
and this occurs mainly by epigenetic modification of the MLHJ gene and may also be 
characterized by somatic mutation in MLHJ gene (33). 
CpG island methylator phenotype pathway 
Defects in methylation patterns are also observed in colorectal cancer. For 
example, defects in the DNA methylation lead to genomic instability in colorectal cancer 
cell lines (34-36). 
The 5' region of genes contains the promoter and the transcription initiation site 
(37). Regions rich in CpG sequences are referred to as CpG island and nearly 50% of 
human genes contain CpG island sequences in their 5' region (37). In colorectal cancer, 
aberrant methylation of CpG dinucleotides takes place in tumour suppressor genes which 
results in the CpG island methylator phenotype (CIMP). CIMP serves as an alternative 
pathway for tumour progression (3 7). Defects in the CIMP are the predominant 
epigenetic alterations found in colorectal cancer tumours (38). CIMP is classified into 
33 I Page 
CIMP-1 (CIMP high), CIMP-2 (CIMP low) and CIMP (-) (CIMP negative) based on the 
degree of methylation (37). CIMP is associated with MSI-H and BRAF mutations in 
sporadic cases (39). For example, nearly 80% of the colorectal cancer tumours with 
CIMP-1 have MSI-H phenotype and nearly 50% of tumours carry mutations in the BRAF 
gene (37). The same study also reported that while fewer patients with CIMP-1 tumours 
have mutations in KRAS (16%) and TP 53 ( 11%) genes, the majority of the colo rectal 
cancer patients with CIMP-2 tumours are characterised by KRAS (93%) and TP53 
mutations (31 %). But, CIMP-2 colorectal tumours are characterised by very low 
frequency of BRAF mutations (4%) and MSI-H (0%) phenotype. This study also showed 
that in CIMP(-) colorectal cancer cases, the frequency of mutations is high in TP 53 (71 %) 
and the tumours are characterised by low frequency of MSI-H (12%) and very low 
frequency of BRAF mutations (2%). 
1.2.2) Colorectal cancer treatment options and strategies 
In colorectal cancer, treatment usually involves chemotherapy or radiotherapy 
( 40). Radiotherapy normally involves exposure to X-rays, gamma rays and may be used 
in combination with chemotherapy ( 40). Chemotherapy drugs aim to stop the 
uncontrolled proliferation of cancer cells. Some of them are DNA damaging agents such 
as alkylating agents and intercalating platinum complexes (41-44). There are also a group 
of drugs that inhibit mitosis and tumour progression (such as Paclitaxel) (45). In addition, 
some drugs inhibit DNA synthesis during DNA replication, thereby preventing tumour 
progression (such as Methotrexate (administered along with Leucovorin), 5-Fluorouracil 
34 I Page 
(5-FU), Irinotecan and Mercaptopurine) (46-51). Biological agents such as monoclonal 
antibodies which act on signalling proteins to stop tumour progression are also used in 
treatment of colorectal cancer (52). 
1.3) Prognosis 
Prognostic estimates predict the risk of developing a particular outcome based on 
patients' clinical and non-clinical characteristics (53). In cancer, these outcomes may 
include: death, cancer recurrence, cancer progression, metastasis, changes in quality of 
life or other clinically important outcomes (54-56). 
Prognostic markers 
Clinical variables such as stage, histology, location and tumour grade are used as 
prognostic markers (38). Prognostic markers can also be biological markers such as 
protein, ribonucleic acid or DNA markers (57). For example, genetic markers such as 
single nucleotide polymorphisms (SNPs) (58), copy number variations (CNVs), 
inversions or variability in the trinucleotide CAG repeats are candidate markers. In 
addition, the degree of DNA methylation can also be used to predict prognosis (i.e. 
epigenetic markers) (59,60), although more research is required to use these markers in 
the clinic. These and other markers - also referred to as predictors - can be used to predict 
the outcome in patients diagnosed with a particular disease condition. 
Prognosis of patients may be influenced by a variety of factors such as age, sex, 
familial history, quality of life, symptoms and other clinically relevant variables (61). For 
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example, in colorectal cancer, several reports suggest that older patients have a worse 
prognosis when compared to young patients; female patients have a better prognosis 
when compared to male patients; patients with tumours characterized by mucinous 
tumour phenotype have a worse prognosis when compared to patients with tumours 
characterized by non-mucinous tumour phenotype (62); patients diagnosed at stage IV 
have a worse prognosis when compared to patients diagnosed at earlier stages; patients 
with tumours that show vascular invasion have a worse prognosis when compared to 
patients with tumours without vascular invasion; and patients with MSI-H tumours have a 
better prognosis when compared to patients with microsatellite stable tumours (63). These 
and other prognostic variables in colorectal cancer are discussed in detail in Section 1.4. 
Prognostic studies and models 
According to Hemingway et al (64), the two main aims for prognostic studies are: 
"I) to identifY individual biomarkers that are associated with the outcome independent of 
other biomarkers, and 2) development of multivariable prognostic models that can predict 
an individual outcome using prognostic index or risk score ". Prognostic information is 
commonly used to stratify patients into two or more groups depending upon the 
prognostic criteria. 
Since the characteristics of patients change from population to population and 
within a population ( 65), it is almost impossible to predict the patient outcome with a 
single predictor ( 61 ). In a clinical setting, multiple indicators are used to predict outcome. 
Determining the probability of a dependent event (such as death), using a combination of 
predictors (independent variables) such as disease stage, sex and genotypes, requires 
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specialised multi variable prediction tools ( 61 ). These prediction tools referred to as 
prognostic or prediction models ( 61) are based on statistical methods that simultaneously 
analyze multiple independent predictors (66). 
Before designing a prognostic study, the endpoint or clinical outcome must be 
defined explicitly. It should be measurable, reproducible and there should not be any bias 
involved in the ascertainment of the endpoint (54). Death and recurrence are the most 
frequently investigated endpoints in colorectal cancer. 
In prognostic research, the association of study variables with patient outcome 
may be tested individually in a univariate analysis (61 ,65,67). However, univariate 
analysis does not consider the effect of confounding by other variables. Hence, 
multivariate analysis is used to eliminate the confounding effects of other variables. The 
number of predictor variables should be kept as small as possible since complex models 
are difficult to integrate into a clinical setting (68). The number of predictor variables can 
also be minimized by using selection techniques such as the forward selection, backward 
selection and the best subset method (67). 
Sample size is related to study power, i.e detecting an association. In prognostic 
research, more than the sample size, it is the number of events per variable that influences 
power and variance (69). In an ideal prognostic study, there should be at least ten patients 
who have experienced the event of interest per predictor variable ( 61 ). The variables that 
are included in a prognostic study may have different effect sizes, i.e. , each variable may 
contribute to the outcome with different magnitudes of effect (70). 
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Patients in a prognostic study are followed from a common start point, such as the 
date of diagnosis, until they experience the outcome event of interest (endpoint) (71 ). The 
phase between the common start point and the endpoint is referred to as the "follow-up 
phase". During the follow-up, events of interest experienced by the patients are recorded. 
The observed time between the start and endpoint is referred to as the survival time (71). 
Some patients may not experience the outcome of interest at the end of the follow-up 
period and they are referred to as "censored individuals" during statistical analyses (67). 
The association between the predictor and the outcome is then analysed by using a 
statistical method suited to the study objective. 
Depending on the ease of collecting data, a prognostic study will be 
carried out either prospectively or retrospectively. Both of these methods have advantages 
and disadvantages. Retrospective studies use pre-recorded clinical data, such as hospital 
records, and archived DNA or tissue specimens (72). One of the advantages of a 
retrospective study is that since existing records or archived biospecimens are used, 
retrospective studies take less time and cost less. In prospective studies, patients are 
recruited based on pre-determined eligibility requirements. Their baseline characteristics 
are recorded, and they are followed until the end of the study (73). The main advantage is 
that patients can be followed for any predetermined time interval. Unlike retrospective 
studies, in prospective studies, the follow-up time can be varied to increase the number of 
patients with outcomes. The main disadvantage of prospective studies is the cost and time 
required to recruit study subjects. 
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Statistical data analysis and validation of prognostic models 
After obtaining the required data, different statistical techniques are applied for 
data analysis depending upon the study objectives. The Kaplan Meier method (univariate) 
compares the survival characteristics with respect to time between two or more groups of 
patients who are categorized based on specific criteria (71, 7 4 ). The Cox Proportional 
Hazard model computes the hazard ratio of experiencing the outcome of interest in 
groups of patients categorized based on specific variable characteristics, together with the 
95% confidence intervals (Cis) (75). Similar to Kaplan Meier method, in univariate Cox 
regression analysis, the relation between each variable and the outcome is assessed 
individually. However, in Cox multivariate regression method, several variables are 
assessed for their relation to the outcome simultaneously. Since multivariate models can 
detect and adjust for confounding by other variables, the majority, if not all, of the 
prognostic models are used in the clinic are based on the multivariate analysis. 
A multivariate prognostic model may not have a clinical significance unless its 
credibility and reproducibility have been successfully validated by additional analyses. To 
do so, prognostic models may be first internally validated in an existing data set by split-
group, jackknife (cross validation) or bootstrap methods (66). Additionally, a prognostic 
model should be validated in a patient cohort from a different geographical area or 
preferably in a cohort which has characteristics entirely different from the patient cohort 
that was used to develop the model (external validation) (68,76). By doing so, how well 
the model fits in a different setting may be determined, so that expert panels may 
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investigate these findings and consider recommending it for implementation in clinical 
settings. 
1.4) Prognostic indicators in colorectal cancer 
1.4.1) Pathological prognostic markers in colorectal cancer categorized by the 
American Pathologists Consensus Statement 
There are many markers that have been reported to be of prognostic significance 
in colorectal cancer. However, conflicting results obtained in different studies call into 
question the reliability of a particular marker in predicting outcome in cancer patients. For 
assessing the usefulness of prognostic markers in colorectal cancer, the College of 
American Pathologists (CAP) reviewed medical literature and grouped markers according 
to their prognostic significance (77). 
Category I markers include those that have been validated using multiple robust 
studies; category IIA includes markers that have been studied extensively, are of 
sufficient importance, but have not yet been validated; category liB includes other 
promising markers. Category III includes markers that have not been studied extensively 
to elucidate their prognostic significance; and category IV includes variables that have 
been studied extensively but lack prognostic significance. Select markers that fall under 
these four categories in colorectal cancer are discussed below. 
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Tumour stage 
The tumour stage remains the most significant prognostic indicator for prediction 
of prognosis in colorectal cancer patients (38). Although colorectal cancer patients with 
same cancer stage may have variable survival times, the tumour stage is an important 
indicator when predicting whether patients will need therapy (38). The tumour stages 
were classified according to the following criteria by American Joint Committee on Cancer 
Sixth Edition Staging as follow: "Tl = tumor invades submucosa; T2 = tumor invades 
muscularis propria; T3 = tumor invades through the muscularis propria into the 
subserosa or into nonperitonealized pericolic tissues; T4 = tumor directly invades other 
organs or structures and/or perforates visceral peritoneum; NO = no regional lymph 
node metastasis; Nl = metastasis to one to three regional lymph nodes; N2 = metastasis 
to four or more regional lymph nodes; MO = no distant metastasis; Ml = distant 
metastasis "(78). According to recent nomenclature (1 0), colorectal cancer stages are 
classified as stage I, stage II (subgroups A and B), and stage III (subgroups A, B, C, D, 
and E) and stage IV (subgroup A and B) as shown in Table 1. In this table, the 5 year 
survival rates of different stages and their subgroups are also shown (1 0). 
It is evident from Table 1 that stage I has a favorable prognosis and stage IV has 
the poorest prognosis in colorectal cancer. In short, disease stage remains the most useful 
indicator in predicting the outcome (79) and is a category I marker (77). 
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Table 1: Stage classification of colorectal cancer patients and their corresponding 5 year 
survival rates. 
Stage Subgroup 
Stage I 
A 
Stage II 
B 
A 
B 
Stage III c 
D 
E 
Stage IV 
5 year survival 
rates(%) 
93 .2 
84.7 
72.2 
83.4 
62.4 
52.3 
43 
26.8 
8.1 
Adapted from the American Joint Committee on Cancer Sixth Edition Staging (10) 
Tumour differentiation 
The degree of cell differentiation in tumours is referred to as tumour grade. 
Although the American Pathologists' Consensus Statement recommended that grade be 
classified as either high or low grade it is generally classified as grade I, grade II and 
grade III (38). In grade I, cells are well differentiated and uniform without any nuclear 
stratification or polarity (38). Grade II cells are moderately differentiated, with 
disorganized or lost nuclear polarity and with irregular glandular formations (38). In 
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grade III, cells are poorly differentiated, accompanied with loss of tubular differentiation 
and polarity (38). There are several studies examining the prognostic role of tumour grade 
in colorectal cancer. For example, it has been demonstrated that tumour differentiation is 
an independent prognostic factor in colorectal cancer in a multivariate analysis (38). In 
this study, grade III (poorly differentiated) tumours were associated with increased 
invasion, nodal metastasis and recurrence. Hence, grade III colorectal cancer patients 
were reported to have poor prognosis (38). In short, tumour grade falls under the category 
IIA of the American Pathologists' Consensus Statement (77), and hence is a prognostic 
marker that is of sufficient importance. However, its clinical value remains to be 
validated before it can be used in the clinic for predicting the prognosis of colorectal 
cancer patients. 
Tumour histology 
Depending on their histological characteristics, colorectal tumours can be mainly 
classified as mucinous and non-mucinous tumours. Mucinous tumours are characterised 
by abundant extracellular mucin and as tumours with more than 50% extracellular mucin 
(80). Mucinous tumour phenotype is stage dependent and is associated with recurrence, 
metastasis and advanced stage in colorectal cancer (38). Mucinous histology is found in 
colorectal tumours with a high degree of DNA methylation and is associated with MSI-H 
in both sporadic colorectal and Lynch syndrome cases (38). Tumour histology falls under 
category III of the American Pathologists' Consensus Statement (77), which indicates that 
it has to be studied extensively to elucidate its prognostic significance. 
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Lymphatic and venous invasion 
Lymphatic and venous mvaswns are usually considered important stage 
independent prognostic markers (81 -83 ). Both lymphatic and venous invasions contribute 
to metastasis (79,84,85). Specifically, minimal lymphatic penetration is enough to implant 
distant metastases (86) and invasion of thick walled blood vessels by tumours is 
prognostically more significant than invasion of thin walled blood vessels (81 ,82). 
Lymphatic and venous invasions come under category III of the American Pathologists' 
Consensus Statement, which indicates that their predictive potential has not been studied 
extensively (77). 
Angiogenesis 
Angiogenesis is the process of new blood vessels development and is a naturally 
occurring process for tissue repair and growth (87). However, in cancer, this process 
facilitates disease progression. Growth of cancer cells depends on their ability to have 
blood vessels around them (87). Pro-angiogenic factors favour angiogenesis and this 
increases the capability of cancer cells to metastasize to distant organs (87). Therefore, 
angiogenesis can influence patient outcome and thus it is classified as a category III 
marker according to the American Pathologists' Consensus Statement, which indicates 
that angiogenesis-markers have to be studied extensively (77). 
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1.4.2) Genetic prognostic markers in colorectal cancer categorized by the American 
Pathologists Consensus Statement 
Microsatellite instability high (MSI-H) 
MSI-H is caused by inactivation of mismatch repair genes in the case of Lynch 
syndrome (88) or by hypermethylation of MLHJ gene promoter in the case of some 
sporadic colorectal cancer (79). Around 15-20% of colorectal cancer patients have MSI-H 
tumours which are characterised by lymphatic invasion, poor differentiation, mucinous 
histological type and proximal location (79). 
There are conflicting reports over the prognostic significance of the MSI 
phenotype. Previously, it has been reported that patients with MSI-H tumours have a 
better prognosis when compared to those with MSS tumours (3 1 ,33). It has also been 
reported that colorectal cancer patients with MSI-H tumours show resistance to 5-FU, the 
most commonly used chemotherapeutic agent in the treatment of colorectal cancer. 
Therefore, MSI-H was suggested as a potential marker to differentiate patients who may 
not benefit from 5-FU treatment (89). However, there are also conflicting reports showing 
that the MSI-H phenotype can neither predict outcome nor response to 5-FU (90-92). 
Nevertheless, MSI-H is categorized as a category IIA marker by the American 
Pathologists' Consensus Statement (77), which indicates that it is a promising molecular 
marker in colorectal cancer. 
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Loss of heterozygosity of 18q in tumour cells 
Seventy percent of colorectal tumours have allelic imbalance at chromosome 18q 
and the biological effect of this chromosomal loss is directly implicated in colorectal 
carcinogenesis (89). LOH of 18q causes haploinsuffciency, which results in relatively low 
protein expression. DCC is an example of a gene affected by LOH at 18q. 18q LOH is 
associated with aggressive tumours in stage II colorectal cancer patients (39) and is 
associated with worse prognosis (89), including poor response to 5-FU based adjuvant 
chemotherapy (38) in colorectal cancer patients. A meta-analysis of 17 studies involving 
2189 colorectal cancer patients concluded that LOH of 18q can be used to stratify patients 
for adjuvant chemotherapy and can also predict outcome (93). The American 
Pathologists' Consensus Statement (77) categorizes LOH 18q as a category liB marker, 
which indicates that it is a candidate marker, but at the time being lacks sufficient data to 
confirm its prognostic significance. 
KRAS mutations 
KRAS (Kirsten rat sarcoma-2) belongs to the RAS gene family. It encodes p21 
protein, a 21 kDa membrane protein, with GTPase activity, which controls cell 
proliferation and differentiation by acting as a molecular switch in response to 
extracellular mitogenic signals (89). Over-expression of KRAS results in increased 
production of proteases which increase degradation of the extracellular matrix and thus 
increase the ability of cells to metastasize (89). KRAS mutations are found in 15-20% of 
all human cancers and in 30-40% of colorectal cancer tumours (94). KRAS plays an 
important role in the EGFR pathway and mutant KRAS protein confers resistance to anti-
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EGFR agents, such as Cetuximab or Panitumumab (94). Clinical prognostic markers such 
as tumour budding and podia formation are associated with KRAS mutations (95) and 
colorectal cancer patients with KRAS mutated tumours have poor prognosis (89). The 
presence of KRAS mutations is also a strong indicator for adjuvant chemotherapy (89). 
According to the American Pathologists Consensus statement (77), KRAS mutations are 
category III markers which need to be studied further to elucidate their potential 
prognostic significance. 
Epithelial growth factor receptor (EGFR) 
The EGFR pathway plays an important role in cell proliferation, migration and 
differentiation (89). EGFR is differentially expressed in normal, pre-cancerous and 
advanced cancer cells (94). More importantly, the expression of EGFR seems to be 
critical in metastatic colorectal cancer (89,96). EGFR expression is related to advanced 
disease stage, poor histological grade and lymphatic invasion (97-99). However, there are 
conflicting reports showing that EGFR status is not associated with histology, grade, 
stage or patient survival (1 00-1 02). In another study, inhibition of EGFR expression 
showed an anti-tumour activity and hence EGFR inhibition may be a treatment option for 
colorectal cancer patients (79). The American Pathologists Consensus statement 
categorizes EGFR under category III, which indicates there is insufficient data to 
conclude its prognostic significance. 
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1.4.3) Other potential prognostic markers in colorectal cancer 
BRAF mutations 
BRAF belongs to the RAF gene family which codes for kinases that mediate the 
cellular response to growth factor signals (89). BRAF mutations are found in 5-1 5% of 
colorectal cancer tumours (89). Colorectal cancer patients having tumours with MSS and 
BRAF mutations have worse prognosis (38). Patients with tumours carrying the BRAF 
activating Val600Glu somatic mutation show resistance to anti-cancer drugs and have 
'poor prognosis (1 03). BRAF mutations are also used to predict resistance to anti-EGFR 
targeted therapies in colorectal cancer patients (39). In addition, it has been reported that 
BRAF mutations are present at very low frequency in the tumours of stage II and stage III 
patients, but those patients who have tumours with BRAF mutation have a poor overall 
survival rate when compared to patients with the wild type BRAF (104). Clearly 
additional studies are needed to identify whether BRAF somatic mutations have 
prognostic importance in colorectal cancer. 
Single nucleotide polymorphisms (SNPs) as genetic prognostic markers 
Recently, there has been an interest to test SNPs as prognostic markers in cancer 
in addition to point mutations, deletions, copy number variations and gene expression 
profiles. Many studies have investigated SNPs from various pathways such as 
angiogenesis (58), hypoxia (105,106), DNA repair (107) and micro RNA genes (108). 
However, these kinds of studies are still in the research phase and the majority of these 
SNPs have to be validated for their prognostic significance before they can be used as 
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prognostic predictors in the clinic. The research described in this Master' s thesis focuses 
on SNPs and their potential prognostic significance in colorectal cancer. 
1.5) General rationale and objectives 
The main objective of this project is to identify genetic markers that can predict 
outcome in colorectal cancer patients. This thesis focuses on genetic markers from 
mitochondrial DNA (Chapter 2) and hypoxia pathway genes (Chapter 3). Genetic markers 
in mitochondrial DNA have been implicated in cancer progression. However, the 
prognostic role of these and other variations have not been well characterized. Similarly, 
hypoxic conditions have been shown to favor aggressive tumor phenotype, and to 
facilitate resistance to anti-cancer therapies. Currently, there are no comprehensive 
studies which look at the association of the vast majority of the SNPs in the hypoxia 
pathway genes with the patient prognosis (Chapter 3). Therefore, in this thesis, we 
hypothesize that, genetic variations in the mitochondrial DNA and hypoxia pathway 
genes may be prognostic markers in colorectal cancer. 
The specific objectives of this thesis are to: 
1. Test the association of select genetic markers in the mitochondrial DNA 
with prognosis in a colorectal cancer patient cohort (Chapter 2). 
11. Test the association of select genetic markers in the hypoxia pathway genes with 
prognosis in two colorectal cancer patient cohorts (Chapter 3). 
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CHAPTER 2: MITOCHONDRIAL DNA (mtDNA) 
VARIATIONS AND THEIR RELATION TO PROGNOSIS IN 
COLORECTALCANCER 
2.1) Introduction to mtDNA and cancer 
Organisation of the mtDNA genome 
Mammals have two genomes - a nuclear genome and a mitochondrial genome 
(1 09). The mitochondrial DNA (mtDNA) is a double stranded, circular molecule of 
16,568 bp ( 1 09) (Figure 3). It has 3 7 genes, of which 13 code for polypeptides which are 
involved in respiration and oxidative phosphorylation (OXPHOS), two code for rRNAs, 
and 22 genes code for tRNAs (1 09). The mitochondrial genome undergoes replication 
and transcription independent of the nuclear DNA (nDNA) (11 0). MtDNA lacks histones 
and introns, and has short reading frames when compared to nDNA (34). The D-loop 
region lacks coding sequences and it is where the replication and transcription of mtDNA 
start ( 4). A portion of the D-loop is triple stranded (7S DNA) because of repetitive 
synthesis ( 4). MtDNA is repaired as short patches through base pair excision repair 
(BER) and other than BER, the mtDNA does not have sophisticated DNA repair 
mechanisms (34). Hence, the mutation rate of mtDNA is ten times higher than that of 
nDNA (34). 
MtDNA has a heavy (H) strand and a light (L) strand. The light and heavy strands 
have high cytosine and guanine contents, respectively ( 4 ). The replication of 
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Figure 3: Mitochondrial DNA organisation 
Adapted from Park and Larsson (111). ATP-6: mitochondrial encoded ATP 
synthase 6; ATP-8 mitochondrial encoded ATP synthase 8; CO-I: cytochrome c oxidase 
subunit I; CO-II: cytochrome c oxidase subunit II; CO-III: cytochrome c oxidase subunit 
III; ND-I: NADH dehydrogenase I ; ND-2: NADH dehydrogenase 2; ND-3: NADH 
dehydrogenase 3; ND-4: NADH dehydrogenase 4; ND-4L: NADH dehydrogenase 4L; 
ND-5: NADH dehydrogenase 5; Cyt-B: cytochrome B gene; I2S and I6S: rRNAs; and 22 
tRNAs shown as vertical rectangular blocks. Drawn not to scale. 
each strand takes place in opposite directions. Initially the H-strand is synthesized using 
the L-strand as template, and when two-thirds of H-strand is synthesized, the synthesis of 
the L-strand takes place in the opposite direction using the H-strand as a template ( 4). 
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Function of mitochondria 
Also known as the power house of the cell, the mitochondria regulate 
programmed cell death, energy metabolism and cell proliferation (6,112). Mitochondria 
are involved in energy production through OXPHOS, a metabolic process which produces 
reactive oxygen species (ROS) (113). ROS are mutagenic agents and can induce 
mutations in DNA (6). Generation of ROS and absence of histones as well as 
sophisticated DNA repair mechanism make mtDNA susceptible to high mutation rates 
(5, 113). A mammalian cell has approximately 1000 mitochondria with multiple copies of 
mtDNA in each. The total number of mitochondria and thus mtDNA molecules differs 
from one cell type to another depending on the energy requirements of the cell (5). Since 
apoptosis is energy dependent, an increase or decrease in mtDNA copy number may 
affect apoptosis and thus may have an effect on cancer progression. Furthermore, the 
amounts of transcriptional products of mitochondria are directly proportional to its 
mtDNA copy number. Hence, the mtDNA copy number might act as a surrogate marker 
of mitochondrial function as well as its dysfunction. 
Role of mtDNA in carcinogenesis and cancer progression 
There is mounting evidence that mitochondrial dysfunctions are associated with 
tumourigenesis and cancer progression. 
There are also reports regarding the metabolic and molecular differences between 
normal and malignant cells (4). In 1930, Warburg (114) proposed that alterations in 
mitochondrial function might favour glycolysis. Production of adenosine tri-phosphate 
(ATP) molecules occurs in normal cells by oxidative phosphorylation pathway, whereas 
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m cancer cells, energy is produced mainly through glycolysis. Hence mitochondrial 
alterations that favor glycolysis may be implicated in cancer progression. In addition, 
alterations of activities of mitochondrial proteins such as ATPase and cytochrome C 
oxidase (5) are observed in cancer cells, indicating that alteration of mitochondrial 
function may be involved in tumourigenesis and cancer progression. 
Apoptosis, the process of programmed cell death, is energy dependent. Therefore 
alterations in 13 mtDNA genes coding for proteins involved in ATP production may also 
affect apoptosis. In addition, mutations impaired mitochondrial BER, could result in 
impaired DNA repair system, that could lead to higher mutation rate and may facilitate 
tumour progression (34). Therefore, it is evident that there is a link between cancer and 
mtDNA abnormalities. 
Alterations in mtDNA - either qualitative (e.g. point mutations, microsatellite 
instability in the hyper variable D-loop region) or quantitative (e.g. copy number 
variations) - are frequent in colorectal cancer tumours (112). For example, mtDNA 
somatic variations were detected in 70% of the colorectal cancer cell lines (seven of 1 0) 
and in 45% (20 of 45) of the colorectal tumours (115). There are also other homoplasmic 
(i.e. observed in all mtDNA samples of an individual or a cell) and heteroplasmic (i.e. 
observed in only a portion of the mtDNA molecules of an individual or a cell) mtDNA 
alterations that may contribute to progression in colorectal cancer (109). A comparative 
proteomic study also identified differences in the mitochondrial proteins produced in the 
colorectal tumour tissues when compared to adjacent normal tissues (116). These findings 
illustrate the role of mtDNA in cancer progression and suggest that it may also play a role 
53 I Page 
in influencing the prognosis. Therefore, mtDNA markers may also be prognostic markers 
in colorectal cancer (1 09). 
Role of mtDNA in colo rectal cancer prognosis 
MtDNA point mutations and copy number changes are associated with tumour 
progression and drug resistance. Therefore, they may be candidate prognostic markers in 
predicting the survival of colorectal cancer patients (113). For instance, the presence of 
somatic mutations in the D-loop of mtDNA was previously associated with poor 
prognosis in colorectal cancer patients (112, 117). In another study, stage II colorectal 
cancer patients with the mtDNA D-loop mutations had resistance to 5-FU based 
chemotherapy (5). Similarly, it has been reported in colorectal cancer patients that 
mitochondrial dysfunction results in lower level of ~-F1-adenosine triphosphatase (ATP) 
and intracellular adenosine triphosphate, which triggers anti-apoptotic activity, resulting 
in resistance to 5-FU (118). In addition to this study, Lievre and colleagues (119) reported 
that the three year survival rate of colorectal cancer patients with D-loop mutations was 
lower when compared to those without D-loop mutations. 
Recently, a study (120) examined 140 tagging mtDNA variants for their potential 
relationship with the colorectal cancer mortality in a Scottish cohort. This study found 
that two SNPs (G752A and G 1440A) in the 12S ribosomal RNA gene and one SNP 
(G4770A) in the nicotinamide adenine dinucleotide dehydrogenase subunit 2 (ND-2) gene 
were significantly associated with colorectal cancer mortality (120). To our knowledge, 
this is the only study which comprehensively investigated the association of mtDNA 
polymorphisms and prognosis in colorectal cancer. 
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Copy number changes in mtDNA are also suggested to have an effect on the 
prognosis of patients. Since mutations in the D-loop region affect the copy number of 
mtDNA and mtDNA copy number is related to mitochondrial function, copy number 
variation ofmtDNA can be a prognostic marker in cancer prognosis (6,113,121). Both an 
mcrease and decrease in the mtDNA copy number have been reported in colorectal 
tumours (122). In one study, it has been shown that an increase in copy number of 
mtDNA harboring the 4977 bp common deletion (in tumour tissues when compared to 
normal tissues) were associated with advanced stages and metastasis in colo rectal cancer 
patients (112). Conflicting with this finding, it has also been reported that there was an 
association between the decreased mtDNA copy number (in colorectal cancer cells versus 
normal cells) with higher TNM stages and poor differentiation (118). This study also 
reported that an increase in the mtDNA copy number was associated with longer OS in 
colo rectal cancer patients ( 118). Due to the conflicting nature of these results, it can be 
suggested that a prognostic role for changes in mtDNA copy number in colorectal cancer 
has not been established yet. 
2.2) Rationale, hypothesis and objectives described in Chapter 2 
The main function of mitochondria is energy production. Cancer cells are usually 
characterised by molecular aberrations which include abnormal energy production and 
metabolism. However, despite being implicated in cancer progression, the potential 
prognostic roles of mtDNA variations in colorectal cancer are understudied. In this study, 
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we hypothesize that alterations in mtDNA might facilitate cancer progression and may be 
potential prognostic markers in colorectal cancer. 
The objective of the study described in this chapter is to: 
1. test the association of six mtDNA polymorphisms and its copy number 
variation with outcome in colorectal cancer. 
2.3) Contributions and credits 
Asan M.S. Haja Mohideen: Obtained the genotypes of2 mtDNA SNPs (mt16189 (T/C) 
and mtl 0398 (A/G)) using the TaqMan® SNP genotyping experiments, performed the 
qPCR analysis to determine the relative mtDNA/nDNA copy number ratio in tumour and 
non-tumour tissues, organised and coded the genotypes prior to statistical analysis, 
performed the statistical analyses and interpreted the results. 
Dr. Sevtap Savas: Processed and coded the prognostic data for the NFCCR cohort and 
performed the Mann-Whitney U and Chi square statistical tests to compare the 
differences between the entire NFCCR cohort (n=736) and sub-group of this cohort used 
in the qPCR analysis (mtDNA copy number analysis cohort; n=279) as well as the 
genotype analysis (NFCCR SNP genotyping cohort; n=537), provided the baseline table 
for the entire NFCCR cohort. 
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Dr. Roger Green and Dr. Patrick Parfey: Provided the DNA samples, 
clinicopathological and prognostic information for the patients, as well as the genotype 
data for the four mtDNA SNPs obtained by a genomewide SNP genotyping method 
investigated in this study. 
2.4) Materials and methods 
2.4.1) Ethics approval 
Ethics approval was obtained from the Human Investigation Committee (HIC) of 
Memorial University ofNewfoundland (HIC #: 11.102). 
2.4.2) Solutions 
In this project, 5X and lX Tris-Borate-EDTA (TBE; adjusted to pH 8.3) and l X 
Tris-EDTA (TE) buffers were used. Further information on these buffers can be found in 
Appendix 1. 
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2.4.3) Patient cohorts 
NFCCR cohort 
This study investigates patients registered with the Newfoundland Colorectal 
Cancer Registry (NFCCR). Patients in NL diagnosed with colorectal carcinomas, who 
were under 75 years of age at the time of diagnosis, were recruited to the NFCCR over a 
5 year period between January 1, 1999 and December 31, 2003 (123). The NFCCR 
obtained written consent from the patients to withdraw their blood samples, as well as to 
permit access to their tumour tissue samples and medical records (123). When patients 
were unable to provide their consent, the NFFCR obtained consent from their proxies 
(123). 
The pathological and molecular data for patient tumours were also ascertained by 
the NFCCR as follows: the familial risk stratification was done according to Amsterdam 
and revised Bethesda criteria (123,124); MSI status was ascertained using 
immunohistochemistry analyses and by analysing five different microsatellite markers 
recommended by the National Cancer Institute (123); and BRAF somatic mutation status 
(Val600Glu) was ascertained by an allele specific PCR method (123). Stage and other 
pathological features were ascertained based on the tumour size, nodal status and 
metastasis data. The NFCCR also collected other patient clinicopathological and 
prognostic information such as date of death, recurrence of colorectal cancer, age, sex and 
other characteristics studied in this project. Patients were followed until201 0. 
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NFCCR patient sub-cohorts investigated in this study 
DNA samples used in this study were obtained from the NFCCR. While the 
NFCCR cohort has 736 stage I-IV patients, for this project, we have used two sub-cohorts 
of NFCCR patients (Table 2). Out of 736 patients, 537 patients with available DNA 
(extracted from blood cells) were included into SNP analyses in both Chapter 2 and 
Chapter 3. This subcohort of 53 7 NFCCR patients is named the "NFCCR SNP genotyping 
cohort" throughout this thesis. Similarly, for the mtDNA copy number analysis, DNA 
samples extracted from tumour and the adjacent non-tumour tissue were available only 
for 276 patients out of the 537 NFCCR patients when this study was conducted. This 
subcohort is named as the "mtDNA copy number analysis cohort" throughout this thesis. 
The baseline characteristics of the entire NFCCR cohort, the NFCCR SNP genotyping 
cohort, and the mtDNA copy number analysis cohort are summarised in Table 3. 
Table 2: Two NFCCR sub-cohorts used in this project 
Sub-cohort Source of DNA Number of patients 
NFCCR SNP genotyping Blood 537 
cohort 
mtDNA copy number Tumour and 
adjacent non- 276 
analysis cohort 
tumour tissue 
For SNP genotyping and mtDNA copy number analysis, each DNA plate 
containing a stock DNA concentration of 10 ng/!J.l were provided by NFCCR. The stock 
DNA solutions were diluted to 4 ng/!J.l for TaqMan® SNP genotyping reactions and 5 
ng/!J.l for quantitative polymerase chain reaction (qPCR) with sterile dH20. 
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Table 3: Baseline and prognostic characteristics of the entire NFCCR, mtDNA copy number analysis and the NFCCR SNP 
genotyping cohorts 
Entire NFCCR mtDNA copy number 
*p- NFCCRSNP **p-
Variables cohort analysis cohort values genotyping cohort values 
Total=736 Total=276 Total=537 
n (%) n (%) n (%) 
Sex 0.387 0.964 
female 286 (38.9) 116 (42.03) 208 (38.73) 
male 450 (61.1) 160 (57.97) 329 (61.27) 
Location 0.496 0.355 
colon 506 (68.5) 183 (66.3) 356 (66.29) 
rectum 230 (31 .5) 93 (33.7) 181 (33.71) 
Histology 0.915 0.537 
non-mucmous 644 (87.5) 243 (88.04) 476 (88.64) 
mucmous 92 (12.5) 33 (11.96) 61 (11.36) 
Stage 0.167 <0.001 
I 112(15.2) 31 (11.23) 98 (18.25) 
II 244 (33.2) 94 (34.06) 207 (38.55) 
III 227 (30.8) 101 (36.6) 179 (33.33) 
IV 153 (20.8) 50 (18.11) 53 (9.87) 
Grade 0.489 0.089 
well/moderate! y differentiated 651 (88.4) 243 (88.04) 494 (92) 
poorly/undifferentiated 73 (10) 32 (11.6) 39 (7.26) 
unknown 12 (1.6) 1 (0.36) 4 (0.74) 
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Vascular invasion 0.454 0.013 
398 (54.1) 139 (50.36) 327 (60.9) 
+ 282 (38.3) 111 (40.22) 171 (31.84) 
unknown 56 (7.6) 26 (9.42) 39 (7.26) 
Lymphatic invasion 0.455 0.034 
389 (52.9) 137 (49.64) 316 (58.85) 
+ 285 (38.7) 113 (40.94) 179 (33.33) 
unknown 62 (8.4) 26 (9.42) 42 (7.82) 
Familial risk 0.571 0.52 
Low 354(48.1) 142 (51.45) 256 (47.67) 
High/intermediate 361 (49) 133 (48.19) 281 (52.32) 
unknown 21 (2.8) 1 (0.36) 
MSI-H status 0.813 0.601 
Yes 634 (86.1) 248 (89.86) 457 (85.10) 
No 73 (10) 26 (9.42) 58 (1 0.80) 
unknown 29 (3.9) 2 (0.72) 17 (3 .17) 
BRAFJ Val600Glu mutation status 0.503 0.3 18 
589 (80) 219 (79.35) 437 (81.38) 
+ 80 (10.9) 35 (12.68) 49 (9.12) 
unknown 67 (9.1) 22 (7.97) 51 (9.5) 
Prognostic and follow up information 
OS status 
alive 380 (51.6) 141 (51.09) 354 (65.92) 
dead 355 (48.2) 134 (48.55) 182 (33.89) 
unknown 1 (0.2) 1 (0.36) 1 (0.19) 
Median OS follow-up: 5.6 years (range: 6.2 years (range:0.036- 6.3 years (range: 0.04-11.1) 10.88) 0.38-10.88) 
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DFS status 
recurrence/metastasis/death ( +) 348 (47.2) 149 (53.99) 213 (39.66) 
recurrence/metastasis/death (-) 387 (52.6) 126 (45.65) 323 (60. 15) 
Unknown 1 (0.2) 1 (0.36) 1 (0.19) 
Median DFS follow-up: 5 years (range: 5.1 years (range:0.036- 5.97 years (range: 0.04-11.1) 10.88) 0.22-1 0.88) 
Age 0.95 0.219 
Median Age: 62.3 years 62.4 years (31. 75- 61.22 years (range: (range: 20.7-75) 74.94) 20.7-74.98) 
(+):presence, (-): absence, DFS: Disease Free Survival, MSI-H: Microsatellite Instability-High, OS: Overall Survival. * p-values for 
differences between the entire NFCCR and the mtDNA copy number analysis cohort, ** p-values for differences between the entire 
NFCCR and the NFCCR SNP genotyping cohort. A p-value (obtained by Chi-square or Mann-Whitney U test) less than 0. 05 for a variable 
denotes significant differences between the compared cohorts. Familial risk refers to risk stratification based on Amsterdam and revised 
Bethesda criteria. Please note that Disease specific survival data for these cohorts were not available. 
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2.4.4) Selection of genetic markers in mtDNA 
mtDNA polymorphisms genotyped in this study 
The first mtDNA polymorphism investigated in this study, the mt16189 (T/C) 
substitution, is located in the D-loop region (125). This 16189 T to C substitution leads to 
the formation of a homopolymeric cytosine (homopolymeric C) tract between the 
positions 16189-16194 resulting in a heteroplasmic length variation of the number of 
cytosine residues (126). It has been reported that there are differences in the mean 
mtDNA copy numbers based on the differences in the number of poly-cytosine (poly-C) 
variants (125). In this study, samples with an uninterrupted poly-C tract (cases with 
mt16189 C allele) had the lowest mtDNA copy number and samples with the interrupted 
poly-C tract (cases with mt16189 T allele) had the highest mtDNA copy number (125). 
There is also a similar study where heteroplasmic length variation has been suggested to 
affect the mtDNA replication (127). This may be explained by the fact that the SNP 
16189 (T/C) is located in the Terminated Associated Sequences that play a major role in 
the termination of mtDNA synthesis (128). In addition, this polymorphism has been 
reported to be associated with increased oxidative damage and altered anti-oxidative 
status (129). 
The second mtDNA polymorphism investigated in this study, mt10398 (A/G), is 
located in the ND-3 gene, which encodes one of the respiratory subunits of the oxidative 
phosphorylation pathway. In a study performed on cell lines derived from breast cancer 
patients, cell lines containing G allele have been reported to have elevated levels of ROS 
and de-polarized mitochondria when compared to cell lines containing A allele for 
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mt10398 polymorphism (125,130). In addition, cell lines with the 10398 G allele showed 
increased colony forming ability. The same study also found that the 10398 G allele 
promotes metastases in mice (125,130). Therefore, this polymorphism may facilitate 
cancer progression and worsen outcome in patients. 
Since both polymorphisms may disrupt vital biological mitochondrial functions, in 
this study we hypothesized that they may be associated with outcome in colorectal cancer 
patients. 
Selection of mtDNA SNPs from the genome-wide SNP genotyping data 
Using the Illumina® HumanOmni-1 Quad BeadChip genome wide SNP 
genotyping platform the NFCCR obtained genotype data for approximately one million 
SNPs. The genotyping reaction was performed by the Centrillion® Genomic Services 
(CA, USA). These genotype data also contained the genotypes for 25 mtDNA SNPs for 
537 NFCCR patients with available prognostic data (i.e. NFCCR SNP genotyping cohort) 
(Appendix 2). Upon further analysis, we found that seven of these SNPs were mono-
allelic, some SNP-flanking sequences had a significant sequence homology with nDNA 
sequences (thus it was not clear whether these SNPs were mtDNA or nDNA SNPs, n=7), 
seven SNPs had very low MAFs (<4%) (Appendix 2) and as a result, 4 out of 25 SNPs 
from the genomewide SNP genotype data were included in the statistical analysis for this 
project (Table 4). The locations ofthese four mtDNA SNPs as well as the two additional 
mtDNA SNPs genotyped by the TaqMan® SNP genotyping method in this study are 
shown in Figure 4. 
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Table 4: The mtDNA polymorphisms obtained from the genomewide SNP genotyping 
data that are included in this study 
Number 
Number Number of of Number of 
SNPID of samples samples samples that MAF 
missing with major with are (%) 
genotypes allele minor heteroplasmic 
allele 
MitoT479C 6 506 25 0 4.07 
MitoT491C 32 478 27 0 5.35 
MitoT10035C 501 35 0 6.53 
MitoA13781G 13 490 34 0 6.49 
Heteroplasmic: patients with both alleles for a particular polymorphism, MAF: minor allele 
frequency 
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Figure 4: Locations of the six mtDNA polymorphisms investigated in this study 
16189 C) 
MitoAI378IG 
MitoT10035C 
MitoT49IC, MitoT479C and 16189(T/C) are located in the D-loop region. MitoA13 78JG 
is located in the ND-5 gene, 10398 (A/G) is located in the ND-3 gene and Milo TI0035C 
is located in a tRNA gene that is specific for glycine codon. Drawn not to scale. 
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2.4.5) Experimental procedures 
2.4.5.1) TaqMan® SNP genotyping (5' nuclease) assays 
Principle 
The TaqMan® SNP genotyping assays use fluorogenic probes and utilize the 5' 
nuclease activity of the Taq DNA polymerase. A typical TaqMan® probe contains a 
reporter fluorescent dye at the 5' end and a quencher dye on the 3' end. When the 
quencher dye is in close proximity to the reporter dye (which happens before the reporter 
dye cleavage), the quencher dye suppresses the fluorescence emitted by the reporter dye. 
During the PCR reaction, if the target sequence is present, the probe binds to the specific 
target sequence and the forward and reverse primers also bind to their complementary 
sequences (Figure 5). During the polymerization step, the probe is cleaved by the 5' 
nuclease activity of the Taq DNA polymerase. By this process the reporter dye is 
removed from the probe. Since the reporter dye is no longer in close proximity to the 
quencher, the fluorescent signal of the reporter dye increases. During each cycle, 
additional reporter dye molecules are cleaved from the probe and thus the reporter 
fluorescence signal increases every cycle and is proportional to the number of amplicon 
produced. Depending upon the genotype, the fluorescence intensity of each probe differs 
for each amplified sample and this information is used to determine the genotypes of the 
DNA samples. 
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Figure 5: Principle ofTaqMan® genotyping assay 
Allele 1 V 
IIIII! 0 
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SNP position 
AmpliTaq Gold DNA 
Polymerase 
Quencher 
The probe binds to the specific target sequence and the forward and reverse primers also 
bind to their complementary sequences. The probe is cleaved by the 5 ' nuclease activity 
of the Taq DNA polymerase 
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Primer and probe information for the mtDNA 16189 (TIC) TaqMan® SNP genotyping 
assay 
The TaqMan® SNP genotyping assay containing the primers and probes (one 
probe for each allele) for the mtDNA 16189 (T/C) SNP was custom designed using the 
Applied Biosystems' assay design tool (https://www5.appliedbiosystems.corn/tools/cadt/) 
(Table 5) as follows: the updated complete mtDNA reference genome sequence (the 
revised Cambridge sequence; (NC_012920.1)) was obtained from the NCBI's (National 
Center for Biotechnology Information) nucleotide database. The location of the mtDNA 
16189 (T/C) was located on the reference mtDNA genome sequence by manual 
inspection. The SNP flanking sequences ( ~80 bases) in both directions were then 
Table 5: Primer and probe information for the mtDNA 16189 (T/C) TaqMan® SNP 
genotyping assay 
Forward primer 
CACCTGTAGTACATAAAAACCCAATC 
CA 
VIC probe (T allele) 
CCCCCICCCCATGCT 
Reverse primer 
GGGTTGATTGCTGTACTTGCTTG 
TA 
FAM probe (C allele) 
CCCCCCCCCATGCT 
The underlined nucleotides in the sequences above correspond to location of the polymorphic site, 
the mtDNA 16189 (TIC), which is recognized by the VIC and FAMprobes. 
imported. The location of other SNPs adjacent to the mtDNA 16189 (T/C) SNP within 
the SNP flanking sequences were obtained from the mtdbSNP database (131) and were 
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marked as "N" (i.e. masked nucleotides) before entering into the assay design tool, as 
recommended by Applied Biosystems. 
Primer and probe information for the mtl 0398 (A/G) TaqMan® SNP genotyping assay 
The probe and primer sequences for the mt10398 (A/G) SNP were obtained from 
a published article (132) (Table 6), and manufactured by Applied Biosystems (USA) and 
Integrated DNA Technologies (IDT) (USA), respectively. 
Table 6: Primer and probe information for the mtDNA 10398 (A/G) TaqMan® SNP 
genotyping assay 
Forward primer 
CTAGCCCTAAGTCTGGCCTATGA 
VIC probe (A allele) 
ATTAGACTGAACCGAATTG 
Reverse primer 
AATGAGTCGAAATCATTCGTTT 
TGTTTAAACT 
FAM probe (G allele) 
ACTGAGCCGAATTG 
The underlined nucleotides in the sequence above correspond to location of the polymorphic site, 
the mt10398 (A/G), which is recognized by the VIC and FAMprobes. 
Procedure for preparing and storing the TaqMan® SNP genotyping assays 
The 40X TaqMan® assay mix (Applied Biosystems, CA, USA) for mtDNA 
16189 (T/C) SNP was directly purchased by the Applied Biosystems (CA, USA). The 
40X TaqMan® assay mix was aliquoted into separate tubes and were preserved at -20°C. 
The stock solution was preserved until after the aliquot tubes were consumed up. The 
assay mix (40X) solutions were diluted to 20X using IX TE buffer and stored at -20°C. 
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For the mtDNA 10398 (A/G) SNP, probes and primers were obtained in separate 
tubes from different manufacturers. Therefore, the 40X assay mixture containing the 
primers and probes were prepared in our laboratory. The primers were received in 
pelletized form from the manufacturer (Integrated DNA Technologies, USA) and were 
suspended in appropriate amounts of de-ionized water to have primer solutions with a 
concentration of 1 OOf.LM. The stock primer tubes were then tapped and vortexed gently to 
ensure that the contents were dissolved completely. 100 f.Ll of the stock primer solution 
was then aliquoted into 2-3 aliquot tubes and stored at -20°C. 
The 20X TaqMan® SNP genotyping assay mix for the 10398 (A/G) was prepared 
by adding 56 fll of IX TE buffer, 18 f.Ll of forward and reverse primer (100 f.LM each), 4 
fll of stock probe 1 and 2 (1 00 f.LM each) and by mixing in a 1.5 ml micro tube. The 20X 
assay mix was then spinned down in a mini-centrifuge, aliquoted, and stored at -20°C. 
TaqMan® SNP genotyping methodology 
These reactions were performed in 96-well amplification plates. For each reaction 
plate, the concentration and volumes of reagents in the reaction mix are provided in 
Table 7 below. 
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Table 7: Volume of reagents needed for setting up a TaqMan® SNP genotyping reaction 
mix (for a 96 well plate reaction) 
Contents 
PCR Master Mix (2X) 
TaqMan® Assay Mix 
(20X) 
Sterile water 
Sub-total 
Volume 
5 fll X 11 0= 550p.tl 
0.25J.!l X 110= 27.5p.tl 
3.75J.!l X 110= 412.5p.tl 
990 p.tl 
Before starting each experiment, all reaction mixes as well as the DNA plates 
were spinned down briefly. 80 J.!l of the master reaction mixes were transferred into the 
well of a 12-well strip tube. These aliquot mixes were then pipetted (9 J.!l each) into each 
of the 8 columns of a MicroAmp® Fast Optical 96-well reaction plate (Part number. 
4346906, Applied Biosystems, CA, USA) using a twelve channel pipette. These reaction 
plates are compatible with the 7900HT Fast Real Time PCR System (Part number. 
4330966, Applied Biosystems, CA, USA). 1 J.!l of the DNA solution from the DNA plates 
with a concentration of 4ng/fll were added to the corresponding wells in the 96-well 
reaction plate. The 96-well reaction plate was covered with a compatible optical adhesive 
film (Part number. 4360954, Applied Biosystems, CA, USA). The optical film was sealed 
tightly at the edges as well as on the surface to make sure that the reaction solution does 
not evaporate during the PCR amplification process. The base of the plate was also 
covered with a Kimwipe to avoid any possible source of contamination until it was placed 
into the equipment. After that step, the reaction plate was centrifuged at 1000 revolution 
per minute (rpm) in a bench top centrifuge (catalogue number: 75004367, Sorvall Legend 
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T + Centrifuge, Thermo Fisher Scientific, MA, USA) for approximately 10 seconds. The 
reaction plate was then placed in the Applied Biosystems 7900HT Fast Real Time PCR 
system (Applied Biosystems -USA) or the Veriti thermocycler (Applied Biosystems-
USA) for PCR amplification. 
There are two file formats that are associated with Applied Biosystems 7900HT 
Sequence Detection Systems (SDS) software: allelic discrimination file (AD) and the 
allelic quantification (AQ) file. Both the AD and AQ files were created prior to running 
the PCR reactions using the SDS software package as described in the 'Applied 
Biosystems 7900HT Fast Real-time PCR System Allelic Discrimination Getting Started 
Guide ' manual. In short, the AD files were used to discriminate the different alleles of a 
particular SNP and it contains the marker (detector) information and reporter dye 
information (VIC and F AM). On the other hand, the AQ file is required to run the 
amplification reaction on the Applied Biosystems 7900HT Fast Real Time PCR system 
equipment. A typical AD file was used for two processes, the pre-read and post-read 
processes; both were performed in the 7900HT Fast Real time PCR system equipment 
(Applied Biosystems, CA, USA). 
The pre-read step was performed before the PCR amplification process. During 
the pre-read step, the fluorescence intensity (background signal) of the passive reference 
dye (ROX) is measured. After that step, the PCR amplifications were performed using 
either the Veriti thermocycler (Part number: 4375305, Applied Biosystems, CA, USA) or 
the Applied Biosystems 7900HT Fast Real Time PCR equipment (Part number: 4330966, 
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Applied Biosystems, CA, USA). The PCR thermocycling conditions are provided in 
Appendix 3. 
After the PCR amplification was completed, the post-read step was performed in 
the Applied Biosystems 7900HT Fast Real-time PCR equipment using the AD file. 
During the post-read, the final fluorescence intensities at the end of the reaction are 
recorded by the Applied Biosystems 7900HT Fast Real Time PCR System. The pre-read 
and post-read data stored in the AD file were then processed by the SDS software during 
which the fluorescence intensity at the end of the PCR reaction was subtracted from the 
passive reference signal and the fluorescence intensities were plotted in a scatter plot by 
the SDS software (Figure 6). 
In a typical scatter plot, there are two fluorescence intensity scales mapped to X 
(Xn) and Y (Yn) axis; one for each probe (allele) respectively. Thus, in a typical plot 
(Figure 6), one can see three genotypes; homozygous for X allele (XX - inclined to X 
axis), homozygous for Y allele (YY- inclined towards Y axis); and heterozygous (XY-
midway between the two axes). Both mtDNA SNPs that are genotyped in this project 
were almost always homoplasmic. Therefore, only two genotypes in the scatter plots were 
observed (except one heteroplasmic sample for each mtDNA SNP). The NTCs typically 
should occupy the region closer to the center of origin of both the axes, unless there is a 
contamination. The genotypes called automatically were also inspected manually by an 
independent scientist (Dr. Savas) to confirm the genotype calls. 
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Figure 6: An example of an allelic discrimination (AD) plot for the mtDNA 16189 (T/C) 
polymorphism 
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The black squares near the center of origin show no amplification and are NTCs. The red 
dots represent those samples which are homoplasmic for the T allele. The blue dots are those 
samples which are homoplasmic for the C allele. The green dot, which is midway between 
the two homo plasmic clusters, is a heteroplasmic sample. There a f ew outlier red dots that 
represents DNA samples with low amplification which might be due to the low quality of 
DNA samples or due to the presence of PCR inhibitors. 
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2.4.5.2) qPCR analysis 
Selection of target gene sequences to be amplified in qPCR reaction 
In brief, to quantify mtDNA copy number with respect to nDNA in tumour versus 
non-tumour cells using the qPCR method, we first selected target genes to be amplified 
based on previously published studies. Because the aim of this study is to identify the 
differences between the mtDNA copy number between the tumour and adjacent non-
tumour tissue, we performed additional analyses to make sure the selected gene 
sequences are not altered (i.e. deleted or somatically mutated) in colorectal tumours. The 
presence of polymorphisms at primer and probe binding sequences were also avoided. 
Since this experiment was quantitative, we also checked to make sure that the control 
gene in the nDNA did not have a copy number variation (CNV) among individuals. These 
procedures are described in detail below. 
For selecting gene regions for qPCR amplification, initially about 100 nuclear 
genes were randomly investigated. For this purpose, first, genes were analyzed for 
deletions (LOH) in gastrointestinal tumour tissue samples using the information published 
in the CONAN (copy number analysis) database of the Wellcome Trust Sanger Institute, 
as of October 2011 (133). The FASLG showed the least structural variation (one LOH 
(3% in analyzed cell lines (n=39)) among several genes examined this way (133). A 
previous study had primer and TaqMan® probe sequences for the target sequence in this 
gene (134). The same study (134) also had the primer and TaqMan® probe sequences for 
an mtDNA gene fragment (ND-2). These primers and probes were selected to be used in 
the qPCR method. Additional steps were taken to ensure that known sequence alterations 
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would not affect binding of the primers and the probe. These steps are explained in 
Appendix 4. The primer and probe sequences for F ASLG and ND-2 are provided in 
Table 8. 
Table 8: Primers and probe for the F ASLG and ND-2 gene fragments used in the qPCR 
method 
GenD IR (primer) 
GenREV (primer) 
Probe 
mtDNA DIR 
(primer) 
mtDNAREV 
(primer) 
Probe 
FASLG 
GGC TCT GTG AGG GAT ATA AAG ACA 
CAA ACC ACC CGA GCA ACT AA T CT 
VIC-CTGTTCCGTTTCCTGCCGGTGC-TAMRA 
ND-2 
CAC AGA AGC TGC CAT CAA GTA 
CCG GAG AGT ATA TTG TTG AAG AG 
FAM-CCT CAC GCA AGC AAC CGC ATC C- TAMRA 
Primer and probe information was obtained from a previous literature report (134). These 
primers and probes were separately ordered from the Integrated DNA Technologies (USA) and 
Applied Biosystems (USA), respectively. 
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The qPCR methodology 
A set of reactions were performed to identify the optimum primer and probe 
concentration for this reaction. To prepare a 50 fll of 20X qPCR assay mix, primers and 
probes were mixed together as shown in Table 9. 
Table 9: Volumes of reagents needed to prepare 50 fll of qPCR assay mix (20X) 
Reagent Volume (J.tl) 
Forward primer ( 1 00 2.25 
f.!M) 
mtDNA Reverse primer (1 00 2.25 f.!M) 
(ND-2) Probe (1 00 f.!M) 0.5 
Forward primer ( 1 00 18 f.!M) 
nDNA Reverse primer ( 1 00 18 f.!M) 
(FASLG) Probe (1 00 f.!M) 4 
IX TE buffer 5 
Total 50 
All qPCR reactions were performed in the 7900 HT Fast Real-Time PCR system. 
For each patient, two separate qPCR reactions were performed in triplicates: one for the 
tumour extracted DNA and the other for the non-tumour extracted DNA. The DNA 
samples extracted from tumour and non-tumour samples from each patient were 
amplified in the same reaction plate to minimize inter-assay variability. In qPCR reaction, 
each well contained the following reagents as shown in Table 10. 
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Table 10: The qPCR reaction mix 
Reagent 
PCR Master Mix (2X) 
TaqMan® Assay Mix 
(20X) 
Sterile water 
DNA solution (5 ng/1-1l) 
Total volume 
Volume 
0.25!-11 
3.25!-11 
1.5 !-11 
10.0 !-11 
According to the Applied Biosystems' guidelines, the SDS Relative Quantitation 
(SDS-RQ) file was set up prior to the reaction. The reaction condition for qPCR was as 
follow: 1) Activation of AmpErase® UNG at 50 °C for 2 mins, 2) AmpliTaq Gold 
Polymerase activation at 95 °C for 10 mins, and 34-35 cycles of 3) denaturation of DNA 
at 9 5 °C for 15 sec and 4) primer annealing and extension at 60 °C for 1 min. 
After the qPCR reaction was over, the empty wells were excluded from the 
analysis to eliminate background noise. The SDS file was saved and the SDS-RQ file was 
analyzed using the RQ manager software. The RQ manager software generates two 
different plots, namely fluorescence intensities (Rn) versus cycle number and baseline 
normalized fluorescence intensities (~Rn) versus cycle number. As recommended by 
Applied Biosystems, in order to reduce the background noise, a baseline correction was 
performed. This was performed by selecting the start and end cycle values from the Rn 
versus cycle number plot (Figure 7). The start cycle range value was set to cycle number 
three and the end cycle value was selected by choosing the amplification curve that had 
the lowest CT 
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Figure 7: Rn versus cycle number plot in qPCR 
Baseline 
tart cycle 
t 
Endcycle is fixed three cycles below the cycle number at which a detectable amplification starts 
(the cycle value at which amplification begins) value in the Rn versus cycle number plot 
and subtracting three cycles from it. The corrected baseline cycle values were then set for 
each reaction file. In addition, the RQ manager software generates a threshold line for 
threshold cycle (CT) (the cycle number at which the threshold line crosses the 
amplification curve) calculation, separately for mtDNA and nDNA in the delta Rn plots 
(Figure 8). This threshold was set either automatically by the software or manually in the 
exponential phase as recommended by Applied Biosystems. The cycle value which 
intersects the threshold line is called the threshold cycle (CT). 
80 I Page 
The exported Cr values were then organized and analyzed for standard deviation 
(SD) among the three replicate amplifications (triplicates) for each sample using a 
Microsoft Excel® program. Since qPCR for each DNA sample was performed in 
triplicates, initially there were three Cr values for every DNA sample. For reliable qPCR 
results, according to the Applied Biosystems guidelines, the Cr values should be 
normalized based on at least two repeated (replicated) reactions (i.e. within triplicates of 
each DNA sample) and with a SD value of Cr <0.30. 
Figure 8: ~Rn versus cycle number plot in qPCR 
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In other words, the variability among the repeated amplifications of a DNA 
sample should be minimal. Samples that did not satisfy the criterion (i.e. SD <0.3) 
between triplicates were reanalyzed by excluding an outlier Cr value. SD was then re-
calculated based on the remaining two Cr values. If still the SD was >0.3 in these two Cr 
values, the qPCR reactions for these patients (for both the tumour and non-tumour tissue 
extracted DNA) were repeated. Once Cr values that satisfied the above criteria were 
obtained, average Cr values were calculated for each sample group (i.e. tumour and non-
tumour DNA of each patient). From the average Cr value, the mtDNA copy number 
change between the tumour and non-tumour tissue for each patient were determined using 
the delta-delta Cr (L'lL'lCr) method (135), as shown in the equation below: 
-L'lL'lC 
mtDNA copy number change=2 T 
=2-( !::.C T (tumour)-!::.C T (non-tumour)) 
Where, 
!::.C T (tumour) = Cr (tumour mtDNA)- Cr (tumour nDNA) 
!::.C T (non-tumour) = Cr (non-tumour mtDNA) - Cr (non-tumour nDNA) 
In the above equation, for each sample, the quantity of the mtDNA amplification 
(i.e. mtDNA copy number) is normalized to the quantity of nDNA amplification to 
calculate the relative number of mtDNA with respect to nDNA. This information is then 
used to calculate the relative mtDNA copy number of the tumour tissue when compared 
82 I Page 
with the non-tumour tissue sample of each patient. When the mtDNA copy number ratio 
is less than one it means there is a decrease in the number of mtDNA copies in the tumour 
tissue when compared to normal tissue. When the mtDNA copy number ratio is one or 
greater than one then there is an increase in the mtDNA copy number in tumour when 
compared to non-tumour tissue. For statistical analyses, mtDNA ratios were rounded to 
three decimals. 
2.4.6) Quality control measures and statistical analyses 
Calculation of genotype replication rate 
When performing genotyping reactions usmg the TaqMan® SNP genotyping 
method, genotyping reactions for a number of samples were repeated to check if results 
obtained were consistent. The duplication rates for the samples were calculated by the 
following equation: 
. . number of samples genotyped succesfully at least twice 
Duphcatwn rate = ------------------------
total number of samples genotyped successfully 
Calculation of genotype concordance rate 
The concordance rate was calculated using the genotyping results for samples 
genotyped twice by the TaqMan® SNP genotyping method using the following formula: 
83 I Page 
Concordance rate 
Number of duplicated samples with concordant genotypes 
Number of samples duplicated 
Determination of minor allele frequencies 
The genotypes for each of the 6 mtDNA SNPs (obtained by both the TaqMan® 
SNP genotyping method and the genomewide SNP genotyping method) were organized 
and examined in Microsoft® Excel sheets to identify the major homozygotes, minor 
homozygotes and heterozygotes for each SNP. For each SNP, the minor allele frequency 
(MAF) was also computed using the numbers of major homozygotes, heterozygotes and 
minor homozygotes using the following equation: 
((2 * aa) + Aa) 
MAF = -------
2 * ( AA + Aa + aa) 
where, "A" is the major allele and "a" is the minor allele. 
Coding of categorical variables for statistical analysis 
For statistical analysis of mtDNA SNPs in relation to prognosis, the organized 
genotype data were coded for statistical analysis based on the genotypes: the major 
genotypes were coded as zero and the minor genotypes were coded as one. This way, the 
minor genotype is compared to the major genotype during the statistical analysis. In the 
case of mtDNA 16189 TIC and mtDNA 10398 A/G polymorphisms, there was one 
(separate) patient who was heteroplasmic for these SNPs. These patients were excluded 
from the statistical analysis. Other clinicopathological variables were coded as follows: 
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male=l and female=O; mucmous histology=! and non-mucinous histology =0; rectal 
cancer=l and colon cancer=O; poorly or undifferentiated tumours=! and well or 
moderately differentiated tumours=O; presence of vascular invasion in tumours=! and 
those with no vascular invasion=O; presence of BRAF (Val600Glu) mutation =1 and 
absence of BRAF (Val600Glu) mutation=O; high or moderate familial risk=l and low 
familial risk=O; MSI-H=l and MSS/MSI-L absence of MSI-H=O; and stage 1=1 , stage 
11=2, stage 111=3 and stage IV=4. Since age is a continuous variable it was not 
dichotomised; rather it was analyzed as a continuous variable. For statistical analysis of 
the per results, the increase in mtDNA in tumour tissue with respect to non-tumour tissue 
was coded as one and samples with decreased mtDNA copy number in tumour tissues 
with respect to non-tumour tissues were coded as zero. 
Measures of outcome 
Survival analyses were performed to test whether the mtDNA genetic variations 
investigated were associated with outcome. For this analysis, we used two measures of 
outcome: overall survival (OS) was the primary outcome and disease free survival (DFS) 
was the secondary outcome. OS is the time interval from diagnosis to the last follow up 
or to the date of death from any cause. DFS is the time interval from diagnosis to the last 
follow up or to the date of death from any cause, recurrence or metastasis, whichever has 
occurred earlier. 
Kaplan Meier curves 
The Kaplan Meier method is used to compare the survival characteristics over 
specified time interval for two or more group of patients stratified based on specific 
85 I Page 
clinicopathological characteristics (136). Kaplan Meir method was used to generate the 
survival curves in this project. 
Univariate Cox regression analysis 
In this method, patients are grouped in two or more groups based on their variable 
characteristics. The probability of occurrence of an event in one group of patient when 
compared to another group of patients is called the hazard ratio (HR) (71). In the 
univariate analysis, each of the variables is analyzed individually to find out whether they 
are correlated with the outcome separately. In our study, for univariate analysis, age was 
analyzed as a continuous variable. The remaining variables were categorized into two 
groups, except for stage which had four categories (categories coded as "0" were used as 
reference group) except in stage where stage II, stage III, and stage IV patients were 
separately compared to stage I patients (the reference group). 
Chi-square test 
The Chi-square test statistic compares the difference between the observed and 
expected frequencies for groups of patients for a categorical variable. This test was used 
to compare the differences between patient cohorts, as well as the associations of 
genotypes with clinicopathological features. 
Mann-Whitney U test 
The Mann-Whitney U test was used to compare the differences in the age 
distribution between the patient cohorts, (Table 3), as age was not normally distributed in 
these patient cohorts (data not shown). 
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All statistical analyses were performed using the Statistical Package for the Social 
Sciences (SPSS) (version 19), unless otherwise stated. The statistical significance level 
was set at p<O.OS and all statistical tests were double-sided. Due to the hypothesis 
generating nature ofthis study, no correction for multiple testing was performed (137). 
2.5) Results 
2.5.1) mtDNA polymorphisms 
Characteristics of the NFCCR SNP genotyping cohort 
The baseline characteristics of the cohort investigated for the mtDNA SNPs (i.e. 
the NFCCR SNP genotyping cohort) are shown in Table 3. In this cohort (n=537), the 
median age at diagnosis was 61.2 years, the median OS follow up time was 6.3 years, and 
the median DFS follow up time was ~6 years. When compared to the entire NFCCR 
cohort, this cohort had fewer stage IV patients (20.8% versus 9.9%; p<0.001), fewer 
patients with tumours characterized by vascular invasion (38.3% versus 31.8%, p=0.013), 
and fewer patients with tumours characterized by lymphatic invasion (38.7% versus 
33.3%; p=0.034). 
Statistical analysis results of the mtDNA polymorphisms 
The genotype frequencies of the six mtDNA SNPs included in this study are 
shown in Table 11. The genotype frequencies were generally similar to the frequencies 
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reported in the dbSNP database (138) or previous findings published in the literature 
(127,139-142) for Caucasian populations. 
For the two mtDNA SNPs (10398 (AJG) and 16189 (T/C)) (Table 11), 13.4% and 6.5% 
of the genotypes were duplicated, respectively. The replicate genotypes were 100% 
concordant. 
Table 11: Genotype frequencies of the six mtDNA polymorphisms investigated in this 
study 
Heteroplasmy No. of Major Minor patients 
SNP genotype genotype with 
(%) (%) (%) missing 
genoty~e 
10398 (AJG) A (83.6) G (16.2) 0.19 
16189 (T/C) T(87.15) c (12.66) 0.19 
MitoT479C T (95.3) c (4.7) 6 
MitoT491C T (94.65) c (5.35) 32 
MitoT1 0035C T (93.47) c (6.53) 1 
MitoA 13 781 G A (93.51) G (6.49) 13 
Using univariate analysis to test the association of these six mtDNA SNPs with 
survival, the survival differences of the patients grouped based on their genotypes were 
not found to be significantly different. The univariate Kaplan-Meier survival curves for 
the six mtDNA SNPs for OS and DFS are presented in Figures 9 and 10, respectively. 
The univariate Cox regression analysis results for OS and DFS are also summarized in 
Tables 12 and 13, respectively. 
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In OS univariate analysis, sex, stage, vascular invasion, lymphatic invasion and 
MSI status were significantly associated with OS (Table 12). Specifically, male patients 
had increased risk of death when compared to female patients. Stage III and IV patients, 
when compared to the stage I patients had shorter OS times. Patients with tumours 
characterized by vascular or lymphatic invasions had increased risk of death when 
compared to patients without lymphatic or vascular invasion. Patients with MSI-H 
tumours had longer OS compared to patients with the non-MSI tumours. For these 
variables, similar results were obtained in the DFS analysis as well (Table 13). In 
addition, in the DFS analysis, rectal cancer patients had increased risk of event (i.e. 
recurrence, metastasis, or death; Table 13) when compared to colon cancer patients. 
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Figure 9: Kaplan Meier plots for six mtDNA polymorphisms investigated in this study (overall survival) 
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OS time is defined as the time interval from the time of diagnosis to the date of last follow up or the date of death. Cumulative survival 
refers to the proportion of patients who are alive at a particular point of time. Survival plots were generated by the Kaplan Meier method. 
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Figure 10: Kaplan Meier plots for six mtDNA polymorphisms investigated in this study (disease free survival) 
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DFS time is defined as the time interval from the time of diagnosis to the date of last follow up or the date of recurrence or metastasis 
or death. Cumulative survival ref ers to the prop ortion of p atients who are alive at a particular point of time. Survival p lots were 
generated by Kaplan Meier method. 
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Table 12: Univariate analysis results for the six mtDNA polymorphisms and clinico-
pathological variables (overall survival) 
Number of 95%CI 
Variables n patients in p- HR 
each value Lower Upper 
category 
MitoT479C (C vs T) 530 (25 vs 505) 0.455 0.733 0.324 1.656 
MitoT491C (C vs T) 504 (27 vs 477) 0.625 1.172 0.619 2.221 
MitoT10035C (C vs T) 535 (35 vs 500) 0.923 0.97 0.527 1.785 
MitoA13781G (G vs A) 523 (34 vs 489) 0.74 0.897 0.474 1.699 
mtDNA 10398 (G vs A) 529 (86 vs 443) 0.605 0.897 0.595 1.353 
mtDNA 16189 (C vs T) 529 (66 vs 463) 0.803 0.943 0.592 1.502 
Sex (male vs female) 536 (329 vs 207) 0.012 1.493 1.092 2.042 
Histology (mucinous vs non- 536 (61 vs 475) 0.898 0.97 0.61 1.544 
mucinous) 
Location (rectum vs colon) 536 (180 vs 356) 0.193 1.22 0.905 1.645 
Stage <.001 
Stage (II vs I) 
536 (206 vs 98) 0.176 1.455 0.845 2.507 
Stage (III vs I) (179 vs 98) 0.004 2.199 1.289 3.751 
Stage (IV vs I) (53 vs 98) <.001 10.14 5.769 17.822 
Grade (poorly 
differentiated/undifferentiated 532 (38 vs 494) 0.673 0.877 0.476 1.614 
vs well/moderately 
differentiated) 
Vascular invasion(+ vs -) 497 (171 vs 326) <.001 1.724 1.274 2.333 
Lymphatic invasion(+ vs -) 494 (179 vs 315) 0.003 1.581 1.171 2.136 
Familial risk (high/moderate vs 536 (281 vs 255) 0.65 1.07 0.799 1.433 low) 
MSI-H status 514 (58 vs 456) <.001 0.233 0.103 0.527 (Yes vs No) 
BRAF mutations status ( + vs -) 485 (49 vs 436) 0.404 0.797 0.468 1.357 
Age 536 * 0.438 1.006 0.99 1.023 
(+):presence, (-): absence, Cl: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite 
Instability-High, vs: versus. Values that are balded are statistically significant (p value <0. 05). 
*Age is analyzed as a continuous variable. 
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Table 13: Univariate analysis results for six mtDNA polymorphisms and clinico-
pathological variables (disease free survival) 
Number of 95%CI 
Variables n patients in p- HR 
each value Lower Upper 
category 
MitoT479C (C vs T) 529 (25 vs 504) 0.923 0.968 0.496 1.889 
MitoT491C (C vs T) 503 (26 vs 477) 0.179 1.47 0.838 2.582 
MitoT1 0035C (C vs T) 534 (35 vs 499) 0.963 1.014 0.578 1.776 
MitoA13781G (G vs A) 522 (34 vs 488) 0.841 0.942 0.526 1.688 
mtDNA 10398 (G vs A) 528 (85 vs 443) 0.934 1.016 0.7 1.474 
mtDNA 16189 (C vs T) 528 (66 vs 462) 0.544 0.874 0.567 1.349 
Sex (male vs female) 535 (328 vs 207) 0.009 1.473 1.103 1.967 
Histology (mucinous vs non- 535 (61 vs 474) 0.785 0.941 0.611 1.452 
mucinous) 
Location (rectum vs colon) 535 (180 vs 355) 0.029 1.359 1.031 1.79 
Stage <.001 
Stage (II vs I) 
535 (206 vs 97) 0.244 1.327 0.825 2.133 Stage (III vs I) (179 vs 97) 0.002 2.121 1.332 3.378 
Stage (IV vs I) (53 vs 97) <.001 5.737 3.458 9.518 
Grade (poorly differentiated/ 
undifferentiated vs 531 (38 vs 493) 0.487 0.813 0.454 1.456 
well/moderately differentiated) 
Vascular invasion(+ vs -) 496 (171 vs 325) 0.001 1.644 1.241 2.177 
Lymphatic invasion(+ vs -) 493 (179 vs 314) 0.003 1.534 1.161 2.028 
Familial risk 535 (280 vs 255) 0.291 1.157 0.883 1.517 (high/moderate vs low) 
MSI-H status 513 (57 vs 456) 0.001 0.347 0.183 0.655 (Yes vs No) 
BRAF mutations status ( + vs -) 485 (49 vs 436) 0.66 0.899 0.56 1.444 
Age 535 * 0.9 1.001 0.986 1.016 
(+ ): presence, (-): absence, CI: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite 
Instability-High, vs: versus. Values that are balded are statistically significant (p value <0. 05) 
*age is analyzed as a continuous variable. 
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Other clinicopathological variables such as age, histology, grade, familial risk status, and 
BRAF-Val600Glu mutation status were not significantly associated with either OS or 
DFS, while certain other clinicopathological variables remained significant (Tables 12 
and 13). 
2.5.2) mtDNA copy number 
Characteristics of the mtDNA copy number change cohort 
The baseline characteristics of 276 patients investigated in this analysis (the 
mtDNA copy number analysis cohort) are summarised in Table 3. The median age was 
62.3 years and the median OS and DFS follow up times were 6.2 and 5.1 years, 
respectively. The clinico-pathological features of these 276 patients did not differ from 
those of the entire NFCCR cohort (Table 3). 
Distribution of the mtDNA copy number change 
The mtDNA copy number ratio was estimated for 274 patients. The distribution of 
the mtDNA copy number ratio for this patient cohort is illustrated in Figure 11. 
As shown in Figure 11, a wide range of mtDNA copy number ratio was detected 
in this patient cohort (i.e. 0.003-11.02). The majority of patients had a ratio between 0.5-
2.0 (n=172, 62.8%). A decrease of mtDNA copy number in tumour tissue was observed 
in 166 (60.6%) of the patients and increase in the mtDNA copy number was observed in 
108 (39.4%) ofthe patients. 
94 I Page 
"' Gl
"' ..u 
~ 
'"' Gl 
.ta 
E 
:s 
z 
Figure 11: Distribution ofthe relative mtDNA/nDNA ratio in tumour tissue when 
compared to non-tumour tissue 
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The histogram shows the distribution of the mtDNA copy number ratio in 274 colorectal cancer 
patients. Bars with mtDNA ratio less than I (i.e. the bars with asterisks) corresponds to patients 
with decreased mtDNA copy number in tumour tissue with respect to non-tumour tissues, 
whereas patients with ratio equal to or greater than one had increase in mtDNA copy number in 
tumour tissue with respect to non-tumour tissues. mtDNA ratios were rounded to three decimals 
for this analysis. 
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According to the univariate analysis the mtDNA copy number change was not 
associated with either OS (Table 14) or DFS (Table 15). Yet, there were other clinic-
pathological variables that were significant in both OS and DFS analysis. 
To see if there were differences in the baseline characteristics of patients with 
increased or decreased mtDNA copy number, a Chi-square analysis was also performed. 
As a result, no significant association between any of these variables and the mtDNA 
copy number change was detected (Table 16). 
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Table 14: Overall survival univariate analysis for the mtDNA copy number change and 
clinicopathological variables 
No of 95.0% CI for 
Variables compared n patients in p- HR HR 
each value 
category Lower Upper 
Sex (male vs female) 273 (158 vs 115) 0.055 1.412 0.993 2.009 
Histology (mucinous vs non- 273 (33 vs 240) 0.73 0.91 0.531 1.557 
mucinous) 
Location (rectum vs colon) 273 (92 vs 181) 0.376 0.85 0.594 1.217 
Stage 273 31 <0.001 
Stage (II vs I) (91 vs 31 ) 0.297 1.597 0.663 3.847 
Stage (III vs I) (101 vs 31) <0.001 3.065 1.314 7.15 
Stage (IV vs 1) (50 vs 31) <0.001 17.45 7.385 41.25 
Grade (poorly 
differentiated/undifferentiated vs 272 (31 vs 241) 0.019 1.796 1.103 2.926 
well/moderately differentiated) 
Vascular invasion ( + vs -) 247 (111 vs 136) <0.001 2.187 1.527 3.131 
Lymphatic invasion(+ vs -) 247 (113 vs 134) <0.001 1.937 1.355 2.77 
Familial risk (high/moderate vs low) 272 (132 vs 140) 0.973 1.006 0.715 1.415 
MSI status (MSI-H vs MSS/MSI-L) 271 (26 vs 245) 0.004 0.23 0.085 0.623 
BRAF status 600Va1Glu (+ vs -) 251 (35 vs 216) 0.195 1.374 0.85 2.22 
Age 273 * 0.025 1.023 1.003 1.043 
mtDNA copy number (increase vs 273 (108 vs 165) 0.389 1.163 0.825 1.64 decrease) 
(+) : presence, (-) :absence, CI: Confidence Interval, HR: Hazard Ratio, MSI-H · Microsatellite 
Instability-High, vs: versus. Values that are balded are statistically significant (p value <0. 05). * 
age was analyzed as a continuous variable. 
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Table 15: Disease free survival univariate analysis for the mtDNA copy number change 
and clinicopathological variables 
No of 95.0% CI for 
Variables compared patients in p- HR HR n 
each value 
category Lower Upper 
Sex (male vs female) 272 (157vs115) 0.046 1.41 1.007 1.964 
Histology (mucinous vs non- 272 (33 vs 239) 0.757 0.923 0.557 1.531 
mucinous) 
Location (rectum vs colon) 272 (92 vs 180) 0.969 0.993 0.709 1.393 
Stage 272 30 <0.001 
Stage (II vs I) (91 vs 30) 0.324 1.474 0.682 3.185 
Stage (III vs I) (101vs30) 0.006 2.85 1.36 5.985 
Stage (IV vs 1) (50 vs 30) <0.001 11 5.155 23.558 
Grade (poorly 
differentiated/undifferentiated vs 271 (3 1 vs 240) 0.029 1.69 1.055 2.716 
well/moderately differentiated) 
Vascular invasion(+ vs -) 246 (111 vs 135) <0.001 2.05 1.457 2.877 
Lymphatic invasion(+ vs -) 246 (113 vs 133) <0.001 1.88 1.34 2.644 
F arnilial risk (high/moderate vs 271 (131 vs 140) 0.567 1.099 0.795 1.52 low) 
MSI status (MSI-H vs MSS/MSI- 270 (25 vs 245) 0.014 0.39 0.181 0.826 L) 
BRAF status Val600Glu (+ vs -) 251 (35 vs 216) 0.049 1.56 1.003 2.421 
Age 272 * 0.103 1.015 0.997 1.034 
mtDNA copy number (increase vs 272 (108 vs 164) 0.389 1.1 54 0.833 1.601 decrease) 
(+): presence, (-) : absence, CI: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite 
Instability-High, vs: versus. Values that are balded are statistically significant (p value <0. 05 ) . * 
age was analyzed as a continuous variable. 
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Table 16: Differences in the clinicopathological features of patients with increased or 
decreased mtDNA copy number (in tumour tissue when compared to non-tumour tissue) 
Variables compared p-value 
Sex 0.352 
Histology 0.998 
Location 0.34 
Stage 0.075 
Grade 0.306 
Vascular invasion 0.935 
Lymphatic invasion 0.977 
Familial risk 0.754 
MSI status 0.074 
BRAF mutation status 0.148 
BRAF mutation status: presence or absence ofVal600Glu mutation status MSI: 
Microsatellite Instability. P-values are calculated by Chi square test. 
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2.6) Discussion 
Mitochondrial dysftmctions are implicated in cancer progression (113). Therefore, 
it can be hypothesized that genetic alterations in mtDNA (such as polymorphisms) can 
influence cancer progression and affect outcome. Despite this biological relevance, 
genetic alterations in mtDNA have not been investigated for their prognostic significance 
in colorectal cancer extensively. In this study, the genotypes obtained for the six mtDNA 
polymorphisms in 537 colorectal cancer patients were analyzed for their associations with 
patient prognosis. In addition, change in the mtDNA copy number in tumour tissue with 
respect to non-tumour tissue was investigated in relation to prognosis in 276 colorectal 
cancer patients. 
mtDNA SNPs and prognosis in colorectal cancer 
The results obtained in this study showed that none of the six mtDNA SNPs 
genotyped using the DNA samples extracted from blood cells was correlated with 
prognosis in colorectal cancer. 
Out of the six SNPs investigated in this study, the mtDNA 10398 (NG) SNP is a 
non-synonymous substitution (Thr114Ala) located in the ND3 gene (Figure 3), which 
encodes for one of the respiratory subunits of the oxidative phosphorylation pathway. 
This SNP has been reported in ftmctional studies to promote metastasis, increase the 
production of reactive oxygen species and promote resistance to apoptosis (130). 
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The second SNP, mtDNA 16189 (T/C), is located in the D-loop region (Figure 3), 
which is the non-coding regulatory region of mtDNA (125). It has been shown that the 
mtDNA 16189 (T/C) may result in a homopolymeric C-tract and this might result in 
replication slippage, which in turn results in heteroplasmic length variation in the number 
of cytosine residues (126). This heteroplasmic length variation has also been 
hypothesized to affect the mtDNA replication and hence the mtDNA copy number (1 27). 
In the case of the remaining four mtDNA SNPs included in this study, two SNPs 
MitoT479C and MitoT491C are located in the D-loop, MitoA13781G is a non-
synonymous substitution (Ile482Val) located in the ND5 gene, and the MitoT10035C is 
located in a tRNA gene specific for glycine codon (Figure 3). These four SNPs have been 
previously investigated for their associations with all cause and cancer specific mortalities 
in a Scottish cohort of colorectal cancer patients (142). Similar to the findings obtained in 
this study, these authors did not find these SNPs to be associated with the patient 
outcomes (142). Although these SNPs have been investigated in relation to prognosis in 
colorectal cancer before and were not associated with outcome, these SNPs were 
investigated in this study as there may be cohort specific differences such as event rate, 
length of follow up. This was the main rationale in testing these four SNPs in the current 
study 
One limitation of the present study was the significant difference between the 
entire NFCCR cohort and the NFCCR SNP genotyping cohort in terms of baseline 
clinicopathological features, such as stage (p<0.001) and vascular (p=0.013) and 
lymphatic invasions (p=0.034) as only patients with available DNA samples extracted 
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from blood were included in this study (Table 3). Specifically, there were a lower 
proportion of stage IV patients (9.9% versus 20.8%) and a higher proportion of patients 
with tumours characterized by the presence of vascular (31.8% versus 38.3%) and 
lymphatic invasion (33.3% versus 38.7%) in the NFCCR SNP genotyping cohort 
compared to the entire NFCCR cohort. Because of these clinical differences, the NFCCR 
SNP genotyping cohort was not representative of the NFCCR cohort (a population-based 
patient cohort). This study also did not include all known polymorphisms on the mtDNA. 
On the other hand, this study is the first study that investigated the association of the 
mtDNA 10398 (A/G) and the mtDNA 16189 (T/C) SNPs with prognosis in colorectal 
cancer patients. The sample size was quite large (n=537), though it is possible that the 
sample size was not large enough to detect the possible prognostic effects of the mtDNA 
polymorphisms analyzed in this study. 
mtDNA copy number change and prognosis in colorectal cancer 
Increase or decrease in the mtDNA copy number in tumour tissue with respect to 
the non-tumour tissue has been detected in several cancer types before. For example, 
increase in mtDNA copies in tumour tissues have been observed in renal oncocytomas 
(143,144), salivary gland oncocytomas (144), head and neck cancers (145), papillary 
thyroid carcinomas (146), endometrial cancer (14 7), ovarian cancer (148) and prostate 
cancer (149). On the other hand, decrease in the mtDNA copy numbers has also been 
observed in renal carcinomas (143,144,150,151 ,151), hepatocellular carcinomas (151-
153), gastric cancer (154) and breast cancer (146,155,156). In colorectal cancer, increase 
in mtDNA copy number was observed in 40% of the patients in one study (122) and 39% 
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of the patients in another study (118). It should also be noted that there is variability 
between studies in detecting and defining the mtDNA copy number change and hence the 
categorization of colorectal cancer patients based on the mtDNA copy number status also 
differs among these studies. Therefore, our results cannot be compared directly to 
previously published results. In our study, increase in the mtDNA copy number in tumour 
tissues was observed in 39.4% colorectal cancer patients with respect to non-tumour 
DNA. 
Previously, change in mtDNA copy number and its association with patient 
prognosis has also been investigated in different cancer types. For example, decrease in 
the mtDNA copy number was associated with poor patient prognosis in breast cancer 
(157) and increase in the mtDNA copy number was associated with higher grade tumours 
in ovarian cancer (148). 
There are a limited number of reports, often with conflicting results regarding the 
prognostic significance of the mtDNA copy number change in colorectal cancer. For 
example, Chen and his co-authors investigated the mtDNA copy number change (in 
tumour versus non tumour cells) in 1 04 colo rectal cancer patients from China and found 
that the increased mtDNA copy number in patients (also harboring a 4977 bp mtDNA 
deletion) was associated with advanced stage and high risk of metastasis in colorectal 
cancer patients (112). On the other hand, Lin and his co-authors investigated 153 
colorectal cancer patients from Taiwan and found that decreased mtDNA copy number 
(in tumour versus non tumour cells) was associated with advanced stage and poor 
differentiation (118). In the same study, it has also been reported that the increase in the 
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mtDNA copy number was associated with longer OS. Similarly, Chang and his co-
authors investigated the mtDNA copy number change in 194 colorectal cancer patients 
from Taiwan and found that the decrease in the mtDNA copy number change in tumour 
tissues with respect to normal tissues was associated with worse outcome (158). 
In this thesis project, no association between the mtDNA copy number change and 
prognosis in colorectal cancer (in either the OS or the DFS analysis) was detected (Tables 
14 and 15). Likewise, no association between mtDNA copy number change and patient 
clinicopathological features, including the disease stage, was detected (Table 16). 
Therefore, the results obtained in this project are different from the results published 
previously (112,118,158), which may be attributed to reported associations being false-
positive associations, different definitions and categorizations of mtDNA copy number 
change in different studies, or the ethnic or other differences between these cohorts and 
the cohort investigated in this study. In addition, positive results are more preferred to be 
published over negative results and hence due to this selective reporting, there is a 
possibility that other studies similar to the finding reported in this study might not have 
been published. 
To our knowledge, this thesis study is the first to be conducted on Caucasian 
colorectal cancer patients looking at the association of mtDNA copy number change with 
prognosis. In addition, the cohort investigated in this study is larger than other studies 
described above (112,118,158), and so likely to produce more reliable results. 
Furthermore, there were no significant differences between the cohort investigated for the 
mtDNA copy number change in this study and the entire NFCCR cohort (Table 3). Thus, 
1041 Page 
patients analyzed in the mtDNA copy number analysis in this thesis represent the entire 
NFCCR cohort, which is a population based cohort. 
In conclusion, although it is possible that associations of these genetic variations 
with prognosis may be detected in larger patient cohorts, the results presented in this 
thesis do not support a role for mtDNA SNPs (mtDNA 10398 (A/G), mtDNA 16189 
(TIC), MitoT479C, MitoT491C, MitoA13781G and MitoT10035C) and the mtDNA copy 
number change in prognosis of colorectal cancer patients. 
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CHAPTER 3: POLYMORPHISMS IN THE HYPOXIA 
PATHWAY GENES AND THEIR RELATION TO 
PROGNOSIS IN COLORECTAL CANCER PATIENTS 
3.1) Introduction to hypoxia and its role in cancer 
Hypoxia 
The normal oxygen (02) concentration fluctuates in tissues between 2-9%, which 
is called normoxic condition. Hypoxia (<2% oxygen concentration) frequently occurs in 
solid tumours due to restricted blood flow. Subsequent cellular response to hypoxia is 
facilitated by Hypoxia Inducible Factors (HIFs). 
Hypoxia Inducible Factors (HIFs) 
HIFs are heterodimeric transcription factors consisting of a and ~ subunits (159). 
In mammals, a and ~ subunits dimerize together to form a transcriptionally active HIF. 
HIFIA, HIFIB, HIF2A, HIF2B, and HIF3A genes codes for these subunits. 
Transcriptional regulation by HIFs is accomplished by binding of HIFs to the hypoxia 
responsive elements (HREs) located near the promoter region of target genes. These 
target genes include genes that control functions such as angiogenesis, metastasis, oxygen 
and glucose regulation, cell motility, glycolysis and cell adhesion. Hypoxia-regulated 
genes are thus implicated in cancer progression and include genes such as MIF (160,161), 
CXCLJ2 (162,163) and LOX(164). 
106 I Page 
Hypoxia and its role in cancer 
Hypoxic conditions promote cancer progression and invasiveness in solid 
tumours. When human embryo cells grown in vitro under both extreme hypoxia and 
normoxic conditions were exposed to radiation, cells grown under hypoxic conditions 
show a 2.5 fold increase in colony forming ability compared to cells grown under 
normoxic conditions ( 165). It has also been shown that hypoxia confers stem cell like 
properties to cancer cells and also increases the colony forming ability (1). Since 
embryonic cells share a similarity with cancer cells in terms of rapid proliferation, cancer 
cells exposed to hypoxic conditions may have an aggressive tumour phenotype and have 
pronounced invasiveness (165). In addition, HIFs are over-expressed in various types of 
cancers and are also implicated in metastasis and tumour invasion (166). Hypoxic 
conditions have also been reported to increase the metastatic potential of tumour cells 
(167) and to stimulate the production of stress proteins, which in turn have been reported 
to be responsible for abnormal cell growth and metabolism (168) and promote tumour 
progression through angiogenesis (169). These findings suggest an inherent relation 
between hypoxia and cancer progression. 
It has also been shown that solid tumours characterised by hypoxic conditions 
show resistance to anti-cancer therapies. In one study, the damage caused by exposure to 
radiation under well-oxygenated conditions was found to be three times greater than the 
damage caused by radiation under hypoxic conditions (170, 171 ). Under normoxic 
conditions when cells are irradiated, free radicals are produced and these free radicals are 
responsible for causing cellular or DNA damage. But under hypoxic conditions, due to 
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low oxygen concentrations, an insufficient level of free radicals is produced and this may 
confer the hypoxic cells resistance to radiation (170,171). In addition, some 
chemotherapeutic agents require sufficient oxygen concentrations for their cytotoxic 
activity and therefore cells that are characterized by hypoxic conditions are found to be 
resistant to certain commonly used chemotherapeutic drugs (172). In summary, hypoxia 
is one of the factors that drives the selection of metastatic and treatment-resistant tumour 
phenotypes and maybe a marker for poor survival in cancer patients (173). 
3.2) Role of hypoxia pathway genes in cancer progression 
HIFJA 
There are various reports investigating the potential role of HIFIA in facilitating 
tumour progression under hypoxic conditions (174-177), albeit with conflicting results. In 
some studies it has been reported that increased HIFIA expression is correlated with 
increased metastatic capacity, tumour growth, invasion and survival, and angiogenesis 
(174-177). On the other hand, other studies reported that HIFIA expression or its 
increased expression was correlated with tumour inhibition by either inducing 
programmed cell death or cell cycle arrest (178-181 ). Therefore, the functional 
significance of HIF I A expression in relation to clinical outcome in cancer is currently not 
well understood. 
The role of HIFIA expression in clinical outcome in colorectal cancer is also not 
well established. For example, increased expression of HIFIA has been shown to be 
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correlated with poor prognosis, vascular invasion and TNM stage in rectal cancer patients 
(182). In another study, HIF1A over expression was found to be significantly associated 
with worse prognosis after adjusting for other variables such as MSI, Line 1 
hypomethylation, BRAF and PIK3CA somatic mutations, and CpG island methylator 
phenotype (183). Some other studies also have reported HIF1A gene expression as an 
independent prognostic marker in colorectal cancer (184, 185). However, these findings 
were not replicated in other studies (186,187). 
So far there have been only a few studies that tested the association of genetic 
polymorphisms in HIF1A and their relation to outcome. Szkandera and his co-authors 
investigated the HIF 1 A C 1772T (rs 11549465) and G 1790A (rs 11549467) polymorphisms 
in a Caucasian colorectal cancer cohort (n=336) and found no association between the 
polymorphisms and patient prognosis (1 05). Previously, individuals carrying the variant 
allele for the HIF1A C1772T and HIF1A G1790A polymorphisms were shown to have 
higher transcriptional activity of HIF 1 A gene when compared to persons carrying the wild 
type alleles (188). Lee and co-authors investigated the same polymorphisms in relation to 
outcome in 445 Korean colorectal cancer patients and obtained similar results; these two 
SNPs were not associated with outcome (189). However, in another study, the C1772T 
polymorphism was found to be significantly associated with increased progression-free 
survival (PFS) in a univariate analysis (190). 
ARNT (HIFJB) 
Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT), otherwise known as 
HIF1B, is a regulatory subunit of HIFl (107). It is a basic-Helix-Loop-Helix (bHLH) 
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protein that controls expression of several genes by forming heterodimeric transcriptional 
factors with other bHLH proteins (191). Unlike HIF1A, which is degraded by ubiquitin 
mediated protein degradation under hypoxic conditions, HIF1B is expressed and is active 
under both hypoxic and normoxic conditions (192,193). Dimerization of this subunit with 
the a subunit of HIF1 (HIF1A) or the a subunit of HIF2 (HIF2A) is necessary for the 
regulation of genes involved in the hypoxia response pathway (159, 194, 195). 
There are several reports about the role of HIF I B in tumourigenesis. In a study, 
HIFIB down-regulation (mediated by estrogen receptor beta or IFN-8) resulted in HIFl 
repression through disrupting the formation of HIF1A-HIF1B complex (196,197). It has 
also been reported that HIF 1 B recruits the co-activators necessary for HIF transcriptional 
complex formation and HIF transactivation (198, 199). In addition, epidermal growth 
factor (EGF) activates the HIF1B signalling pathway, which in tum up-regulates cyclo-
oxygenase gene expression. That, in tum, has been implicated in squamous cell 
carcinoma formation (200). In another study, blocking HIF1B under normoxic conditions 
has been reported to inhibit P21 (WAF 1 /CIP 1) (20 1 ), which is a tumour suppressor 
protein (202). It has also been reported that HIF1B plays a significant role in tumour 
growth and progression (203). These findings illustrate the functional significance of 
HIF I B in cancer. 
So far, there is only one study that has investigated a polymorphism (rs2228099 
G>C) in the HIFIB gene in relation to outcome in colorectal cancer. This polymorphism 
was investigated in relation to OS and PFS in a small colorectal cancer cohort with mixed 
ethnicities, but no association was observed (190). Thus, the role of HIF I B 
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polymorphisms and their relation to prognosis in colorectal cancer remains unclear due to 
insufficient data. 
EPASl (HIF2A) 
EPASl (HIF2A) is a PAS (Period/ARNT/Single-minded) domain protein and one 
of the heterodimeric subunits of the HIF2 subclass of the HIF protein family. There are 
conflicting reports about HIF2A and its relation to cancer progression and clinical 
outcome. A number of knock-out and expression studies showed that HIF2A expression 
favours cancer progression (204-206), but other reports showed that HIF2A expression 
favours tumour inhibition (207-209). There are also conflicting reports on the role of 
HIF2A on prognosis. For example, in rectal cancer patients, HIF2A was reported to be 
expressed constitutively, but its expression was not correlated with patient survival (182). 
Similarly, in a study performed on 731 colorectal cancer patients, HIF2A expression was 
not found to be significantly associated with the patient outcome (183). On the other 
hand, in another study investigating colorectal cancer patients, HIF2A expression was 
found to be statistically significantly associated with poor prognosis (21 0). 
To our knowledge, previously SNPs in this gene have not been investigated in 
relation to prognosis in colorectal cancer patients. 
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ARNT2 (HIF2B) 
Similar to HIF1B, HIF2B belongs to the basic helix-loop-helix (bHLH) PAS 
domain protein family. It dimerizes with HIF2A and results in the formation of 
transcriptionally active HIF2. Similar to HIF1B, HIF2B has also been implicated in 
xenobiotic metabolism (211 ). There is one functional study investigating the relation 
between HIF2B and cancer. In this study, it was reported that HIF2B plays a role in 
tumour angiogenesis and hypoxia response in neurons (212). However, to date, there are 
no functional or prognostic studies investigating the relationship between HIF2B and 
colorectal cancer. 
HIF3A 
HIF3A encodes for the alpha heterodimeric subunit ofHIF3. It has been shown in 
functional studies performed in embryonic stem cells that HIF3A up-regulates the HIF2A 
expression and blocks the expression of HJFJA. Therefore, it is evident that HIF3A act as 
a control unit in regulating the hypoxia-response in cells. To our knowledge, as of 
October 2012, there were no published studies investigating the prognostic significance of 
HIF3A SNPs in colorectal cancer patients. 
MIF 
Macrophage migration inhibitory factor (MJF) gene encodes for aT-cell derived 
polypeptide, which modifies the mobility of the macrophages in response to biological 
and physiological factors (213,214). It is secreted from the anterior pituitary and its main 
function is to mitigate the immunosuppressive effects induced by glucocorticoids 
(215,216). In the mid-60s, MIF was reported to have macrophage activation functions 
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such as adherence, phagocytosis, tumouricidial activity, and phage activation (217-220). 
But recently, its possible role in cell proliferation, survival, angiogenesis and response to 
hypoxia has started to emerge. For example, in a study performed on colorectal cancer 
cell lines that looked at the effect of hypoxia on MIF function, it was found that MIF is 
influential in triggering apoptosis of cells that are exposed to hypoxic conditions (221 ). 
The same study also indicated that MIF had a direct effect on the survival of the 
colorectal cancer cell lines under hypoxic conditions (221 ). Therefore, the authors 
suggested that MIF expression may be used as a marker for anti-angiogenic therapies or 
therapies that rely on hypoxia-induced apoptosis (221 ). 
MIF is one of the hypoxia regulated genes. A HRE is located in the 5' end of MIF 
gene and MIF gene is over-expressed under hypoxic conditions (160,222). HIF1A 
activation of MIF results in premature cell senescence (223) and MIF is needed for 
stabilization of HIFlA under hypoxic conditions (224). It also regulates the VEGF 
expression under both hypoxic (224) and normoxic conditions, and mediates inhibition of 
TP53 tumour suppressor gene at chronic inflammatory sites (225,226). It has also been 
shown that MIF is an important factor required for endothelial cell proliferation initiated 
by tumour growth and this has a profound effect on the tumour size. For example, chronic 
inflammation favours tumour growth (227). Therefore, it has been hypothesized that there 
is a link between the MIF expression, chronic inflammation condition and cancer 
development (228). Expression profile studies have also revealed that MIF is over-
expressed in metastatic tumours when compared to normal tissue (229) and it is 
associated with aggressive tumours and tumours that have a higher potential to 
113 1Page 
metastasize (230-232). Additionally, other studies showed that MIF is a pro-angiogenic 
factor and suppressing MIF expression using a MIF inhibitory antibody leads to 
suppressed tumour growth and suppressed tumour associated angiogenesis (233). MIF 
expression also activates other pathways and induces the production of proteins that 
promote tumour growth, thereby proving its role as a tumour promoter (161 ,234 ). In 
summary, literature findings indicate that the MIF expression is regulated by hypoxia and 
it may promote tumour progression. 
There have been conflicting reports about the MIF gene and its relation to patient 
prognosis in cancer. Both increased (230,235,236) and decreased (23 1,237) expression of 
MIF gene have been reported to be associated with poor outcome in various different 
types of cancers. In colorectal cancer, one study found that MIF was expressed in higher 
amounts in colorectal cancer when compared to malignant melanoma (238). 
Currently, there is no study published investigating the relationship between SNPs 
in the MIF gene and prognosis in colorectal cancer. Therefore, additional studies are 
needed to elucidate the genetic variations in this gene and their potential role in 
prognosis. 
CXCLJ2 
CXCL12 is a 8 kilo Dalton CXC chemokine family member (239). CXCL12 is 
primarily involved in immunological processes, but its various pleiotropic effects have 
also been reported, such as chemotaxis, hematopoiesis and neo-vascularization (240-242). 
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CXCL12 has two HIFl binding sites and its expression is upregulated under hypoxic 
conditions (162). 
Although many pleiotropic effects that have been documented, CXCL12' s main 
function is to trigger ankiosis, which is a form of programmed cell death caused by the 
loss of anchorage of cells to the extracellular matrix. Most of the metastatic cancers are 
characterized by presence of ankiosis. There have also been reports that CXCL12 reduces 
the capacity of cells to metastasize by activating ankiosis. In a study performed on 
mammary carcinoma cells, epigenetic silencing of CXCL12 resulted in increased 
metastatic capacity (243). Also, in a study performed on colorectal carcinoma cells, 
CXCL12 expression has been found to induce apoptosis (244). In addition, high 
expression of CXCL12 was found to be associated with poor prognosis when compared to 
its low expression; and patients with high CXCL12 expression and high grade tumours 
were reported to have the worst outcome in colorectal cancer (245). It has also been 
shown that CXCL12 expression is correlated with tumour cell proliferation and migration 
in colorectal cancer (246). These finding suggest a role of CXCL12 in tumour 
progression. 
Contrary to these reports, down-regulation of CXCLJ2 expression by 
hypermethylation has also been shown to promote metastasis of colorectal cancer 
carcinomas (247). A similar finding was reported in another study where the authors have 
showed that CXCLJ2 prevents cells from metastasizing and thus, maintaining CXCL12 
expression may reduce tumour progression in colorectal cancer (244). 
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Six SNPs in CXCL12 have been investigated so far in relation to outcome in 
colorectal cancer patients. In one study performed in a Caucasian cohort (n=328), a G/ A 
polymorphism in the 3'-UTR of CXCLJ2 (rs1801157) was not found to be associated with 
DFS and other prognostic variables such as stage, sex, age of onset, histological grade or 
tumour size (248). In another study performed with a Asian cohort (n=424), a CXCL12 
SNP (C14478T; rs1065297) was not found to be associated with the lymph node 
metastasis (1 06). In the same study, the authors also reported that the A allele of another 
SNP (G80 1 A, rs 180 1157) was correlated with higher CXCL12 mRNA levels and the GG 
genotype was found to be associated with better DFS in patients without the lymph node 
metastasis, but not in patient with the lymph node metastasis (1 06). In the same study, 
four other CXCLJ2 SNPs, namely G8906A (rs2297630), G6201A (rs266085) G5887 A 
(rs2839693) and G5753A (rs754618) were not found to be associated with DFS (106). 
LOX 
The Lysyl oxidase gene (LOX) is located on 5q23.1 and encodes the lysyl oxidase 
enzyme which is a copper dependent amine-oxidase (249). It is responsible for the 
deamination of peptidyllysine residues to form a-aminoadipic o-semialdehydes. These a-
aminoadipic o-semialdehydes undergo a condensation reaction with other aldehydes or 
other amino acids resulting in a cross-linking between collagen and elastin. This cross-
linking plays a crucial role in maintaining the structural integrity of the connective tissues 
(164,250). LOX has a HRE in its promoter region and interaction of this HRE with HIF1 
results in increased expression of the LOX gene (251 ). In a microarray differential 
expression analysis, increased expression of LOX has been observed in tumour cells 
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under hypoxic conditions, (251 ); suggesting that LOX expression is regulated by oxygen 
concentration. 
The LOX gene has roles in several processes such as tumourigenesis, chemotaxis 
and cell aging. In one study blocking the expression of the LOX showed less cell 
proliferation in agar medium, probably because of the inability of cells to communicate 
with each other resulting in inhibition of tumour formation (252,253). Loss of LOX 
function during tumour development as a result of somatic mutations has been shown to 
play a role in colon cancer pathogenesis. Thus, LOX gene may have a tumour suppressor 
role (254). 
A few studies have examined the over expresswn of the LOX in relation to 
prognosis m colorectal cancer. For example, increased expression of LOX has been 
observed in colon cancer cells (255). Increased expression of the LOX has also been 
reported in other tumours (256-258). To our knowledge, SNPs in LOX have not been 
investigated in relation to prognosis in colorectal cancer. 
3.3) Rationale, hypothesis and objectives specific to Chapter 3 
Hypoxic conditions promote angiogenesis, resistance to conventional anti-cancer 
therapy, aggressive tumour phenotype and increased metastatic potential in solid tumours. 
Therefore, it was hypothesized that polymorphisms in hypoxia pathway genes may be 
associated with outcome of colorectal cancer patients. 
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1. The main objective of this project is to test the associations of genetic 
variants in the hypoxia pathway genes with outcome in colorectal cancer 
patients. 
3.4) Contributions and credits 
Asan M. S. Haja Mohideen: organized and coded the genotype data prior to statistical 
analysis for the polymorphisms in phase I of this project; performed the statistical 
analyses for phase I and phase II polymorphisms; and interpreted the results. 
Dr. Sevtap Savas: coded the pilot study and the NFCCR SNP genotyping cohort 
clinicopathological and prognostic data; genotyped the HIF I B-rs 1084 7 using the 
TaqMan® SNP genotyping method; provided the Table 19; provided the baseline table 
for the pilot study samples (Table 17); constructed the LD maps; selected the tag SNPs in 
phases I and II and coded the SNP genotypes in phase II for statistical analysis. 
Jessica Squires: Genotyped 13 polymorphisms in phase I using the TaqMan® SNP 
genotyping method and compiled their genotype data. 
Dr. Angela Hyde: Provided the clinicopathological and prognostic data for the pilot 
study samples (phase I). 
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Dr. Roger Green and Dr. Patrick Parfey: Provided the clinicopathological and 
prognostic data for the NFCCR cohort; provided the DNA samples of pilot study 
samples; provided the genotype data of the patient cohort in phase II. 
3.5) Materials and methods 
Ethics approval for this project was obtained from HIC (HIC #: 11.1 02). 
3.5.1) Project phases and genes and polymorphisms studied 
In this project (hypoxia pathway SNPs project) a number of genes and their 
genetic variations were investigated in relation to prognosis in two separate colorectal 
cancer patient cohorts in two project phases. A summary of these phases are shown in 
Figure 12. 
Among the several genes involved in the hypoxia pathway, a number of candidate 
genes were prioritized in this study based on literature evidence showing their biological 
roles under hypoxic conditions or in regulating the response to hypoxic conditions 
(Section 3.2). Specifically, this project investigated five HIP-coding genes (HIFIA , 
HIFIB, HIF2A , HIF2B, and HIF3A) and three biologically well-characterized genes 
regulated by HIFs (CXCL12, MIF, and LOX). 
In order to avoid investigation of highly correlated SNPs in the same analysis, the 
genotype data for polymorphisms in selected genes was extracted from the HapMap 
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database (HapMap Data Rel24/Phase II Nov08, on NCBI B36 assembly, dbSNP B126) 
for Caucasian samples (259). SNPs with a MAF > 10% were used to calculate the 
correlation coefficients (r2; minimum 0.8 for highly correlated SNPs) between SNPs and 
to select tagging SNPs (tagSNPs) using the pair wise tagger function in the Haploview 
program (ver 4.2) (260). l values were used to remove the highly correlated SNPs from 
analysis to reduce data redundancy. 
Overall, in phase I of this study, 49 SNPs in six prioritized genes (HJFJA, HIFJB, 
HIF2A, LOX, MIF and CXCLJ2) were investigated in 272 colo rectal cancer patients (a 
patient cohort called the pilot project study cohort (Section 3.5.2)). In phase II of this 
project, 77 SNPs from five genes (HIFJA, HIFJB, HIF2A, LOX and CXCLJ2) included in 
phase I and two additional genes (HIF2B and HIF3A) were investigated in 536 colorectal 
cancer patients (the NFCCR SNP genotyping cohort; Section 2.4.3). 
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Figure 12: Flowchart of the hypoxia pathway project: phase I and phase II 
Phase I 
1 
49 SNPs from six hypoxia 
genes(~lA,~lB, 
HIF2A, LOX, MIF and 
CXCL11) 
14 SNPs genotyped by 
TaqMan® genotyping a ssay 
35 SNPs genotyped by 
Sequenom Mass® array 
n= 272, phase-lcohort 
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3.5.2) Patient cohorts 
This project involves investigation of two separate colorectal cancer patient 
cohorts from NL. 
Patient cohort studied in phase I (the pilot project study samples) 
In the first phase of this project, we have analyzed a colorectal cancer cohort, 
which is termed "the pilot project study cohort", by our team. These patients (n=280) 
were all from the A val on Peninsula in Newfoundland, and were diagnosed with primary 
colo rectal cancer during 1997-1998. These patients were recruited based on the following 
criteria (Dr. Angela Hyde, personal communication): 
1) Patients diagnosed with carcinoma in the polyp were included provided that 
there was invasion of carcinoma into the stalk. 
2) Patients with primary carcinoma of the colon or rectum were included. 
3) Patients were included irrespective of their age at diagnosis. 
4) Patients with carcinoma in situ, mucosal carcinoma, polyps without invasive 
carcinoma, carcinoid tumours and tumours arising due to F AP were excluded. 
The baseline characteristics of patients included in the pilot project study are 
shown in Table 17. DNA samples from 272 patients were available for the genotype 
analysis. 
Clinicopathological and prognostic data for this cohort were collected using the 
medical records by Dr. Angela Hyde. The last date of patient follow up was July 2009. 
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Table 17: Baseline and prognostic characteristics of the pilot project study samples 
(phase I). 
Variables n o;o 
Sex 
Male 150 53.6 
Female 130 46.4 
Median age at diagnosis 68.42 years range (25.29-91.61 ) 
Grade 
poorly differentiated/undifferentiated 42 15 
well/moderately differentiated 234 83.6 
Unknown 4 1.4 
Histology 
Mucinous 43 15.4 
non-mucmous 237 84.6 
Location 
Rectum 57 20.4 
Colon 223 79.6 
Lymphatic invasion of tumor 
Lymphatic invasion(+) 110 39.3 
Lymphatic invasion (-) 70 25 
Unknown 100 35.7 
Stage 
I 54 19.3 
II 94 33.6 
III 76 27.1 
IV 47 16.8 
Unknown 9 3.2 
MSI-H status 
Yes 34 12.1 
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No 
Dead 
Alive 
Unknown 
246 
Prognostic and follow up information 
OS status at the time of last follow up 
172 
108 
0 
87.9 
61.4 
38.6 
0 
Median OS and DSS (follow up) time 5.31 years range (0-12.52 years) 
DFS status at the time of last follow up 
recurrence/metastasis/death(+) 184 65.7 
recurrence/metastasis/death(-) 96 34.3 
Unknown 0 0 
DFS (follow up) time 3.37 years range (0-12.52 years) 
DSS status at the time of last follow up 
death from colorectal cancer 113 40.4 
death from other causes/alive 167 59.6 
Unknown 0 0 
(+):presence, (-) : absence, DFS: Disease Free Survival, DSS: Disease Specific Survival, MSI-H: 
Microsatellite Instability-High, MSI-L: Microsatellite instability-Low, MSS: Microsatellite Stable, 
n: number, OS: Overall Survival. 
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Patient cohort studied in phase II (the NFCCR SNP genotyping cohort) 
The patient cohort investigated in phase II of the hypoxia project is almost 
identical to the NFCCR SNP genotyping cohort described in Section 2.4.3 (Table 3), 
except for the fact that there was one fewer patient in the cohort investigated in phase II 
(total n=536). 
3.5.3) Genotyping of DNA samples extracted from blood 
Phase I 
In phase I, 35 SNPs were genotyped using the Sequenom MassArray® technique 
at an outsourced facility (Analytical Genetics Technology Centre, Toronto, Canada) and 
14 other SNPs were genotyped using the TaqMan® SNP genotyping technique. The 
TaqMan® SNP genotyping methodology is described in Section 2.6.1. (the reaction 
conditions were the same except for the cycle number which was 40 in the case of these 
SNPs) and the assay IDs are shown in Appendix 5. Genotyping reactions were repeated 
two additional times for DNA samples that failed the TaqMan® SNP genotyping 
reactions in the first attempt. Overall, 49 of 53 selected SNPs were successfully 
genotyped and were included in phase I of this study (Table 18). Further information on 
the 53 polymorphisms is shown in Appendix 6. 
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Table 18: List of SNPs included in phase I. 
Genotyping *Concordance *Duplication Missing Missing Missing MAF **Deviation SNP technique rate(%) rate(%) genotype genotype data <10% fromHWE (n) (%) >15% 
LOX rs2956540 MassArray 100 5.2 9 3.21 
LOX rs2288393 MassArray 100 5.2 9 3.21 
LOX rs 1 0040971 MassArray 100 5.2 8 2.86 yes 
LOXrs10519694 MassArray 100 5.2 8 2.86 
HIFIA rs2301106 MassArray 100 5.2 9 3.21 
HIFIA rs2301111 MassArray 100 5.2 8 2.86 
HIFIA rs2301113 MassArray 100 5.2 8 2.86 
HJFIA rs11158358 MassArray 100 5.2 8 2.86 
HIF I B rs2228099 MassArray 100 5.2 8 2.86 
HIFJB rs3738483 MassArray 100 5.2 8 2.86 yes 
HIFIB rs11204737 MassArray 100 5.2 9 3.21 
HIFIB rs10847 TaqMan® 100 10.6 19 6.79 yes 
CXCLI2 rs2236534 MassArray 100 5.2 9 3.21 yes 
CXCL12 rs2839688 MassArray 100 5.2 16 5.71 
CXCL12 rs2236533 TaqMan® 100 7.6 8 2.86 yes 
CXCL12 rs11592974 TaqMan® 100 37.83 8 2.86 yes 
MIF rs2096525 MassArray 100 5.2 17 6.07 
HIF2A rs2121266 TaqMan® 100 8.76 29 10.36 
HIF2A rs2346175 TaqMan® 100 12.97 65 23.21 yes 
HIF2A rs3768730 TaqMan® 100 9.31 33 11.79 
HIF2A rs4952818 TaqMan® 100 8.8 30 10.71 
HIF2A rs4953340 TaqMan® 100 12.9 32 11.43 
HIF2A rs6753127 TaqMan® 100 8.33 28 10 yes 
HIF2A rs7583558 TaqMan® 100 11.98 38 13.57 
HIF2A rs9679290 TaqMan® 100 6.35 28 10 
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HIF2A rs9973653 TaqMan® 100 13.22 38 13.57 yes 
HIF2A rs10178633 TaqMan® 100 12.4 40 14.29 
HIF2A rs11687512 TaqMan® 100 11.6 30 10.71 yes 
HIF2A rs 1 0199201 MassArray 100 5.2 30 10.71 
HIF2A rs11125070 MassArray 100 5.2 33 11.79 
HIF2A rs12614710 MassArray 100 5.2 32 11.43 
HIF2A rs13019414 MassArray 100 5.2 29 10.36 
HIF2A rs13412887 MassArray 100 5.2 31 11.07 
HIF2A rs1374748 MassArray 100 5.2 30 10.71 
HIF2A rs1562453 MassArray 100 5.2 32 11.43 
HIF2A rs 1868084 MassArray 100 5.2 31 11.07 
HIF2A rs1868087 MassArray 100 5.2 30 10.71 
HIF2A rs 1992846 MassArray 100 5.2 31 11.07 
HIF2A rs2034327 MassArray 100 5.2 37 13.21 
HIF2A rs2044456 MassArray 100 5.2 41 14.64 
HIF2A rs2346176 MassArray 100 5.2 29 10.36 
HIF2A rs3768728 MassArray 100 5.2 29 10.36 
HIF2A rs4145836 MassArray 100 5.2 29 10.36 yes 
HIF2A rs4953344 MassArray 100 5.2 32 11.43 
HIF2A rs4953349 MassArray 100 5.2 35 12.5 
HIF2A rs4953353 MassArray 100 5.2 29 10.36 
HIF2A rs6706003 MassArray 100 5.2 30 10.71 
HIF2A rs6712143 MassArray 100 5.2 29 10.36 
HIF2A rs7583392 MassArray 100 5.2 29 10.36 
SNPs successfully genotyped, the genotyping technique applied, duplication and concordance rates, missing genotype iriformation, minor 
allele .frequencies, and Hardy-Weinberg equilibrium calculations(**See Section 3.7 and *See Section 2.7 )in phase I of this project. 
HWE: Hardy Weinberg Equilibrium, MAF: Minor allele frequency. 
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Phase II 
While phase I was in progress, NFCCR obtained the genotypes of a large number 
of SNPs (> 1 million) using the Illumina Human Omni 1-Quad Bead Chip genotyping 
platform at an outsourced genomics facility (Centrillion Genomic Services, USA) for 
NFCCR patients. Using this data, in phase II we aimed to have a more comprehensive 
analysis of the key genes functioning in the hypoxia pathway. Thus, in addition to the 
genes in phase I, the genotypes for genetic variations in two additional HIP -coding genes, 
namely HIF2B and HIF3A were also included. TagSNP and r2 values based on HapMap 
Caucasian samples were used to select the SNPs in HIF2B and HIF3A as well. As a 
result, genotypes for a total of 125 SNPs were available in the genomewide SNP 
genotyping data. Among these SNPs, 44 SNPs with a highly correlated proxy SNP (r2 
>0.8) were excluded to avoid data redundancy, leaving 81 SNPs. Four additional SNPs 
were excluded from the statistical analysis based on their small MAP. Therefore, a total 
of 77 SNPs were investigated in phase II (Table 19). These SNPs included in this study 
together with their proxy SNPs and r2 values are shown in Appendix 8 and the list of 
SNPs excluded is shown in Appendix 9. 
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Table 19: List of SNPs included in phase II. 
Major Minor Missing Total Heterozygote genotyped Gene SNPID homozygote (n) homozygote genotype patients MAF (n) (n) (n) (n) 
HIFJA rs2301106 TT=405 TC=118 CC=13 0 536 0.13 
HIFIA rs12434438 AA=329 AG=176 GG=31 0 536 0.22 
HIFIA rs2057482 CC=391 CT=132 TT=13 0 536 0.15 
HIFIB rs10847 GG=281 AG=221 AA=34 0 536 0.27 
HIFIB rs2228099 GG=229 GC=245 CC=62 0 536 0.34 
HIFIB rs11204737 TT=186 TC=260 CC=90 0 536 0.41 
HIF2A rs1867785 GG=212 AG=259 AA=65 0 536 0.36 
HIF2A rs2121266 AA=203 AC=262 CC=70 1 535 0.38 
HIF2A rs17034950 GG=289 AG=218 AA=29 0 536 0.26 
HIF2A rs9973653 GG=279 TG=214 TT=43 0 536 0.28 
HIF2A rs4953342 AA=272 AG=208 GG=56 0 536 0.3 
HIF2A rs1868089 TT=139 TC=268 CC=129 0 536 0.49 
HIF2A rs6758592 TT=167 TC=263 CC=106 0 536 0.44 
HIF2A rs12614710 GG=149 TG=269 TT=118 0 536 0.47 
HIF2A rs4953352 TT=140 TC=267 CC=129 0 536 0.49 
HIF2A rs4953353 GG=230 TG=247 TT=59 0 536 0.34 
HIF2A rs2346175 TT=159 TC=264 CC=113 0 536 0.46 
HIF2A rs6756667 AA=144 AG=266 GG=126 0 536 0.48 
HIF2A rs1868086 GG=343 GT= 171 TT=21 1 535 0.2 
HIF2A rs6712143 AA=292 AG=203 GG=41 0 536 0.27 
HIF2A rs10176396 CC=253 CT=228 TT=55 0 536 0.32 
HIF2A rs1 374748 GG=407 GT= 120 TT=9 0 536 0.13 
HIF2A rs3768728 TT=402 TC= 123 CC=11 0 536 0.14 
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HIF2A rs2346176 TT=207 TC=252 CC=77 0 536 0.38 
HIF2A rs10178633 GG=173 GA=257 AA=106 0 536 0.44 
HIF2A rs7594912 AA=165 AC=260 CC=111 0 536 0.45 
HIF2A rs7557402 GG=161 GC=251 CC=124 0 536 0.47 
HIF2A rs7571218 GG=205 GA=259 AA=72 0 536 0.38 
HIF2B rs12591286 GG=216 AG=260 AA=60 0 536 0.35 
HIF2B *rs8041826 AA=376 AG=138 GG=22 0 536 0.17 
HIF2B rs1446337 GG=306 GA=193 AA=37 0 536 0.25 
HIF2B rs12593988 GG=350 GA=164 AA=22 0 536 0.19 
HIF2B rs3848206 AA=132 GA=274 GG=129 1 535 0.5 
HIF2B rs3848207 GG=405 GA=117 AA=14 0 536 0.14 
HIF2B *rs7172914 CC=343 CT=160 TT=33 0 336 0.34 
HIF2B rs10431813 GG=291 AG=205 AA=38 2 534 0.26 
HIF2B rs3910982 GG=262 GT=220 TT=54 0 536 0.31 
HIF2B rs11635014 CC=187 TC=255 TT=94 0 536 0.41 
HIF2B *rs1020398 TT=278 TC=231 CC=27 0 536 0.27 
HIF2B *rs11633642 GG=246 GA=219 AA=71 0 536 0.34 
HIF2B rs7184010 CC=291 CT=212 TT=32 1 535 0.26 
HIF2B rs3848170 CC=426 CT=101 TT=9 0 536 0.11 
HIF2B rs4778791 GG=141 AG=276 AA=119 0 536 0.48 
HIF2B rs8034535 AA=388 AG=137 GG=11 0 536 0.15 
HIF2B rs895442 CC=429 CT=99 TT=8 0 536 0.11 
HIF2B rs1037124 GG=383 GA=l38 AA=15 0 536 0.16 
HIF2B rs1374213 TT=160 TC=275 CC=100 1 535 0.44 
HIF2B rs3901896 CC=184 TC=274 TT=78 0 536 0.4 
HIF2B rs2278709 CC=270 CT=217 TT=49 0 536 0.29 
HIF2B rs8028295 CC=164 CT=264 TT=108 0 536 0.45 
HIF2B rs4609803 GG=294 GA=199 AA=43 0 536 0.27 
HIF2B rs4778800 GG=325 GT=184 TT=27 0 536 0.22 
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HIF2B rs7178902 TT=173 TC=257 CC=106 0 536 0.44 
HIF2B rs4238521 GG=382 GA=143 AA=11 0 536 0.15 
HIF2B rs4331301 GG=208 AG=245 AA=83 0 536 0.38 
HIF2B *rs4778600 GG=392 GT=124 TT=19 1 535 0.15 
HIF2B rs11856676 CC=162 TC=259 TT=115 0 536 0.46 
HIF2B rs4238522 TT=197 TC=250 CC=89 0 536 0.4 
HIF2B rs4074666 CC=146 TC=276 TT=114 0 536 0.47 
HIF2B rs11635554 AA=283 AG=210 GG=43 0 536 0.28 
HIF2B rs4778818 AA=296 AG=205 GG=35 0 536 0.26 
HIF2B rs4778819 CC=275 TC=210 TT=51 0 536 0.29 
HIF2B rs7403706 TT=347 TC=167 CC=22 0 536 0.2 
HIF2B rs6495509 GG=332 GA=181 AA=23 0 536 0.21 
HIF2B rs8039725 AA=349 AG=165 GG=22 0 536 0.19 
HIF2B *rs8033706 TT=141 TC=207 CC=132 56 480 0.49 
HIF2B rs4301984 GG=328 GA=182 AA=26 0 536 0.22 
HIF2B rs4459508 GG=279 GA=212 AA=45 0 536 0.28 
HIF3A rs2072491 CC=424 CT=104 TT=8 0 536 0.11 
HIF3A rs757638 GG=388 GA=133 AA=15 0 536 0.15 
HIF3A *rs12461322 GG=427 AG=97 AA=12 0 536 0.11 
HIF3A rs887946 AA=255 AG=224 GG=57 0 536 0.32 
HIF3A rs376461 0 CC=374 TC=140 TT=22 0 536 0.17 
HIF3A *rs11665853 AA=430 AG=95 GG= 11 0 536 0.11 
LOX rs3792802 GG=366 GA=160 AA=9 1 535 0.17 
LOX rs1800449 GG=364 GA=157 AA=15 0 536 0.17 
CXCL12 rs2839695 TT=345 TC=170 CC=21 0 536 0.2 
MAF: minor allele frequency. * genotypes of polymorphisms deviated from HWE. 
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3.5.4) Quality control measures and statistical analyses 
The genotype replication rates (see description in Section 2.7) for the 49 SNPs 
included in phase I of this project are shown in Table 18. The genotypes of at least 5.2% 
of the DNA samples were successfully replicated for each SNP. All replicated genotypes 
yielded identical genotypes. Replicated genotype data was not available for phase II 
SNPs. 
Calculation of deviations from the Hardy Weinberg Equilibrium (HWE) 
The Hardy-Weinberg principle states that both genotype and allele frequencies 
remain constant in a population unless the population is subjected to external influences 
such as migration into and out of the population, gene flow, genetic drift or selection 
(261 ). Therefore, deviation from the HWE implies either one or a combination of these 
external influences. Since the Newfoundland population is characterized by founder 
effects and genetic isolation, HWE may not be applicable to our cohorts. Deviation from 
HWE may also occur due to genotyping errors (261 ). 
To ascertain whether the genotype frequencies of SNPs investigated in this study 
deviated from the HWE, the observed genotype frequencies were compared with the 
expected frequencies. This was checked usmg an online tool (262) 
(http://www.oege.org/software/hwe-rnr-calc.shtml) and they were verified manually by 
computing in a Microsoft® Excel sheet. In brief, the genotypes were sorted in an Excel 
spread sheet into major homozygotes, minor homozygotes and heterozygotes. The major 
allele is designated as "A", minor allele is designated as "a" and their corresponding 
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allele frequencies are designated as p and q respectively. Minor and the major allele 
frequencies were computed using the equation p=l -q. According to the Hardy-Weinberg 
equation (p2+2pq+q2), genotype frequency of major homozygotes are designated as p2 
(AA), genotype frequency of minor heterozygotes are designated as 2pq (Aa) and 
genotype frequency of minor homozygotes (aa) are designated as q2 . The expected 
genotype frequencies are computed using these formulas: 
Expected frequency f (AA) = p2 n 
Expected frequency f (Aa) =2 pqn 
Expected frequency f (aa) = q2 n 
Where, n represents the number of genotypes that have been successfully 
genotyped for each polymorphism. 
Once the expected frequencies are calculated, they are compared with observed 
genotype frequencies to see whether they deviate from the HWE using the Pearson Chi-
square test. This equation is as follow: 
x 2 =I (Observed- Expected) 2 /Expected 
As evident from the equation above, the change in frequencies between observed 
and expected frequencies normalized to the expected frequencies were calculated for each 
of the three genotypes and summed up. For this analysis, the null hypothesis is that the 
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genotype frequencies are in HWE and the alternative hypothesis is that they are not in 
HWE. The resulting Chi-square values were then concurrently analyzed with the Chi-
square table for 5% significance level and their respective degree of freedom in order to 
check whether it satisfies the null or alternative hypothesis. The degree of freedom is 
calculated using the formula: 
Degree of freedom = number of genotypes - number of alleles 
In this study, the number of genotypes is three and the number of alleles is two. 
Thus, the degree of freedom is one. For one degree of freedom, the 5% significance level 
for Chi-square value is 3.84. Therefore, when the Chi-square value is less than 3.84, the 
alternative hypothesis is rejected. When it is above 3.84, the null hypothesis is rejected. In 
other words, when the Chi-square value is less than 3.84 for a particular polymorphism it 
implies that it does not deviate from HWE, but if it is above 3.84 then it implies that it 
does deviated from HWE. 
The HWE test results for the polymorphisms investigated in these projects are 
shown in Table 18 for phase I and Table 19 for phase II SNPs. 
Genetic model used 
In order to increase study power, we have analyzed the SNP genotypes assuming 
the dominant genetic model. This model assumes that patients with major homozygote 
genotypes (AA) have an increased (or decreased) risk when compared to heterozygous 
patients (Aa) and patients with minor homozygote genotypes (aa) [AA vs (Aa+aa)] (263). 
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Statistical analyses 
The relationship between genotypes and outcome were analyzed usmg the 
statistical tests explained in Section 2.7. In addition to OS and DFS, in phase I, we also 
investigated the disease specific survival (DSS), which is the time interval from date of 
diagnosis to date of the last follow up or date of death from colorectal cancer. In the 
multivariate Cox regression analysis, variables that had a p <0.05 in the univariate 
analysis were entered into the model. Additionally, the polymorphisms whose genotype 
data deviate from the HWE were investigated in the univariate analysis for exploratory 
purposes, but were excluded from the multivariate analyses. 
3.6.1) Phase I results 
Description of the patient cohort 
3.6) Results 
For the study samples (i.e. the pilot project study samples) investigated in phase I 
of this project, the median age at diagnosis was 68.4 years, the median OS and DSS 
(follow up) time was 5.3 years and the DSS median (follow up) time was 3.4 years. Other 
characteristics ofthis cohort are summarised in Table 17. 
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Overall survival analysis (phase I) 
In univariate analysis, three of the 49 polymorphisms investigated (rs1 0519694 in 
LOX, rs11125070 and rs1868084 in HIF2A) were significantly associated with OS (Table 
20). The genotype distributions of these three polymorphisms were in HWE. Their 
Kaplan Meier survival curves are shown in Figure 13.A. The univariate analysis results 
of other polymorphisms and clinicopathological features can be found in Appendix 10. 
Table 20: Polymorphisms significantly associated with outcome in univariate analysis 
(phase I, overall survival) 
Number of 
patients in p- 95%CI Variables n 
each value HR 
category 
Lower Upper 
LOX rs10519694 272 (137 vs 135) 0.046 0.735 0.543 0.99 (CT +TT vs CC) 
HIF2A rs11125070 247 (126 vs 121) 0.003 0.616 0.447 0.85 (AT+TT vs AA) 
HIF2A rs1868084 249 (95 vs 154) 0.024 0.678 0.483 0.95 (GC+GG vs CC) 
For the multivariate analysis, variables with > 15% of missing data (i.e. the 
lymphatic invasion) were excluded. The results of the multivariate analysis demonstrated 
that while the increasing age, stage, grade, and MSS/MSI-L status were associated with 
shorter OS, the three polymorphisms that were significantly associated with OS in the 
univariate analysis had lost their statistical significance (Table 21). 
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Figure 13: Kaplan Meier survival plots for polymorphisms whose associations were significant in univariate analysis (phase I) 
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OS time is defined as the time interval from the time of diagnosis to the date of last follow up 
or the date of death. DFS time is defined as the time interval from the time of diagnosis to the 
date of last follow up or the date of recurrence or metastasis or death. Cumulative survival 
refers to the proportion of patients who are alive at a particular point of time. Survival plots 
were generated by Kaplan Meier method. 
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Table 21: Multivariable model for overall survival (phase I) (n=234) 
Number of 95% CI 
Variables patients in p- HR 
each value Lower Upper 
category 
LOX rs 10519694 (116vs 118) 0.129 0.767 0.544 1.08 (CT+TT vs CC) 
HIF2A rs11125070 (119 vs 115) 0.282 0.801 0.535 1.2 (AT+TT vs AA) 
HIF2A rs 1868084 (88 vs 146) 0.293 0.796 0.521 1.218 (GC+GG vs CC) 
Age <0.001 1.045 1.029 1.06 
Grade (poorly 
differentiated/undifferentiated (35 vs 199) <0.001 2.594 1.669 4.03 
vs well/moderately 
differentiated) 
Stage 45 <0.001 
Stage (II vs I) (85 vs 45) 0.247 1.399 0.792 2.472 
Stage (III vs I) (65 vs 45) 0.002 2.534 1.423 4.514 
Stage (IV vs I) (39 vs 45) <0.001 14.4 7.617 27.213 
MSI-H status (22vs 212) 0.002 0.285 0.131 0.62 (Yes vs No) 
CI: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite Instability-High, MSI-L: 
Microsatellite Instability-Low, MSS: Microsatellite Stable, n: number of samples entered into the 
multivariate model, vs: versus. Values that are bolded are statistically significant (p value <0. 05). 
Disease specific survival analysis (phase I) 
In a univariate disease specific survival (DSS) analysis, none of the 49 
polymorphisms in hypoxia related genes was significantly associated with the outcome. 
Univariate Cox regression analysis results for these 49 SNPs are shown in Appendix 10. 
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Disease free survival analysis (phase I) 
In a univariate disease free survival (DFS) analysis (Table 22), two of the 49 
polymorphisms investigated in this study were significantly associated with outcome. 
Figure 13.B shows the Kaplan Meier survival curves for these two SNPs. The univariate 
analysis results of other polymorphisms and clinicopathological features for DFS are 
shown in Appendices 11 and 12. 
In a multivariate analysis of DFS (Table 23), the association of HIF2A 
polymorphism (rs11125070) remained statistically significant (p=0.004; HR=0.619; 95% 
CI: 0.446-0.859) when adjusted for other variables. 
Table 22: Polymorphisms significantly associated with outcome in univariate (phase I) 
disease free survival analysis 
Number of 95%CI 
Variables n patients in p- HR 
each value 
category Lower Upper 
L OX rs10519694 272 (137 vs 135) 0.012 0.69 0.51 0.919 (CT +TT vs CC) 
HIF2A 
rs11125070 247 (126 vs 121) 0.003 0.63 0.461 0.858 
(AT+TT vs AA) 
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Table 23: Multivariable model for disease free survival (phase I) (n=236) 
Number of 95%CI 
Variables patients in p- HR 
each category value Lower Upper 
LOX rs10519694 (117vs 119) 0.113 0.767 0.552 1.065 (CT +TT vs CC) 
HIF2A rs11125070 (119 vs 117) 0.004 0.619 0.446 0.859 (AT+TT vs AA) 
Age <.001 1.034 1.019 1.048 
Grade (poorly/ 
undifferentiated vs (35 vs 201) 0.099 1.437 0.934 2.213 
well/moderately 
differentiated) 
Stage <.001 
Stage (II vs I) (85 vs 46) 0.112 1.553 0.903 2.673 
Stage (III vs I) (65 vs 46) <.001 2.93 1.684 5.095 
Stage (IV vs I) (40 vs 46) <.001 133.7 55.98 319.3 
MSI-H status (22 vs 214) 0.013 0.4 0.194 0.825 (Yes vs No) 
CI: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite Instability-High, vs: versus. 
Values that are balded are statistically significant (p value <0. 05 ). 
Patients with the AT or TT genotypes (containing the minor allele T) had 38% decreased 
risk of recurrence, metastasis, or death when compared to patients with the AA genotype. 
Also in this model, while increasing age and stage were also associated with higher risk 
of recurrence, metastasis, or death, the MSI-H status was associated with the decreased 
risk of these events (Table 23). 
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3.6.2) Phase II results 
Description of the patient cohort 
The patient cohort investigated in phase II (i.e. the NFCCR SNP genotyping 
cohort) is described previously in Section 2.4.3. 
Overall survival analysis (phase II) 
In phase II, 77 hypoxia pathway gene polymorphisms (Section 3.6.) were 
analyzed in univariate analyses and their OS results are shown in Appendix 12. Two 
polymorphisms were associated with overall survival time (Table 24). Presence of one or 
two C alleles for HIF2A rs4953352 polymorphism was associated with increased risk of 
death when compared to the patients with TT genotype. Presence of one or two A alleles 
for HIF2B rs12593988 polymorphism were associated with decreased risk of death when 
compared to the GG genotype. Genotype data for both of these polymorphisms were in 
HWE and Kaplan-Meier survival curves are displayed in Figure 14.A. 
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Table 24: Polymorphisms significantly associated with outcome in OS univariate 
analysis (phase II) 
Number of 95%CI 
Variables n patients in p- HR 
each value Lower Upper 
category 
HIF2A rs4953352 535 (396 vs 139) 0.013 1.59 1.103 2.292 (TC+CC vs TT) 
HIF2B rs12593988 535 (185 vs 350) 0.021 0.69 0.497 0.946 (AG+AA vs GG) 
These two polymorphisms (HIF2A rs4953352 and HIF2B rs12593988) when 
adjusted for sex, stage, vascular invasion and MSI status, were also significantly 
associated with overall survival in a multivariate model (Table 25). Specifically, the 
genotypes containing the minor allele of the HIF2A rs4953352 polymorphism (TC and 
CC genotypes) were associated with poor prognosis, whereas the genotypes containing 
the minor allele of the HIF2B rs12593988 polymorphism (GA and AA genotypes) were 
associated with better prognosis when compared to the major homozygote genotypes (TT 
in HIF2A rs4953352 and GG in HIF2B rs12593988). In addition, MSI and stage were 
also associated with outcome in this OS multivariate analysis (Table 25). 
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Figure 14: Kaplan Meier survival plots for polymorphisms whose associations were significant in the univariate analysis 
(phase II) 
A) Overall survival 
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OS time is defined as the time interval from the time of diagnosis to the date of last follow up or the date of death. Cumulative survival ref ers to 
the proportion of patients who are alive at a particular point of time. Survival plots were generated by the Kap lan Meier method. 
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Table 25: Multivariate model for overall survival (phase II) (n=478) 
Number of 95%CI 
Variables patients in p- HR 
each category value Lower Upper 
HIF2A rs4953352 (352 vs 126) <.001 2.184 1.464 3.257 (TC+CC vs TT) 
HIF2B rs12593988 (165 vs 313) 0.008 0.62 0.437 0.881 (GA+AA vs GG) 
Vascular invasion ( + vs -) (164 vs 314) 0.162 1.268 0.909 1.769 
Sex (male vs female) (297 vs 181) 0.122 1.304 0.932 1.826 
Stage <.001 
Stage (II vs I) (197 vs 90) 0.167 1.489 0.846 2.62 
Stage (III vs I) (154 vs 90) 0.042 1.825 1.021 3.259 
Stage (IV vs I) (47 vs 90) <.001 9.704 5.264 17.89 
MSI-H status (56 vs 422) 0.002 0.27 0.118 0.616 (Yes vs No) 
Cl: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite Instability-High, vs: versus. 
Values that are balded are statistically significant (p <0. 05). 
Disease free survival analysis (phase II) 
In the case of the DFS univariate analysis, significant associations of three out of 
seventy-seven polymorphisms were detected, namely the HIF2A rs4953352, the HIF2B 
rs12593988, and the HIF2B rs8033706 (Table 26). Out of these three polymorphisms, the 
genotype distribution of the HIF2B rs8033706 polymorphism deviated from HWE, which 
was excluded from the multivariate analysis. Univariate analysis for rs8033706 and other 
SNPs are shown in Appendix 14. The Kaplan-Meier survival curves for the remaining 
two polymorphisms are presented in Figure 14.B. 
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Table 26: Polymorphisms significantly associated with outcome in univariate disease free 
survival analysis 
Number 
of 95% CI 
Variables n patients p- HR 
value in each Lower Upper 
category 
HIF2A rs4953352 534 (395 vs 0.01 1.6 1.12 2.2 (TC+CCvsTT) 139) 
HIF2B (185 vs 
rs12593988 534 0.04 0.7 0.54 0.98 
(AG+AAvsGG) 349) 
The association of HIF2A rs4953352 and HIF2B rs12593988 polymorphisms 
remained significant in a multivariate model after adjusting for sex, location, stage, 
vascular invasion and MSI status (Table 27). The combined TC and CC genotypes of the 
HIF2A rs4953352 polymorphism were associated with a 2-fold increased risk of 
recurrence, metastasis or death (p<O.OOl; HR=1.96; 95% CI: 1.362-2.82), when 
compared to the TT genotype. The combined AA and AG genotypes of the HIF2B 
rs12593988 polymorphism were associated with a 33% decreased risk of recurrence, 
metastasis, or death (p=0.014; HR=0.671 ; 95% CI: 0.488-0.922) when compared to the 
GG genotype (Table 27). 
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Table 27: Multivariate model for disease free survival (phase II) (n=477) 
Number of 95%CI 
Variables patients in p- HR 
each value Lower Upper 
category 
HIF2A rs4953352 (TC+CC vs TT) (351 vs 126) <0.001 1.96 1.362 2.82 
HIF2B rs12593988 (GA+AA vs GG) (165 vs 312) 0.014 0.671 0.488 0.922 
Sex (male vs female) (296 vs 181) 0.146 1.26 0.923 1.72 
Location (rectum vs colon) (151 vs 326) 0.111 1.284 0.944 1.746 
Stage <0.001 
Stage (II vs I) (187 vs 89) 0.233 1.351 0.824 2.212 
Stage (III vs I) (154 vs 89) 0.033 1.735 1.045 2.88 
Stage (IV vs I) (47 vs 89) <0.001 5.58 3.178 9.8 
Vascular invasion ( + vs -) (164 vs 313) 0.239 1.206 0.883 1.646 
MSI-H status (Yes vs No) (55 vs 422) 0.019 0.455 0.237 0.876 
CI: Confidence Interval, HR: Hazard Ratio, MSI-H Microsatellite Instability-High. Values that 
are balded are statistically significant (p <0. 05). 
3.6.3) Investigation of identical or highly correlated polymorphisms in both phases 
and the pooled cohort analyses 
A total of 13 polymorphisms were investigated in both phase I and phase II 
(Appendix 14). Association of none of these 13 polymorphisms with outcome was 
detected in either phase I or phase II cohorts. A univariate analysis of the pooled cohort 
data did not find an association of these polymorphisms with OS and DFS. (Appendices 
15 and 16). 
There were 15 additional polymorphisms investigated in phase I whose genotypes 
were highly correlated (r2>0.8) with the genotypes of 15 other polymorphisms 
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investigated in phase II (Appendix 14). These highly correlated polymorphisms can serve 
as surrogates for each other. 
As discussed in Section 3.8.1., HIF2A rs11125070 polymorphism was associated 
with DFS in a multivariate model in phase I patient cohort. There was a polymorphism 
(rs4953342) genotyped in phase II patient cohort, which was highly correlated (r2=0.91) 
with HIF2A rs11125070. Therefore, association ofrs4953342 with DFS was examined in 
phase II cohort. Association of this polymorphism was not detected in phase II patient 
cohort, although there was a trend for association (Appendix 17). In the pooled cohort, 
this association was not detected (Appendix 19). 
On the other hand, in the phase II cohort, HIF2A rs4953352 was associated with 
OS and DFS in multivariate models (Section 3.8.2). However, association of HIF2A 
rs4953352 polymorphism, which is highly correlated with HIF2A rs6706003 (r2=0.87), 
was not associated with OS or DFS in phase I cohort (in univariate analyses) 
(Appendices 9-11). In a univariate analysis of pooled cohort data, a trend towards 
association of this SNP with OS and DFS was observed, but it did not reach statistical 
significance (p=0.091 , HR=1.242, 95%CI: 0.966-1.596 for OS; Appendix 18 and 
p=0.058, HR=1.258, 95%CI: 0.992-1.596 for DFS; Appendix 19). 
For the remaining identical or highly correlated polymorphisms (r2>0.8) with 
outcome, no associations were detected in either OS or DFS in the univariate analyses of 
the pooled cohort (Appendices 15-16 and 18-19). 
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3.6.4) Differences between phase I and phase II cohorts 
In order to test whether the failure to replicate the associations observed (Table 
21, Appendix 17, Tables 26-27 and Appendix 9 and 11) might be explained by the 
differences in the baseline and prognostic characteristics of phase I and phase II cohorts, 
additional statistical analyses were performed. There were significant differences between 
the pilot project study and the NFCCR SNP genotyping cohorts for age (p <0.001), sex 
(p=0.036), grade (p=0.001), lymphatic invasion (p<0.001), location (p <0.001) and stage 
(p=0.018) (Table 28). 
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Table 28: Differences between phase I and phase II cohorts m terms of 
clinicopathological and prognostic characteristics 
Variables p- Comments 
compared value 
Age <.001 
There is a higher proportion of female patients 
Sex .036 in the pilot project study cohort (46.3%) when 
compared to the NFCCR SNP genotyping 
cohort (38.6%) 
Histology .102 
NFCCR SNP genotyping cohort has a higher 
Location <0.001 proportion of patients with rectal tumours (33.6%) when compared to the pilot project 
study cohort (20.2%) 
Pilot project study cohort had 17.4% Stage IV 
Stage .018 patients, whereas the NFCCR SNP genotyping 
cohort had 9.9% stage IV patients 
14.9% patients had poorly differentiated 
tumours in pilot project study ·cohort, whereas in 
Grade .001 the NFCCR SNP genotyping cohort only 7.3% 
of patients had tumours with poor 
differentiation 
61.6% patients in the pilot project study cohort 
had tumours characterized by lymphatic 
Lymphatic invasion <0.001 invasion, whereas, only 36.2% patients in the 
NFCCR SNP genotyping cohort had tumours 
with lymphatic invasion 
62.5% patients experienced death in the pilot 
OS status <0.001 project study cohort, whereas only 34% of patients experienced death in the NFCCR SNP 
genotyping cohort 
66.9% patients experienced DFS outcome in the 
DFS status <0.001 pilot project study cohort, whereas only 39.8% patients experienced outcome in the NFCCR 
cohort 
MSI status .962 
Variables that are balded have a p <0. 05. p-values are based on the Chi-square and the Mann-
Whitney U test results. 
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3. 7) Discussion 
Hypoxia is a common condition in solid tumours (167) and has various effects on 
cancer progression. First, hypoxia results in a metabolic shift from the oxidative 
phosphorylation pathway to aerobic glycolysis pathway. The acidic products produced as 
a result of glycolysis lowers the pH within the tumour (264). This promotes invasion 
(265) and metastasis (264). Second, hypoxia may promote resistance to conventional anti-
cancer therapies (266). Thus, genetic variations in the genes that control the response to 
hypoxia and in other genes that are regulated under hypoxic conditions may be markers 
that can predict outcome. In this study, genetic polymorphisms within select genes of the 
hypoxia pathway were investigated for their potential prognostic significance in 
colorectal cancer. 
This project was performed in two phases. Initially, the prognostic significance of 
49 SNPs from six hypoxia-pathway genes (HIFJA, HIFJB, HIF2A, CXCL12, LOX and 
MIF) were tested in relation to outcome in a colorectal cancer patient cohort (phase I 
cohort, n=272). In phase II, 77 polymorphisms from seven genes were investigated 
(HIFJA, HIFJB, HIF2A, HIF2B, HIF3A, LOX and CXCL12) in a separate cohort (phase 
II cohort, n=536). 
None of the 49 SNPs investigated in phase I were associated with DSS. Two 
polymorphisms (LOX rs 10519694 and HIF2A rs 11125070) were associated with DFS and 
three polymorphisms (LOXrs10519694, HIF2A rs11125070 and HIF2A rs1868084) were 
associated with OS in the univariate analyses. In multivariate analyses, after adjusting for 
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other clinicopathological variables, only one of these polymorphisms (HIF2A 
rslll25070) was significantly associated with outcome (DFS). However, association of 
this polymorphism with DFS was not detected in phase II cohort using the genotype data 
of a highly correlated polymorphism (univarate analysis). This result may be attributed to 
the differences between the two cohorts in terms of their characteristics (Section 3.8.4, 
Table 28). For example, in phase I cohort, there were more patients who had passed away 
or experienced recurrence or metastasis until the end of the follow up period when 
compared to phase II cohort (Table 28). In addition, phase II cohort had a lower 
proportion of stage IV patients than phase I cohort. There were also differences between 
the two cohorts in terms of age, sex and grade distributions (Table 28). Alternatively, the 
replication of association of this polymorphism with DFS may be due to the fact that its 
association detected in phase I was a false-positive detected by chance. Therefore, the 
main conclusion of phase I is that none of the 49 polymorphisms analyzed were 
associated with outcome in colorectal cancer patients. However, due to the small sample 
size of the cohort analyzed (n=272), it is also likely that this study may be underpowered 
to detect effects of these polymorphisms, as the statistical power to detect an association 
increases with increase in sample size (267). 
In phase II, a cohort twice the size of phase I was tested (n=536). The potential 
prognostic associations of 77 polymorphisms in seven hypoxia pathway genes were 
investigated. In this phase of the project, the primary aim was to investigate the 
associations of polymorphisms studied in phase I in a larger colorectal cancer patient 
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cohort. However, genotype data for only 28 polymorphisms (either identical or with 
highly correlated genotypes (r2>0.8)) were available in both cohorts (Appendix 14). 
The main conclusion from phase II is that two of the 77 polymorphisms (HIF2B 
rs12593988 and HIF2A rs4953352) were associated with both OS and DFS in 
multivariable models when adjusted for other variables (Table 25 and Table 27). The 
association of HIF2A rs4953352 with OS and DFS may be a false-positive, since no 
association was detected in phase I patient cohort using the genotype data of a highly 
correlated polymorphism (HIF2A rs6706003) in this cohort. However, it is also possible 
that an association of HIF2A rs6706003 with OS and DFS was missed in phase I patient 
cohort, which has a small sample size (n=272). Associations of HIF2B rs12593988 and 
HIF2A rs4953352/rs6806003 therefore should be tested in another colorectal cancer 
patient cohort. 
Both the HIF2B rs12593988 and the HIF2A rs4953352 polymorphisms are located 
in introns and their minor allele frequencies in phase II patient cohort were 19% and 49%, 
respectively. The linkage disequilibrium (LD) maps of these two regions are shown in 
Figure 15 and Figure 16, respectively. 
As shown in Figure 15, according to the HapMap data (259), the HIF2A rs4953352 
polymorphism is in a 6 kb LD block with five other SNPs in intron 1. HIF2A rs4953352 
is correlated (r2=0.87) with rs6706003, which is located in the same intron as rs4953352. 
Thus, if these associations are true, then either of these polymorphisms may be the causal 
variant. To our knowledge, no functional experiments have been performed to study the 
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biological effects of these two polymorphisms. However, a regulatory role of HIF2A and 
HIF2B in influencing the expression of these genes cannot be ruled out. The HIF2B 
rs12593988 polymorphism is located in a one kb LD block (Figure 16). This 
polymorphism does not highly correlate with any other HapMap polymorphism and its 
functional consequence is unknown. 
Figure 15: Linkage disequilibrium plot showing the position of the HIF2A rs4953352 
polymorphism 
The LD map is based on the HapMap (259) data for the Caucasian population. The HIF2A 
rs4953352 polymorphism is circled. The arrow indicates the highly correlated polymorphism, 
rs6706003 (r2 =0. 87) . 
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Figure 16: Linkage disequilibrium plot showing the position of the HIF2B rs12593988 
polymorphism 
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The HIF2B rsl2593988 polymorphism is circled. The LD map is based on the HapMap (259) 
data for the Caucasian population. 
For the 28 polymorphisms investigated in both phase I and phase II, univariate 
analyses using the pooled patient data were also performed. This pooled cohort analysis 
was done to test whether the increased sample size (and thus the study power) would be 
able to detect the potential effects of these polymorphisms in patient prognosis. Between 
719-807 patients were investigated. However, no significant associations between the 
SNPs and outcomes were detected (Appendices 16-17 and 19-20). These results suggest 
either these hypoxia-pathway polymorphisms are not associated with outcome in 
colorectal cancer or their effects are not large enough to be identified with this sample 
SIZe. 
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This project generated novel scientific knowledge of a total of 97 different 
polymorphisms which were not previously studied in relation to prognosis in colorectal 
cancer. A search in the dbCPCO database (268) (which is a database of SNPs that have 
been tested for their associations with patient prognosis in colorectal cancer) revealed that 
among the 98 SNPs investigated in this study, only the HJFJB rs2228099 polymorphism 
had been investigated by other researchers previously (190). This polymorphism was not 
associated with prognosis which is concordant with the results obtained in this study. 
Every study has its own strengths and limitations, and this study is not an exception. 
A correction for multiple testing was not performed to minimize the false negative 
findings. Because of the large number of statistical tests performed, it is possible that the 
associations detected for the HIF2A rs4953352 and HIF2B rs12593988 in phase II are 
false-positives. These results therefore should be considered as hypothesis-generating and 
be interpreted with caution. The patient cohort studied in phase I had a relatively small 
sample size (n=272). In addition, phase II patient cohort which is a subset of the NFCCR 
patient cohort was inclined towards earlier stages and was not representative of the 
NFCCR cohort. This was because DNA samples (extracted from blood) were not 
available for all stage IV patients recruited to the NFCCR. In other words, this is 
attributed to the fact many stage IV patients were not alive or unable to give blood 
samples. Therefore, stage IV patients were underrepresented in the SNP genotyping 
cohort and this may be one possible reason for missing potential associations between 
majority of the polymorphisms in the hypoxia pathway genes and outcome in the phase-11 
cohort. To our knowledge, phase II cohort (n=536) is also one of the largest to be 
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investigated in such a genetic prognostic study of colorectal cancer. Both of these cohorts 
also had long follow up periods allowing the detection of clinical events of interest over 
time, which increased the study power. This study did not include all the genes ( ~450) 
(269) functioning in the hypoxia pathway; five genes with critical biological roles in 
cellular response to hypoxia (HIFJA, HIFJB, HIF2A , HIF2B, and HIF3A) and three 
biologically well-characterized genes regulated under hypoxic conditions (MIF, CXCL12, 
and LOX) were included in this study. In addition, the polymorphisms included in this 
study were selected based on the tagSNP (or correlation) data, reducing the redundancy in 
experiments and statistical analysis. We should also note that the correlations between 
polymorphisms were calculated based on the genotype data in the HapMap database, 
which does not contain all the polymorphism in the genes studied. For example, 1000 
Genome project generated a more comprehensive catalogue of human genetic variations 
(270). Therefore, a detailed analysis of the hypoxia genes investigated using 1000 
Genome Project data may be helpful in studying the prognostic associations of other 
polymorphisms not included in this project. 
In conclusion, the results obtained in this study suggest no evidence of association 
of the majority of the polymorphisms investigated with outcome in colorectal cancer. 
Association of HIF2A rs4953352 and HIF2B rs12593988 polymorphisms with outcome 
need to be studied in larger colorectal cancer cohorts to either confirm their association 
with outcome or to rule them out as false positive associations. 
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CHAPTER 4: GENERAL CONCLUSIONS 
This is one of the first genetic prognostic studies involving polymorphisms 
conducted in colorectal cancer in Canada (271,272). 
Colorectal cancer is a common disease with a significant impact on mortality rates 
m Canada, especially in Newfoundland (3). In addition to commonly used 
clinicopathological prognostic markers such as age and stage, genetic markers can also be 
used to predict outcome. The main objective of this study was to identify genetic markers 
that can predict outcome in colorectal cancer patients. 
Hypoxic conditions by resulting in aggressive tumour phenotype and resistance to 
anti-cancer therapies, facilitates cancer progression and could affect patient outcome 
(173,266). Similarly, mitochondrion is involved in energy production, cellular 
metabolism and apoptosis. Mitochondrial dysfunction may result in cancer progression 
(113). Thus, in this study it is hypothesized that genetic variations in hypoxia pathway 
genes and mitochondrial DNA may predict outcome in colorectal cancer. To test these 
hypotheses, six mtDNA SNPs and the mtDNA copy number change in colorectal tumours 
were investigated. In addition, in the hypoxia pathway project, a total of 98 different 
SNPs in selected hypoxia genes were investigated in two different cohorts. 
Neither the six SNPs in the mitochondrial DNA nor the mtDNA copy number 
change (in tumours compared to non-tumour colorectal tissues) were significantly 
associated with outcome in colorectal cancer patients. However, detected associations of 
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two SNPs namely HIF2A (rs4953352) and HIF2B (rs12593988) in the hypoxia pathway 
genes with outcome in phase II patient cohort may be promising. Association of one of 
these SNP (HIF2A rs4953352) failed to be replicated in a smaller colorectal cancer cohort 
(phase I cohort). Whether this is due to the small sample size of the phase I cohort or it 
was a false-positive association in phase II cohort can be confirmed by testing the 
association of this SNP in another large cohort. Additionally, association of the HIF2B 
rs12593988 polymorphism with outcome detected in this thesis project has to be 
replicated in another cohort to confirm this result. 
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5) Appendices 
Appendix 1: Solutions used in the project described in Chapter 2 
SX Tris-Borate-EDTA (TBE) adjusted to pH 8.3 
Before preparing the 5X TBE solution the material safety data sheet (MSDS) was 
referred to and precautionary measures such as personal protective equipment (PPE) were 
used as recommended in the MSDS. 
54 gr Tris-HCl (OmniPur® Tris-Hydrochloride (Tris-HCl), Product code 9310, 
EMD Chemicals Inc. NJ, USA) and 27.5 gr Boric acid (Product code BX0865, EMD 
Chemicals Inc. NJ, USA) were weighed in an analytical balance (P/P.I - 214, Denver 
instruments, USA) and transferred to a one-litre glass beaker. Approximately 850 ml of 
deionised water ( dH20) was added and the beaker was placed on a magnetic stirrer/heater 
(AP 195025, Thermo Scientific, USA). The beaker contents were dissolved with the help 
of a magnetic stirrer. 20 ml 0.5M EDTA (pH.8; catalogue number: 46-034-Cl, Mediatech 
Inc, VA, USA) was then added to the solution using a 10 ml serological pipette. When the 
contents got mixed, the solution was transferred to a one-litre measuring cylinder and the 
volume was adjusted to one litre with dH20. Then, the solution was transferred back to 
the beaker and pH of the solution was adjusted as follows: the pH of the solution was 
approximately 4. To increase the pH value to 8.3, sodium hydroxide pellets (NaOH: 
Product code SX0590, EMD Chemicals Inc. NJ, USA) were added in small quantities to 
this solution and the pH was checked each time after the pellets dissolved completely. 
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The process was continued until the pH ofthe solution reached the value of8.3. Then, the 
solution was transferred into a Workplace Hazardous Materials Information System 
(WHIMS) labeled glass bottle using a funnel , autoclaved, and stored at room temperature 
(RT). 
lX TBE buffer 
This solution is prepared by diluting the 5X TBE solution using sterile dH20 for 
the desired volume using the equation V1X1=V2X2, where V1 and X1 are the initial volume 
and concentration and V 2 and X2 are the desired volume and concentration, respectively. 
In short, to prepare IX TBE, a 1:5 dilution of 5X TBE stock solution with dH20 was 
performed. The same precautionary safety measures (such as using the lab coats and 
safety glasses) that were used during the preparation of 5X TBE solution was followed 
during the preparation of IX TBE solution. After dilution, the IX TBE solution was 
transferred to a WHIMS labeled glass bottle and stored at RT. 
lX Tris-EDTA (TE) buffer 
0.3I52 gr of Tris-HCl (Product code 93IO, EMD Chemicals Inc. NJ, USA) was 
weighed in an analytical balance (P/P.I - 2I4 , Denver instruments, USA) and dissolved 
in 200 ml of dH20. To this mixture, 0.4 ml of 0.5M stock solution of EDTA (pH: 8±0.1 ; 
catalogue number: 46-034-Cl, Mediatech Inc, VA, USA) was added using a serological 
pipette. The solution was then mixed, autoclaved, and stored in a WHIMS labeled bottle 
atRT. 
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Appendix 2: List of excluded mtDNA polymorphisms 
Number of Number of Number of Number 
samples samples samples that MAF SNPID of missing 
with major with (%) genotypes minor are 
allele 
allele heteroplasmic 
MitoC1050T 536 0 0 0 
MitoG3667A 536 0 0 0 
MitoC3971T 536 0 0 0 
MitoT6681C 536 0 0 0 
MitoT7176C 536 0 0 0 
MitoT14179C 1 536 0 0 0 
MitoC16149T 8 529 0 0 0 
MitoG7522A 535 0 0.19 
MitoT1191C 513 23 0 4.3 
MitoG4770A 532 4 0 0.75 
MitoG4821A 531 4 1 0.84 
MitoA9668G 524 12 0 2.24 
MitoA12309G 452 84 0 15.7 
MitoA14234G 501 35 0 6.54 
MitoT9951C 535 0 0.19 
MitoA10045G 534 2 0 0.37 
MitoG 10590A 534 2 0 0.37 
MitoAI4583G 531 5 0 0.93 
MitoG 1525 8A 1 535 1 0 0.1 9 
MitoA 16164G 29 507 1 0 0.21 
MitoC16184A 4 525 8 0 1.51 
1) SNPs in black fonts are monoallelic, 2) SNPs in green font had sequence homology 
with nDNA and 3) SNPs in blue font had MAFs less than 4%. Heteroplasmic: patients 
with both alleles for a particular genotype, MAF: minor allele frequency 
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Appendix 3: The PCR thermocycling conditions for both the Veriti and Applied Biosystems 7900HT Fast Real-time PCR 
Systems 
( Stage 1 ] ( Stage 2 Stage 3 ) 
( A y A y A \ 
Step 1 
Step 3 Step 4 
Step 2 Denaturation of Primer annealing Activation of 
AmpliTaq gold DNA and extension 
*AmpErase® 
UNGso oc polymerase 95 oc 60 oc 
activation 15 sec 
2min 1 min 95 oc 
10 min 
\ A A 1 y y y 
( 1 cycle ] ( 1 cycle ] ( 34 cycles J 
*Amp Erase® UNG is used to prevent the carry-over of PCR products from previous reactions and thus help prevent contamination. 
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Appendix 4: Additional steps taken to make sure the selected qPCR primer and probe 
binding sequences did not have known sequence alteartions that can affect the qPCR 
results 
F ASLG target sequence (nuclear gene): Our first step was to make sure that there was 
no somatic mutation in colorectal cancer tumours or SNPs interfering with the primer and 
probe binding regions of the FASLG gene described by Cossarizza and colleagues (134). 
We spotted the location of primer and probes on the FASLG gene sequence by blasting 
the sequences of F ASLG gene with the primer and probe sequences using the BLAST 
program (273). The somatic point mutations in colorectal cancer cell lines for this 
particular gene were also checked in the catalogue of somatic mutations in cancer 
(COSMIC) genomic browser (274). According to this database, there were no non-sense 
or mis-sense substitutions or deletions in the F ASLG gene in tumour samples obtained 
from the large intestine samples. However, there were three mutations after the amino 
acid position 190 in other tissue samples. To check whether these probe and primer 
binding regions fell under the coding region of the first 190 amino acids, we blasted the 
mRNA sequence with the entire FASLG gene sequence and found that both the probes 
and primers binding sites were located within the mutation free region. Additionally, we 
did not find any reported copy number variation for this gene using the Database of 
Genomic Variants in October 2011 (275). We then checked if there were any SNPs 
interfering with the primer and probe binding site using the information in dbSNP 
database (138). None of the SNPs located in primer/probe binding sites were deemed to 
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affect our reactions (i.e. MAFs >0.1 %). Therefore, these investigations showed that the 
selected primers and probes in this gene (134) were suitable for our qPCR design. 
ND-2 target sequence (mtDNA gene): First, there is a 4977 bp common deletion in 
mitochondrial DNA encompassing positions 8469 and 13447 (112). We found that the 
ND-2 primers and probe were not located within this deletion. Second, the exact location 
of the primer and probe binding regions were identified by blasting the entire mtDNA 
sequence with the primer and probe sequences and we found that there were no somatic 
mutations in the primer and probe binding sites using the information from the Mitomap 
database (276). Next, we analysed whether there were any SNPs in the primer and probe 
binding sites using the information in the mtdb database (131 ). According to this 
database, there was a SNP at position 4655 located within the probe binding site. This 
SNP was present in 48 samples out of the 2704 samples analysed, but among the 48 
samples that had this SNP only one was a European sample. Since the SNP is a rare 
variant (frequency less than 0.001) in Caucasians, we came to a conclusion that this SNP 
was not going to confound our quantification reactions substantially. Altogether, we 
concluded that the ND-2 gene was suitable to be used in the qPCR reaction. 
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Appendix 5: Assay IDs for SNPs genotyped by TaqMan® SNP genotyping technique in 
phase I 
SNPID Assay ID 
rs9679290 c 229862 10 
- -
rs4952818 c 2148920 20 
- -
rs2346 175 c 11158065 10 
- -
rs6753127 c 29117756 10 
- -
rs7583554 c 29117759 10 
- -
rs9973653 c 30621213 10 
- -
rs3768730 c 2162965 10 
- -
rs11687512 c 2148916 10 
- -
rs10178633 c 2163036 10 
- -
rs2236533 c 15954640 10 
- -
rs11592974 c 17776531 10 
- -
rs10847 AHHSOC5 
rs2121 266 c 16104055 20 
- -
rs4953340 c 29557501 10 
- -
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Appendix 6: Genes selected and information related to 53 polymorphisms included in 
phase I 
Gene SNP *MAFof 
SNP 
HIFJA rs11158358 0.133 
rs2301106 0.1 
rs2301111 0.161 
rs2301113 0.172 
ARNT (HIFJB) rs10305724 0.125 
rs10847 0.225 
rs11204737 0.473 
rs2228099 0.35 
rs3 738483 0.142 
LOX rs10040971 0.158 
rs1 0519694 0.258 
rs2288393 0.183 
rs2956540 0.431 
MIF rs2096525 0.12 
CXCL1 2 rs11592974 0.138 
rs2236533 0.218 
rs2236534 0.224 
rs2839688 0.1 7 
EPASJ (HIF2A) rs10178633 0.491 
rs10199201 0.2 
rs11125070 0.237 
rsl1687512 0.1 
rs1261471 0 0.367 
rs130 19414 0.424 
rs13412887 0.186 
rsl374748 0.15 
rs1562453 0.458 
rs1562453 0.458 
rs l867783 0.41 7 
rs l868084 0.175 
rs1868087 0.2 
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rs1992846 0.225 
rs2034327 0.4 
rs2044456 0.292 
rs2121266 0.333 
rs2346175 0.458 
rs2346176 0.392 
rs3768728 0.169 
rs3768728 0.169 
rs3768728 0.169 
rs3768730 0.496 
rs4145836 0.167 
rs4953340 0.317 
rs4953344 0.417 
rs4953349 0.417 
rs4953353 0.408 
rs6706003 0.45 
rs6712143 0.319 
rs6753127 0.142 
rs7583392 0.466 
rs7583554 0.358 
rs9679290 0.5 
rs9973653 0.258 
*MAFs are based on the genotype data of the Caucasian samples genotyped in the HapMap 
project (259). 
More detailed information about these SNPs can be found in Appendix 7. 
169 I Page 
Appendix 7: Genes selected in phase II and the information related to their 
polymorphisms 
Gene tagSNP tagged SNP rr 
HIFJA rs11158358 rs2057482 0.929 
rs2301111 rs1951 795 0.938 
rs2301111 rs12435848 0.938 
rs2301111 rs12434438 1 
rs2301111 rs10873142 0.935 
rs2301113 rs2301113 1 
HIFJB rs10305724 rs10305724 1 
rs10847 rs10847 1 
rsl1 204737 rs11204735 1 
rs11204737 rs11204737 1 
rs2228099 rs1889740 1 
rs2228099 rs10305714 0.892 
rs2228099 rs10305711 0.892 
rs2228099 rs3768016 0.892 
rs2228099 rs2256355 1 
rs2228099 rs3768015 0.894 
rs2228099 rs3768013 1 
rs2228099 rs7532045 1 
rs3738483 rs2 134688 1 
rs3738483 rs3820541 0.918 
LOX rs10040971 rs379280 1 0.838 
rs1 004097 1 rs3792802 0.831 
rsl 0519694 rs1 0519694 1 
rs2288393 rs10059661 1 
rs2288393 rs1800449 0.944 
rs2956540 rs2956540 1 
MIF rs2096525 rs2096525 1 
CXCLJ2 rs 11 592974 rs2839695 I 
rs11592974 rs2839692 1 
rs11 592974 rs2839690 0.932 
rsl1592974 rs2839689 I 
rs11592974 rs7092453 I 
rs2236533 rs2236533 1 
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rs2236534 rs2236534 I 
rs2839688 rs2839688 I 
HIF2A rs10178633 rs1374749 0.898 
rs10199201 rs4953354 0.95 
rs 10199201 rs10187368 1 
rslll25070 rs4953342 0.913 
rs11687512 rs11694197 I 
rs12614710 rs12614710 1 
rs13019414 rs3754556 0.807 
rs13019414 rs7565341 0.803 
rs 13019414 rs3088359 0.803 
rs130 19414 rs7571218 0.933 
rs130 19414 rs11690950 I 
rs130 19414 rs7590087 I 
rs13412887 rsl3412887 I 
rsl374748 rs13409493 0.871 
rs1562453 rsl 0191091 0.846 
rs1562453 rs2881324 0.818 
rs 1562453 rs6544887 0.875 
rs 1562453 rs6544888 0.875 
rs 1562453 rs6544889 0.875 
rs 1562453 rs4953356 0.967 
rs1562453 rs6756667 0.967 
rs1562453 rs l562452 0.875 
rs 1562453 rs6735812 0.967 
rs1562453 rs4953358 0.967 
rsl562453 rs4953359 0.966 
rsl562453 rs6743991 0.935 
rs 1562453 rs6707241 0.967 
rs1562453 rs6740096 0.966 
rs 1562453 rs1530631 0.967 
rs1562453 rs 1530633 0.935 
rs 1867783 rs2346417 I 
rs1867783 rs4952818 0.966 
rs1868084 rsl868084 1 
rs 1868087 rs4953355 I 
rsl868087 rs 1868085 0.948 
rs 1868087 rsl868086 1 
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rs1868087 rs1868088 0.898 
rs1992846 rs1992846 1 
rs2034327 rs2034327 1 
rs2044456 rs17034950 0.921 
rs2121266 rs 1867787 0.963 
rs2121266 rs 10211665 0.927 
rs2121266 rs11125068 0.963 
rs2121266 rs11894252 0.963 
rs2121266 rs11684885 0.963 
rs2121266 rs1867785 0.962 
rs2121266 rs7579899 0.891 
rs2121266 rsll689011 0.929 
rs2346175 rs2346175 1 
rs2346176 rs2346176 1 
rs3768728 rs2278754 0.825 
rs3768728 rs3768727 1 
rs3768730 rs7568285 0.871 
rs3768730 rs7594912 0.871 
rs4145836 rs4145836 1 
rs4953340 rs4953340 I 
rs4953344 rs4953344 1 
rs4953349 rs2121267 0.816 
rs4953349 rs4953345 0.963 
rs4953349 rs1868089 1 
rs4953349 rsl2613526 1 
rs4953349 rs10208823 1 
rs4953349 rs12712973 1 
rs4953349 rs4953347 1 
rs4953349 rs6726454 0.86 
rs4953349 rs4145837 0.86 
rs4953353 rs4953353 1 
rs6706003 rs4953352 0.87 
rs6712143 rs6715787 0.849 
rs6712143 rs17035010 0.885 
rs671 2143 rsl7035013 0.885 
rs6712143 rs6743087 1 
rs6712143 rs1562451 1 
rs6712143 rs7589621 1 
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rs6753127 rs6753127 1 
rs7583392 rs11675232 0.934 
rs7583392 rs11692911 0.934 
rs7583392 rs12467821 0.905 
rs7583392 rs11675441 0.966 
rs7583392 rs7606559 0.931 
rs7583392 rs7567582 1 
rs7583392 rs7583088 1 
rs7583392 rs11678465 0.967 
rs7583392 rs7557402 0.964 
rs7583392 rs11694193 0.967 
rs7583392 rs7594278 0.967 
rs7583392 rs7598371 0.966 
rs7583392 rs13006131 1 
rs7583392 rsll690951 0.935 
rs7583392 rs 13019268 0.846 
rs7583554 rs2278753 1 
rs7583554 rs10176396 1 
rs7583554 rs4953360 0.962 
rs7583554 rs6755594 0.963 
rs7583554 rsl530632 0.895 
rs7583554 rs3768729 0.855 
rs9679290 rs4952819 0.934 
rs9679290 rs4953343 0.934 
rs9679290 rs4952820 0.841 
rs9679290 rs11125071 0.841 
rs9679290 rs11900910 0.848 
rs9679290 rs4953348 0.965 
rs9679290 rs6758592 0.967 
rs9679290 rs1261 7313 0.841 
rs9679290 rs11125072 0.841 
rs9973653 rs9973653 1 
HIF2B rs1020398 rs 1020398 1 
rs 1026016 rs7172914 1 
rsl026016 rs6495497 1 
rs1026016 rs6495498 1 
rs1026016 rs16972076 1 
rsl026016 rs7182420 1 
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rs 10431813 rs12594558 1 
rs10431813 rs7172073 0.95 
rs1 0431813 rs3848208 1 
rs10519287 rs7182553 1 
rs10519287 rs1037123 1 
rs10519287 rs1037124 1 
rs10519287 rsl037125 1 
rsl0519287 rs3848173 1 
rs11072917 rs11072917 1 
rs1139651 rs7172733 1 
rsl139651 rs1139650 1 
rs1139651 rs4338755 1 
rs 11629832 rs11635554 1 
rs11629832 rs 10851935 0.915 
rs11633642 rs11633642 1 
rs11635014 rs 1020397 0.805 
rs11635014 rs4778790 1 
rs12439449 rs12439449 1 
rs12591286 rs12591286 1 
rs12593988 rs12593988 1 
rs12908321 rs12908321 1 
rs1374213 rs10851934 1 
rs 1374213 rs8036233 0.88 
rs1374213 rs3858942 1 
rs1374213 rs6495501 1 
rs1374213 rs4778793 1 
rs1374213 rs7168908 1 
rsl374213 rs11072918 1 
rs1446336 rs1446336 1 
rs1446337 rs144633 7 1 
rs 16972160 rs16972160 1 
rs1912 rs1912 1 
rs1979026 rs1125522 1 
rs1979026 rs390 1896 1 
rs1979026 rs2305145 1 
rs1979026 rs2278706 1 
rs1979026 rs3848174 1 
rs1979026 rs4778595 1 
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rs1979026 rs12908010 1 
rs1979026 rs12916797 1 
rs2278709 rs17788150 1 
rs2278709 rs3848175 1 
rs2278709 rs12591546 1 
rs3848170 rs3848170 I 
rs3848206 rs3848206 I 
rs3848207 rs3848207 1 
rs3910982 rs5000770 1 
rs4074666 rs4074666 1 
rs4238521 rs4238521 I 
rs4238522 rs8034361 0.808 
rs4238522 rs4778803 1 
rs4238522 rs4128219 1 
rs4238522 rs7178524 I 
rs4238522 rs7180938 1 
rs4238522 rs11856273 1 
rs4238522 rs7167664 0.884 
rs4238522 rs7169055 0.923 
rs4238522 rs7172094 I 
rs4238522 rs802741 0 I 
rs4238522 rs12148133 0.884 
rs4238522 rs3924894 0.883 
rs4303445 rs12594226 0.821 
rs4303445 rs7178902 0.962 
rs4303445 rsl1858186 0.819 
rs4423382 rs6495506 1 
rs4423382 rs4778810 0.936 
rs4423382 rs4778605 1 
rs4423382 rs4778811 1 
rs4459508 rs3935130 0.95 
rs4459508 rs7172548 1 
rs4459508 rs7172912 1 
rs4459508 rs6495511 1 
rs4459508 rs7484 1 
rs4609803 rs12594341 0.876 
rs4609803 rs4778597 0.838 
rs4609803 rs4778598 I 
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rs4609803 rs4778795 0.838 
rs4609803 rs12905523 0.88 
rs4609803 rs4778796 1 
rs4609803 rs4274393 1 
rs4609803 rs3935990 0.838 
rs4609803 rs12902300 1 
rs4609803 rs4778799 1 
rs4778600 rsl2439920 0.907 
rs4778610 rs4072568 0.841 
rs4778610 rs7178743 0.923 
rs4778610 rs4301984 0.923 
rs4778791 rs4778791 1 
rs4778792 rs895442 1 
rs4778792 rs6495502 1 
rs4778800 rs1 1072922 0.933 
rs4778818 rs4778818 1 
rs4778819 rs4778819 1 
rs6495509 rs6495509 1 
rs7162181 rs11072923 0.848 
rs7162181 rs11856676 1 
rs7 162181 rs4238523 1 
rs7162181 rs4778604 1 
rs7 162181 rs7 168037 0.922 
rs7 175825 rs3936145 0.813 
rs7 175825 rs4331301 0.961 
rs7175825 rs1 1072921 0.885 
rs7180520 rs7180520 1 
rs7184010 rs7184010 1 
rs7403201 rs7403201 1 
rs74034 18 rs74034 18 1 
rs8028295 rs17788120 0.96 
rs8028295 rs8041887 0.96 
rs8033706 rs8033706 1 
rs8034535 rs42385 17 0.825 
rs8034535 rs1 1637295 0.844 
rs8034535 rs4238518 0.838 
rs8039725 rs4778825 0.855 
rs8039725 rs7359233 0.855 
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rs8039725 rs8041814 0.855 
rs8039725 rs6495508 0.855 
rs8039725 rs7403013 1 
rs8039725 rs4778829 1 
rs8041336 rs7403706 1 
rs8041826 rs8041826 1 
HIF3A rsl0411556 rs10411556 1 
rs11665853 rsll672731 0.837 
rs16980445 rs12461322 1 
rs2072491 rs2072491 1 
rs376461 0 rs3764609 0.835 
rs3764610 rs3764611 0.864 
rs757638 rs757638 1 
rs887946 rs887946 1 
/:correlation coefficient based on the data from the HapMap database (259). 
Please note that this table contains more detailed information on the genes and 
their SNPs listed in the previous Appendix. This table also contains the SNP information 
for two additional genes investigated in phase II (HIF2B and HIF3A). 
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Appendix 8: List of SNPs excluded from phase II because of their high correlation with other SNPs or low minor allele 
frequencies 
Excluded based Missing Total 
on correlations Major Heterozygote Minor Gene SNPID 
with other homozygote (n) (n) homozygote (n) genotype genotyped MAF 
SNPs (n) patients (n) 
HIFJA rs l 951795 yes n/a n/a n/a n/a n/a n/a 
HJF JB rs10305724 no CC=473 CT=62 TT=O 535 0.06 
HIFIB rs /889740 yes n/a n/a n/a n/a n/a n/a 
HJF JB rsl0305714 yes n/a n/a n/a n/a n/a n/a 
HI FIB rs3738483 no GG=465 GA=69 AA= l 535 0.07 
HIF IB rs3768016 yes n/a n/a n/a n/a n/a n/a 
HJFJB rs3768013 yes n/a n/a n/a n/a n/a n/a 
HJFIB rs2134688 yes n/a n/a n/a n!a nla n/a 
HI F IB rs7532045 yes n/a n/a n/a n/a n/a n/a 
HI F IB rs l/204735 yes n/a n/a n/a n/a n/a n/a 
HJF2A rsl0211665 yes n/a n/a n/a n/a n/a n/a 
HJF2A rs4952820 yes n/a nla n/a n/a n/a n/a 
HIF2A rs l0191091 yes n/a n/a n/a n/a n/a n/a 
HIF2A rs/7035010 yes n/a n/a n/a n/a n/a n/a 
HJF2A rs6544887 yes n/a n/a n/a n/a n/a n/a 
HIF2A rs l 868088 yes n/a nla n/a n/a n/a n!a 
HIF2A rs4953359 yes n/a n/a n/a n/a n/a n/a 
HJF2A rs6743991 yes n/a n/a n/a n/a n/a n/a 
HIF2A rs6707241 yes n/a n/a n/a n/a n/a n/a 
HJF2A rs l530633 yes n/a n/a n/a n/a n/a n/a 
HIF2A rs l 374749 yes nla nla n/a n/a n/a n/a 
HJF2B rs3848208 yes n/a n/a n/a n/a n/a n/a 
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HIF2B rs4238518 yes n/a n/a n/a n/a n/a n/a 
HIF2B rs6495501 yes n/a n/a n/a nla n/a n/a 
HIF2B rs7168908 yes n/a n/a n/a n/a n/a n/a 
HIF2B rsl6972160 no TT=492 TC=44 CC=O 0 536 0.04 
HIF2B rs4778795 yes n/a n/a n/a n/a n/a n/a 
HIF2B rs l2905523 yes n/a n/a n/a n/a n/a n/a 
HIF2B rs l 2594226 yes nla n/a n/a n/a n/a n/a 
HIF2B rs4778 799 yes n/a n/a nla n/a n/a n/a 
HIF2B rs3936145 yes n/a n/a n/a n/a n/a n/a 
HIF2B rs7178524 yes n/a n/a n/a n/a n/a n/a 
HIF2B rs ll856273 yes n/a n/a n/a n/a n/a n/a 
HIF2B rs7172094 yes n/a nla n/a n/a n/a n/a 
HIF2B rsl2148133 yes n/a n/a nla n/a n/a n/a 
HJF2B rsl0851935 yes n/a n/a n/a n/a n/a n/a 
HIF2B rs4778825 yes n/a n/a n/a n/a n/a n/a 
HJF2B rs6495508 yes n/a n/a n/a n/a nla n/a 
HIF2B rs4778829 yes n/a n/a n/a n/a n/a n/a 
HIF2B rs4072568 yes n/a n/a n/a n/a n/a n/a 
HIF2B rs7172 733 yes n/a n/a n/a n/a n/a n/a 
HJF2B rs71 72548 yes n/a n/a n/a n/a n/a n/a 
HJF2B rs6495511 yes n/a n/a n/a n/a n/a n/a 
HIF2B rsll39650 yes n/a n/a n/a n/a n/a n/a 
HIF2B rs1139651 no GG=471 GA=63 AA=2 0 536 0.06 
HIF2B rs7484 yes n/a n/a n/a n/a n/a n/a 
HIF3A rs3 764609 yes nla n/a n/a nl a n/a n/a 
HIF3A rs3 764611 yes n/a nla n/a n/a n/a n/a 
List of SNPs excluded based on missing genotype or minor allele frequency. MAF: minor allele frequency. 
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Appendix 9: Results of the univariate analysis for overall survival (phase I) 
Number of 95% CI 
Variables n patients in p- HR 
each value Lower Upper 
cate o 
LOX rs2956540 (GC+GG vs CC) 27I (19I vs 80) 0.57I 0.9I 0.656 I.262 
LOX rs2288393 ( CG + CC vs GG) 27I (74 vs 197) 0.946 0.988 0.704 I .387 
LOX rs I 004097I (CT +CC vs TT) 272 (69 vs 203) 0.854 1.033 0.733 I.456 
HJF 1 A rs230 1I 06 (TC + CC vs TT) 27I (52vs2 19) 0.247 0.787 0.524 1.18 
HJFJA rs230IIII (GC+GG vs CC) 272 (82 vs I90) 0.23 0.8I3 0.579 1.14 
HJFJA rs230III3 (CA +CC vs AA) 272 (108 vs I64) 0.721 0.945 0.693 I.289 
HJFIA rsiii58358 (GC+GG vs CC) 272 (62 vs 2IO) O.I06 0.731 0.499 1.068 
HJF I B rs2228099 (GC + CC vs GG) 272 (157 vs 1I5) 0.506 0.902 0.666 1.222 
HJFIB rs3738483 (AG +AA vs GG) 272 (49vs223) 0.24I 1.255 0.858 1.836 
HIF I B rs II204737 ( CT + CC vs TT) 271 (190 vs 81) 0.25 1.22 0.869 1.713 
HIFI B rs10847 (AG +AA vs GG) 261 (110 VS 151) 0.775 1.046 0.767 1.427 
CXCL12 rs2236534 (GT+TT vs GG) 271 (97 vs 174) 0.563 1.097 0.801 1.504 
CXCL12 rs2839688 ( CG + CC vs GG) 264 (60 VS 204) 0.741 1.064 0.738 1.534 
CXCL12 rs2236533 (GA +AA vs GG) 261 (123 vs 138) 0.69 1.065 0.78 1.455 
CXCL12 rs 11592974 (TC + CC vs TT) 267 (102 VS I65) 0.531 0.904 0.66I 1.238 
MJF rs2096525 (TC + CC vs TT) 263 (78 vs 185) 0.77 0.95 1 0.681 1.329 
HJF2A rs2121266 (AC +CC vs AA) 25I (163 vs 88) 0.312 1.191 0.849 1.672 
HIF2A rs2346175 (CT + CC vs TT) 185 (125 vs 60) 0.565 0.889 0.595 1.329 
HJF2A rs3768730 (GT +TT vs GG) 247 (178vs69) 0.92 1.018 0.713 1.454 
HJF2A rs49528 18 (TC + CC vs TT) 250 (180 vs 70) 0.94I 0.987 0.692 1.407 
HJF2A rs4953340 (GC + CC vs GG) 248 (158vs90) 0.722 0.942 0.677 1.3I 
HIF2A rs6753 127 (CT + TT vs CC) 252 (35 vs 2I7) 0.208 0.729 0.446 I.I93 
HJF2A rs7583558 (CT + CC vs TT) 242 (I25 vs 117) 0.324 0.85 0.6I5 1.174 
HJF2A rs9679290 (CG + CC vs GG) 252 (174 vs 78) 0.137 0.777 0.557 1.083 
HIF2A rs9973653 (GT +TT vs GG) 242 (132 vs 110) 0.731 0.945 0.684 1.306 
HIF2A rs10178633 (GA +AA vs GG) 240 (152 vs 88) 0.86 1.031 0.736 1.444 
HIF2A rsi1687512 (GC+CC vs GG) 250 (19vs231) 0.252 0.688 0.362 1.306 
HIF2A rs iOI9920I (CT + CC vs TT) 250 (73 vs I77) 0.849 0.967 0.681 1.37 I 
HIF2A rs126I4710 (GT +TT vs GG) 248 (167 VS 81) 0.532 1.115 0.793 1.566 
HIF2A rsi30I9414 (GC + CC vs GG) 25 I (156 vs 95) 0.254 0.83 0.603 1.143 
HIF2A rsi3412887 (CG+GG vs CC) 249 (89 vs I60) O.IO I 0.752 0.534 1.057 
HJF2A rsi374748 (GT +TT vs GG) 250 (66 vs 184) 0.563 1.11 0.78 1.578 
HJF2A rs 1562453 (CT + CC vs TT) 248 (68vsi80) 0.919 l.OI9 0.714 1.452 
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HIF2A rs 1868087 (AG+GG vs AA) 250 (86 VS 164) 0.823 0.962 0.688 1.346 
HIF2A rsl992846 (CT +TT vs CC) 249 (92 vs 157) 0.424 1.1 4 1 0.826 1.578 
HIF2A rs2034327 (GC + CC vs GG) 243 ( 177 vs 66) 0.875 0.97 1 0.676 1.396 
HIF2A rs2044456 (GA+GG vs AA) 239 (138 VS 101) 0.612 0.919 0.663 1.273 
HIF2A rs2346176 (TC + CC vs TT) 251 (147 VS 104) 0.304 1.185 0.857 1.637 
HIF2A rs3768728 (TC + CC vs TT) 251 (62 vs 189) 0.398 1.166 0.816 1.667 
HIF2A rs4145836 (AG +AA vs GG) 251 (62 vs 189) 0.414 0.855 0.586 1.246 
HIF2A rs4953344 (CT + CC vs TT) 248 (63 vs 185) 0.061 1.391 0.985 1.965 
HIF2A rs4953349 (GT +TT vs GG) 245 ( 175vs70) 0.856 1.033 0.726 1.471 
HIF2A rs4953353 (GT +TT vs GG) 25 1 (139vs 112) 0.402 0.874 0.637 1.198 
HIF2A rs6706003 (CG + CC vs GG) 250 (1 81 vs 69) 0.899 1.023 0.721 1.45 1 
HIF2A rs67 12143 (GA+GG vs AA) 25 1 (I 15 vs 136) 0.948 0.99 0.722 1.357 
HIF2A rs7583392 (AG +AA vs GG) 251 ( 176 VS 75) 0.766 0.95 0.676 1.335 
Sex (male vs female) 280 ( 150 vs 130) 0.094 1.296 0.957 1.757 
Age 280 <.001 1.034 1.021 1.05 
Grade (poorly differentiated/ 
undifferentiated vs well/moderately 276 (42 vs 234) 0.001 1.949 1.325 2.87 
differentiated) 
Histology (mucinous vs non-mucinous) 280 (43 vs 237) 0.603 1.113 0.743 1.669 
Lymphatic invasion(+ vs -) 180 ( 110 vs70) <.001 2.472 1.648 3.71 
Location (rectum vs colon) 280 (57 vs 223) 0.343 1.191 0.83 1.708 
Stage 271 <.001 
Stage (II vs I) (94 vs 54) 0.15 1.458 0.873 2.435 
Stage (Til vs I) (76 vs 54) <.001 2.464 1.483 4.09 
Stage (IV vs I) (47 vs 54) <.001 9.647 5.629 16.5 
MSI-H status (Yes vs No) 280 (34 vs 246) 0.001 0.359 0.195 0.66 
(+ ) : presence, (-): absence, CI: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite 
Instability-High, vs: versus. Values that are balded are statistically significant (p value <0.05). 
Please note that the numbers might have been rounded to fit the table in this page. 
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Appendix 10: Results of the univariate analysis for disease specific survival (phase I) 
Number of 95% cr 
Variables n patients in p- HR 
each category value Lower Upper 
LOX rs2956540 (GC+GG vs CC) 271 (80 vs 191) 0.649 0.911 0.611 1.359 
LOX rs2288393 ( CG + CC vs GG) 27 1 (74 vs 197) 0.995 0.999 0.657 1.519 
LOX rs I 004097 1 (CT +CC vs IT) 272 (69 VS 203) 0.827 1.048 0.687 1.6 
LOX rs I 05 19694 ( CT +TT vs CC) 272 (137 vs 135) 0.284 0.816 0.563 1.183 
HJF JA rs230 1106 (TC + CC vs TT) 27 1 (52vs2 19) 0.092 0.626 0.364 1.08 
HJFJA rs2301 111 (GC+GG vs CC) 272 (82 vs 190) 0.315 0.807 0.53 1 1.226 
HJFJA rs2301 113 (CA +CC vs AA) 272 (108 VS 164) 0.377 1.184 0.814 1.721 
HJF JA rs 11 158358 (GC+GG vs CC) 272 (62vs2 10) 0.099 0.665 0.41 1.079 
HJFJB rs2228099 (GC + CC vs GG) 272 (157 vs 115) 0.279 0.814 0.56 1 1.181 
HJFJB rs3738483 (AG +AA vs GG) 272 (49 VS 223) 0.24 1 1.316 0.832 2.082 
H !Fl B rs1 1204737 ( CT + CC vs TT) 271 (190 vs 81) 0.355 1.218 0.802 1.852 
HJF1Brs 10847 (AG +AA vs GG) 26 1 (110 vs 151) 0.8 1.05 0.719 1.534 
CXCL/2 rs2236534 (GT+TT vs GG) 27 1 (97 vs 174) 0.23 1 1.263 0.862 1.85 
CXCLJ 2 rs2839688 ( CG + CC vs GG) 264 (60 vs 204) 0.949 0.985 0.622 1.561 
CXCL/2 rs2236533 (GA +AA vs GG) 261 (123 VS 138) 0.493 1.142 0.78 1 1.672 
CXCL/2 rs11592974 (TC + CC vs TT) 267 (102 vs 165) 0.11 0.722 0.485 1.077 
MJF rs2096525 (TC + CC vs IT) 263 (78 vs 185) 0.962 0.99 0.656 1.493 
HJF2A rs212 1266 (AC +CC vs AA) 251 (163vs88) 0.711 0.927 0.62 1.385 
HJF2A rs2346175 (CT + CC vs IT) 185 (125 vs 60) 0.275 0.767 0.476 1.235 
HJF2A rs3768730 (GT +TT vs GG) 247 (178 vs 69) 0.638 0.902 0.588 1.385 
HJF2A rs4952818 (TC + CC vs IT) 250 (180 vs 70) 0.226 0.773 0.5 1 1.172 
HJF2A rs4953340 (GC + CC vs GG) 248 ( 158 vs 90) 0.218 0.78 0.525 1.158 
HIF2A rs6753 127 (CT + TT vs CC) 252 (35 vs 217) 0.743 0.91 0.518 1.6 
HJF2A rs7583558 (CT + CC vs IT) 242 (125vs1 17) 0. 127 0.735 0.495 1.092 
HJF2A rs9679290 (CG + CC vs GG) 252 (174 vs 78) 0.275 0.796 0.529 1.198 
HJF2A rs9973653 (GT +IT vs GG) 242 (132vs 110) 0.092 0.7 12 0.48 1.057 
HJF2A rs10178633 (GA +AA vs GG) 240 (152 vs 88) 0.689 0.92 0.612 1.383 
HJF2A rs 116875 12 (GC+CC vs GG ) 250 (19 VS 23 1) 0.687 0.862 0.419 1.775 
HJF2A rs I 019920 I (CT + CC vs TT) 250 (73 vs 177) 0.737 0.928 0.6 1.435 
HJF2A rs l1 125070 (AT+TT vs AA) 247 (12 1 vs 126) 0. 128 0.737 0.497 1.092 
HIF2A rs12614710 (GT +IT vs GG) 248 (81 VS 167) 0.724 1.078 0.71 1 1.634 
H!F2A rs13019414 (GC + CC vs GG) 25 1 (95 vs 156) 0.1 53 0.752 0.508 1.111 
H!F2A rs13412887 (CG+GG vs CC) 249 (89 vs 160) 0.486 0.864 0.572 1.304 
HJF2A rs1374748 (GT +IT vs GG) 250 (66 vs 184) 0.574 1.1 32 0.735 1.742 
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HIF2A rs1562453 (CT + CC vs TT) 248 (80 vs 68) 0.675 0.913 0.596 1.398 
HIF2A rs 1868084 (GC+GG vs CC) 249 (95 vs 154) 0.392 0.838 0.559 1.257 
HJF2A rs 1868087 (AG+GG vs AA) 250 (86 VS 164) 0.927 1.019 0.677 1.534 
HJF2A rsl992846 (CT +TT vs CC) 249 (92 VS 157) 0.184 0.751 0.492 1.146 
HIF2A rs2034327 (GC + CC vs GG) 243 (177 vs 66) 0.768 0.935 0.6 1.458 
HJF2A rs2044456 (GA+GG vs AA) 239 (138 VS 101) 0.088 0.707 0.475 1.053 
HJF2A rs2346176 (TC + CC vs TT) 251 (147 VS 104) 0.896 0.974 0.658 1.442 
HJF2A rs3768728 (TC + CC vs TT) 251 (62 vs 189) 0.543 1.146 0.738 1.78 
HIF2A rs4145836 (AG +AA vs GG) 251 (62vs 189) 0.94 1.017 0.652 1.588 
HIF2A rs4953344 (CT + CC vs TT) 248 (63vs 185) 0.836 1.049 0.667 1.649 
HJF2A rs4953349 (GT +TT vs GG) 245 (70 vs 175) 0.946 1.015 0.66 1.562 
HIF2A rs4953353 (GT +TT vs GG) 251 (139 vs 112) 0.381 0.84 0.57 1.24 
HIF2A rs6706003 (CG + CC vs GG) 250 (181 vs 69) 0.918 1.023 0.665 1.573 
HJF2A rs6712143 (GA+GG vs AA) 251 (115 vs 136) 0.287 0.807 0.544 1.198 
HJF2A rs7583392 (AG +AA vs GG) 251 (176 vs 75) 0.356 0.825 0.548 1.242 
Sex (male vs female) 280 (!50 VS 130) 0.246 1.248 0.858 1.814 
Age 280 0.03 1.02 1.002 1.032 
Grade (poorly/ undifferentiated vs 276 (42 vs 234) <.001 2.33 1.493 3.647 
well!moderately differentiated) 
Histology 280 (43 vs 237) 0.774 0.926 0.545 1.571 (mucinous vs non-mucinous) 
Lymphatic invasion(+ vs -) 180 (110 vs 70) <.001 3.02 1.821 4.998 
Location (rectum vs colon) 280 (57 vs 223) 0.52 1.157 0.742 1.805 
Stage 271 <.001 
Stage (II vs I) (94 vs 54) 0.067 2.324 0.942 5.731 
Stage (III vs I) (76 vs 54) <.001 6.07 2.562 14.36 
Stage (IV vs I) (47 vs 54) <.001 28.1 11.78 66.92 
MSI-H status (Yes vs No) 280 (34 vs 246) <.001 0.2 0.075 0.551 
(+ ): presence, (-): absence, CI: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite 
Instability-High, vs: versus. Values that are balded are statistically significant (p value <0.05). 
Please note that the numbers might have been rounded to fit the table in this page. 
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Appendix 11: Results of the univariate analysis for disease free survival (phase I) 
Number of 95% CI 
Variables n patients in p- HR 
each category value Lower Upper 
LOX rs2956540 (GC+GG vs CC) 271 (191 vs80) 0.225 0.824 0.603 1.126 
LOX rs2288393 ( CG + CC vs GG) 27 1 (74 vs 197) 0.982 1.004 0.725 1.39 
L0X rs1004097 1 (CT+CC vs TT) 272 (69 vs 203) 0.995 1.001 0.718 1.395 
HIF/A rs230 1106 (TC + CC vs TT) 27 1 (52vs2 19) 0.588 0.902 0.621 1.31 
HIF JA rs230 1111 (GC+GG vs CC) 272 (82 vs 190) 0.334 0.853 0.6 18 1.177 
H/FJA rs2301113 (CA +CC vs AA) 272 (108 vs 164) 0.646 0.932 0.691 1.258 
H!F/A rs l1 158358 (GC+GG vs CC) 272 (62vs210) 0.29 1 0.826 0.58 1.177 
H!F 1 B rs2228099 (GC + CC vs GG) 272 (157vs 115) 0.402 0.882 0.658 1.183 
H!F 1 B rs3738483 (AG +AA vs GG) 272 (49 vs 223) 0.253 1.24 0.857 1.794 
H/FJB rsl1204737 ( CT + CC vs TT) 271 (190 VS 81) 0.26 1 1.206 0.87 1.671 
HIFJB rs10847 (AG +AA vs GG) 261 (II 0 vs 15 1) 0.847 1.03 0.763 1.391 
CXCL/2 rs2236534 (GT+IT vs GG) 271 (97 vs 174) 0.553 1.096 0.809 1.485 
CXCL/2 rs2839688 ( CG + CC vs GG) 264 (60 VS 204) 0.776 0.949 0.663 1.359 
CXCL / 2 rs2236533 (GA +AA vs GG) 261 (123 vs 138) 0.52 1. 104 0.81 7 1.49 
CXCL/2 rs 11 592974 (TC + CC vs TT) 267 (102 vs 165) 0.8 0.962 0.711 1.301 
MIF rs2096525 (TC + CC vs IT) 263 (78 VS 185) 0.339 0.852 0.613 1.183 
H!F2A rs2121266 (AC +CC vs AA) 251 (163 vs 88) 0.303 1.187 0.857 1.645 
HJF2A rs2346175 (CT + CC vs IT) 185 (125 vs 60) 0.989 1.003 0.679 1.481 
HIF2A rs3768730 (GT +IT vs GG) 247 (178 VS 69) 0.931 0.985 0.699 1.389 
HIF2A rs4952818 (TC + CC vs IT) 250 (180 vs 70) 0.96 1.009 0.716 1.421 
HIF2A rs4953340 (GC + CC vs GG) 248 (158 vs 90) 0.91 0.982 0.714 1.349 
H!F2A rs6753 127 (CT + TT vs CC) 252 (35 vs 217) 0.32 1 0.793 0.502 1.254 
HIF2A rs7583558 (CT + CC vs IT) 242 (125 VS 117) 0.503 0.899 0.66 1.226 
H!F2A rs9679290 (CG + CC vs GG) 252 (174 vs 78) 0.123 0.777 0.564 1.071 
HIF2A rs9973653 (GT +IT vs GG) 242 (132vs 11 0) 0.908 1.018 0.746 1.391 
H!F2A rs10178633 (GA +AA vs GG) 240 (152vs88) 0.835 1.035 0.747 1.434 
H!F2A rs11687512 (GC+CC vs GG) 250 (19 vs 23 1) 0. 184 0.648 0.342 1.229 
HJF2A rs I 0199201 (CT + CC vs TT) 250 (73 VS 177) 0.734 0.943 0.674 1.32 
HIF2A rsl2614710 (GT +TT vs GG) 248 (167 vs 81) 0.378 1.1 6 0.834 1.6 12 
H!F2A rs l 30194 14 (GC + CC vs GG) 25 1 (156 vs 95) 0.318 0.854 0.627 1.164 
H!F2A rs1 3412887 (CG+GG vs CC) 249 (89 vs 160) 0.14 1 0.782 0.564 1.085 
H!F2A rs l374748 (GT +IT vs GG) 250 (66 vs 184) 0.842 1.035 0.735 1.458 
HIF2A rs 1562453 (CT + CC vs IT) 248 (68 vs 180) 0.825 0.962 0.683 1.356 
HIF2A rs 1868084 (GC+GG vs CC) 249 (95 vs 154) 0. 122 0.776 0.563 1.07 
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HIF2A rsl868087 (AG+GG vs AA) 250 (86 vs 164) 0.638 0.925 0.67 1.278 
HIF2A rs 1992846 (CT +TT vs CC) 249 (92 vs 157) 0.541 1.102 0.807 1.505 
HIF2A rs2034327 (GC + CC vs GG) 243 (177 vs 66) 0.578 0.906 0.64 1.282 
HIF2A rs2044456 (GA+GG vs AA) 239 (138 vs 101) 0.691 0.938 0.684 1.286 
HIF2A rs2346176 (TC + CC vs TT) 251 (147 VS 104) 0.422 1.136 0.832 1.551 
HIF2A rs3768728 (TC + CC vs TT) 251 (62 vs 189) 0.654 1.083 0.765 1.532 
HIF2A rs4145836 (AG +AA vs GG) 251 (62 vs 189) 0.566 0.9 0.629 1.289 
HIF2A rs4953344 (CT + CC vs TT) 248 (63 vs 185) 0.257 1.218 0.866 1.713 
HIF2A rs4953349 (GT +TT vs GG) 245 (175 VS 70) 0.579 1.102 0.782 1.554 
HIF2A rs4953353 (GT +TT vs GG) 251 (139 vs 112) 0.486 0.897 0.662 1.217 
HIF2A rs6706003 (CG + CC vs GG) 250 (181 VS 69) 0.832 1.037 0.74 1.454 
HIF2A rs6712143 (GA+GG vs AA) 251 (115 VS 136) 0.935 0.987 0.729 1.338 
HIF2A rs7583392 (AG +AA vs GG) 251 (176 VS 75) 0.46 0.884 0.637 1.227 
Sex (male vs female) 280 (150 vs 130) 0.23 1.196 0.893 1.601 
Age 280 <.001 1.03 1.012 1.037 
Grade (poorly/ undifferentiated vs 276 (42 vs 234) 0.008 1.67 1.141 2.432 
weJUmoderately differentiated) 
Histology (mucinous vs non-mucinous) 280 (43 vs 237) 0.661 1.092 0.738 1.614 
Lymphatic invasion (+ vs -) 180 (110vs70) <.001 2.08 1.414 3.051 
Location (rectum vs colon) 280 (57 vs 223) 0.273 1.213 0.859 1.711 
Stage 271 <.001 
Stage {II vs f) (94 vs 54) 0.04 1.7 1.024 2.806 
Stage (III vs I) (76 vs 54) <.001 2.88 1.737 4.763 
Stage (IV vs I) (47 VS 54) <.001 106 48.63 232.9 
MSI-H status (Yes vs No) 280 (34 vs 246) <.001 0.35 0.195 0.63 
(+):presence, (-): absence, CI: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite 
Instability-High, vs: versus. Values that are bolded are statistically significant (p value <0. 05 ). 
Please note that the numbers might have been rounded to fit the table in this page. 
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Appendix 12: Results of the univariate analysis for overall survival (phase II) 
Number of 95%CI 
Variables n patients in p- HR 
each category value Lower Upper 
HIFI B rsl0847 (AG+AAvsGG) 535 (255 VS 280) 0.41 0.885 0.66 1.185 
HIF I B rs2228099 (GC+CCvsGG) 535 (306 vs 229) 0.661 1.068 0.795 1.435 
HIFIB rsl1204737 (TC+CCvsTT) 535 (349 vs 186) 0.485 1.116 0.82 1.52 
HIF2A rs1867785 (AG+AAvsGG) 535 (323 vs 212) 0.826 0.967 0.719 1.301 
HIF2A rs2121266 (AC+CCvsAA) 534 (33 1 vs 203) 0.362 0.871 0.648 1.1 71 
HI F2A rs 17034950 (AG+ AA vsGG) 535 (247 vs 288) 0.833 0.969 0.724 1.298 
HIF2A rs9973653 (TG+TTvsGG) 535 (257 VS 278) 0.846 0.972 0.726 1.3 
HJF2A rs4953342 (AG+GGvsAA) 535 (264vs27 1) 0.522 1.1 0.822 1.471 
HI F2A rs 1868089 (TC+CCvsTT) 535 (396 vs 139) 0.56 1 0.906 0.649 1.264 
HIF2A rs6758592 (TC+CCvsTT) 535 (369 vs 166) 0.24 1.212 0.879 1.67 1 
HIF2A rsl2614710 (TG+TTvsGG) 535 (386 vs 149) 0.836 1.035 0.744 1.44 
HIF2A rs4953353 (TG+TTvsGG) 535 (306 vs 229) 0.183 1.224 0.909 1.648 
HIF2A rs2346175 (TC+CCvsTT) 535 (377 vs 158) 0.148 1.276 0.917 1.775 
HIF2A rs6756667 (AG+GGvsAA) 535 (391 VS 144) 0.993 1.001 0.723 1.387 
HIF2A rsl868086 (GT+TTvsGG) 534 (343 vs 191) 0.856 1.028 0.759 1.394 
HIF2A rs6712143 (AG+GGvsAA) 535 (291 vs 244) 0.982 0.997 0.744 1.334 
HIF2A rs10176396 (CT+TTvsCC) 535 (253 vs 282) 0.573 1.088 0.812 1.456 
HIF2A rsl374748 (GT+TTvsGG) 535 (406 vs 129) 0.14 1.281 0.922 1.779 
HIF2A rs3768728 (TC+CCvsTT) 535 (401 vs 134) 0.846 0.967 0.69 1.355 
HIF2A rs2346176 (TC+CCvsTT) 535 (328 vs 207) 0.755 0.954 0.708 1.285 
HIF2A rsl0178633 (GA+AAvsGG) 535 (362 vs 173) 0.933 0.987 0.723 1.346 
HIF2A rs7594912 (AC+CCvsAA) 535 (370 vs 165) 0.481 1.122 0.815 1.542 
HIF2A rs7557402 (GC+CCvsGG) 535 (374 vs 161) 0.888 0.978 0.713 1.339 
HIF2A rs7571218 (GA+AAvsGG) 535 (330 vs 205) 0.533 1.1 0.815 1.487 
LOX rs3792802 (GA+AA vsGG) 534 (169 vs 365) 0.2 16 1.212 0.894 1.644 
LOXrs1800449 (GA+AAvsGG) 535 (172 vs 363) 0.209 1.214 0.897 1.643 
CXCL/2 rs2839695 (TC+CCvsTT) 535 (191 VS 344) 0.136 0.789 0.577 1.078 
HJFJA rs230 1106 (TC+CCvsTT) 535 (130 vs 405) 0.966 0.993 0.709 1.391 
HIFIA rsl2434438 (AG+GGvsAA) 535 (206 VS 329) 0.29 1.172 0.874 1.572 
HIFJA rs2057482 (CT+TTvsCC) 535 (144 vs 391) 0.831 0.965 0.695 1.339 
H!F2B rsl2591286 (AG+AAvsGG) 535 (320vs2 15) 0.272 0.848 0.633 1.137 
H!F2B rs8041826 (AG+GGvsAA) 535 (160 vs 375) 0.848 1.031 0.754 1.411 
H!F2B rsl446337 (AG+AAvsGG) 535 (229 vs 306) 0.062 0.75 1 0.557 1.014 
HIF2B rs3848206 (AG+AAvsGG) 534 (402 vs 132) 0.659 1.08 0.767 1.52 1 
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HIF2B rs3848207 (AG+AAvsGG) 535 (131 vs 404) 0.306 1.187 0.855 1.647 
H!F2B rs7172914 (CT+TTvsCC) 535 (193 vs 342) 0. 134 1.255 0.932 1.688 
HIF2Brs10431813 (GA+AAvsGG) 533 (242 vs 29 1) 0.28 0.85 0.632 1.142 
HIF2B rs3910982 (TG+TTvsGG) 535 (274 VS 261) 0. 159 0.81 1 0.606 1.085 
HIF2B rsl16350 14 (CT+TTvsCC) 535 (348 vs 187) 0.76 1.049 0.773 1.424 
HIF2B rs1020398 (TC+CCvsTT) 535 (257 VS 278) 0.487 0.901 0.673 1.207 
HJF2B rsll633642 (GA+AAvsGG) 535 (289 vs 246) 0.27 0.849 0.635 1.136 
HIF2B rs7184010 (CT+TTvsCC) 534 (244 VS 290) 0.394 1.135 0.848 1.52 
HIF2B rs3848 170 (CT+TTvsCC) 535 (110 VS 425) 0.648 1.087 0.76 1.555 
HIF2B rs4778791 (GA+AAvsGG) 535 (394 vs 14 1) 0.203 0.8 13 0.592 1.118 
HIF2B rs8034535 (AG+GGvsAA) 535 ( 147 vs 388) 0.515 1.112 0.808 1.531 
HIF2B rs895442 (CT+TTvsCC) 535 (107 vs 428) 0.977 1.005 0.698 1.448 
HIF2B rs1037124 (GA+AAvsGG) 535 (153 vs 382) 0.494 1. 116 0.815 1.526 
HIF2B rs 1374213 (TC+CCvsTT) 534 (374 VS 160) 0.844 1.033 0.751 1.42 
HJF2B rs390 1896 (CT + TTvsCC) 535 (35 1 VS 184) 0.292 0.851 0.63 1 1.149 
HIF2B rs2278709 (CT+TTvsCC) 535 (266 VS 269) 0.339 0.867 0.648 1. 161 
HIF2B rs8028295 (CT+TTvsCC) 535 (372 VS 163) 0.608 0.922 0.675 1.259 
HIF2B rs4609803 (GA+AAvsGG) 535 (242 vs 293) 0.146 1.241 0.928 1.659 
H!F2B rs4778800 (TG+TTvsGG) 535 (2 11 vs 324) 0.914 1.017 0.756 1.367 
HIF2B rs7178902 (TC+CCvsTT) 535 (362 VS 173) 0.853 1.03 0.755 1.405 
HIF2B rs4238521 (GA+AAvsGG) 535 (154 vs 381) 0.446 1.128 0.827 1.539 
HIF2B rs433130 1 (GA+AAvsGG) 535 (328 vs 207) 0.874 1.025 0.759 1.383 
HIF2B rs4778600 (TG+TTvsGG) 534 (143 VS 391) 0.964 0.993 0.713 1.381 
HIF2B rs11856676 (CT+TTvsCC) 535 (373vs 162) 0.704 0.94 1 0.687 1.289 
HIF2B rs4238522 (TC+CCvsTT) 535 (339 vs 196) 0.845 1.031 0.759 1.4 
HIF2B rs4074666 (CT+TTvsCC) 535 (389 vs 146) 0.306 0.845 0.612 1.167 
HIF2B rsl1635554 (AG+GGvsAA) 535 (253 VS 282) 0.821 1.034 0.773 1.385 
HIF2B rs4778818 (AG+GGvsAA) 535 (239 VS 296) 0.952 1.009 0.753 1.352 
HIF2B rs4778819 (CT+TTvsCC) 535 (261 vs 274) 0.867 0.975 0.729 1.305 
HIF2B rs7403706 (TC+CCvsTT) 535 ( 188 vs 347) 0.565 1.092 0.808 1.477 
HIF2B rs6495509 (GA+AAvsGG) 535 (204 vs 33 1) 0.608 1.081 0.802 1.457 
HIF2B rs8039725 (AG+GGvsAA) 535 (187 VS 348) 0.729 0.947 0.697 1.287 
HIF2B rs8033706 (TC+CCvsTT) 479 (338 vs 14 1) 0.085 0.75 0.54 1.04 
HIF2B rs430 1984 (GA+AAvsGG) 535 (207 VS 328) 0.97 1.006 0.746 1.356 
HIF2B rs4459508 (GA+AAvsGG) 535 (256 vs 279) 0.849 0.972 0.726 1.301 
HIF3A rs2072491 (CT+TTvsCC) 535 (1 12 vs 423) 0.123 0.737 0.50 1 1.086 
HIF3A rs757638 (GA+AAvsGG) 535 (148 vs 387) 0.482 0.888 0.636 1.238 
HIF3A rs1246 1322 (GA+AAvsGG) 535 (108 VS 427) 0.336 1.188 0.836 1.687 
HIF3A rs887946 (AG+GGvsAA) 535 (280 vs 255) 0.76 1.047 0.782 1.401 
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HIF3A rs3764610 (CT+TTvsCC) 535 (161 vs 374) 0.157 1.249 0.918 1.699 
HIF3A rs11665853 (AG+GGvsAA) 535 (105 vs 430) 0.817 1.044 0.727 1.498 
Lymphatic invasion(+ vs -) 493 (179 VS 314) 0.003 1.58 1.169 2.131 
Sex (male vs female) 535 (329 vs 206) 0.013 1.49 1.088 2.035 
Histology 535 (61 vs 474) 0.893 0.969 0.609 1.542 (mucinous vs non-mucinous) 
Location (rectum vs colon) 535 (179 vs 356) 0.184 1.225 0.908 1.652 
Stage 535 <0.001 
Stage (II vs I) (206 vs 97) 0.183 1.446 0.84 2.491 
Stage (Ill vs J) ( 179 VS 97) 0.004 2.19 1.281 3.727 
Stage (IV vs J) (53 vs 97) <.001 10.1 5.73 17.7 
Grade (poorly differentiated/ 
undifferentiated vs well/moderately 531 (38 vs 493) 0.67 0.876 0.476 1.612 
differentiated) 
Vascular invasion(+ vs -) 496 (171 VS 325) <0.001 1.72 1.271 2.328 
Familial risk (high/moderate vs low) 535 (281 vs 254) 0.663 1.067 0.797 1.429 
MSI-H status (Yes vs No) 513 (48 VS 455) <0.001 0.23 0.103 0.526 
BRAF mutation status ( + vs -) 484 (49 vs 435) 0.401 0.796 0.467 1.356 
Age 535 0.429 1.007 0.99 1.023 
(+): presence, (-) :absence, CI: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite 
Instability-High. Values that are balded are statistically significant (p value <0. 05). Please note that 
the numbers might have been rounded to fit the table in this page. 
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Appendix 13: Results of the univariate analysis for disease free survival (phase II) 
Number of 95%CI 
Variables n patients in p-value HR 
each category Lower Upper 
H!Fl B rs10847 (AG+AAvsGG) 534 (255 VS 279) 0.378 0.9 0.68 1.16 
HIF 1 B rs2228099 (GC+CCvsGG) 534 (305 vs 229) 0.995 0.76 1.31 
HIF I B rs 11204 73 7 (TC+CCvsTT) 534 (348 vs 186) 0.781 0.78 1.38 
HIF2A rs1867785 (AG+AAvsGG) 534 (322 VS 212) 0.771 0.79 1.37 
HIF2A rs2121266 (AC+CCvsAA) 533 (330 vs 203) 0.719 0.72 1.25 
HIF2A rs17034950 (AG+AAvsGG) 534 (246 vs 288) 0.742 1.1 0.8 1.37 
HIF2A rs9973653 (TG+TTvsGG) 534 (256 vs 278) 0.711 1.1 0.8 1.38 
HIF2A rs4953342 (AG+GGvsAA) 534 (263vs271) 0.278 1.2 0.89 1.52 
HIF2A rs 1868089 (TC+CCvsTT) 534 (395 vs 139) 0.624 0.9 0.68 1.26 
HJF2A rs6758592 (TC+CCvsTT) 534 (368 VS 166) 0.343 1.2 0.86 1.55 
HIF2A rs12614710 (TG+TTvsGG) 534 (385 vs 149) 0.67 1.1 0.79 1.45 
HJF2A rs4953353 (TG+TTvsGG) 534 (306 vs 228) 0.365 1.1 0.86 1.49 
HIF2A rs2346175 (TC+CCvsTT) 534 (376vs 158) 0.349 1.2 0.85 1.56 
HIF2A rs6756667 (AG+GGvsAA) 534 (390 VS 144) 0.629 0.9 0.69 1.25 
HIF2A rs1868086 (GT+TTvsGG) 5"'" .).) (191 vs 342) 0.678 0.9 0.7 1 1.25 
HIF2A rs6712143 (AG+GGvsAA) 534 (244 vs 290) 0.775 0.73 1.26 
HIF2A rs10176396 (CT+TTvsCC) 534 (282 vs 252) 0.846 0.74 1.27 
HIF2A rsl374748 (GT+TTvsGG) 534 (128 vs 406) 0.384 1.2 0.84 1.56 
HIF2A rs3768728 (TC+CCvsTT) 534 (134 vs 400) 0.702 0.9 0.69 1.29 
HIF2A rs2346176 (TC+CCvsTT) 534 (327 vs 207) 0.706 0.72 1.25 
HIF2A rs10178633 (GA+AAvsGG) 534 (362 vs 172) 0.717 0.71 1.26 
HIF2A rs7594912 (AC+CCvsAA) 534 (369 vs 165) 0.992 1 0.75 1.34 
HIF2A rs7557402 (GC+CCvsGG) 534 (373 vs 161) 0.417 0.9 0.67 1.18 
HIF2A rs7571218 (GA+AAvsGG) 534 (329 vs 205) 0.908 1 0.75 1.3 
LOXrs3792802 (GA+AAvsGG) 5"" .).) (169 vs 364) 0.166 1.2 0.92 1.62 
LOXrsl800449 (GA+AAvsGG) 534 (1 72 vs 362) 0.241 1.2 0.89 1.57 
CXCLI2 rs2839695 (TC+CCvsTT) 534 (191 vs 343) 0.268 0.9 0.64 1.1 3 
HIF I A rs230 1106 (TC+CCvsTT) 534 (130 VS 404) 0.628 1.1 0.79 1.47 
HIF I A rs 12434438 (AG+GGvsAA) 534 (205 vs 329) 0.066 1.3 0.98 1.69 
HIFIA rs2057482 (CT+TTvsCC) 534 (144 vs 390) 0.708 1.1 0.79 1.43 
HIF2B rs12591286 (AG+AAvsGG) 534 (320 vs 214) 0.339 0.9 0.67 1.15 
HIF2B rs8041826 (AG+GGvsAA) 534 (160 vs 374) 0.358 1.1 0.86 1.53 
HJF2B rs1446337 (AG+AAvsGG) 534 (229 VS 305) 0.108 0.8 0.61 1.05 
HIF2B rs3848206 (AG+AAvsGG) 533 (401 vs 132) 0.596 1.1 0.79 1.5 
HIF2B rs3 848207 (AG+AAvsGG) 534 (1 31 vs 403) 0.244 1.2 0.88 1.62 
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HIF2B rs7172914 (CT+TTvsCC) 534 (192vs342) 0.127 1.2 0.94 1.63 
HIF2B rsl0431813 (GA+AAvsGG) 532 (241 vs 291) 0.511 0.9 0.69 1.2 
HIF2B rs3910982 (TG+TTvsGG) 534 (274 vs 260) 0.274 0.9 0.66 l.l3 
H!F2B rsll635014 (CT+TTvsCC) 534 (347 vs 187) 0.217 1.2 0.9 1.6 
HIF2 B rs I 020398 (TC+CCvsTT) 534 (256 vs 278) 0.974 1 0.77 1.32 
HIF2B rs11633642 (GA+AAvsGG) 534 (289 vs 245) 0.126 0.8 0.62 1.06 
HIF2B rs7184010 (CT+TTvsCC) 533 (243 vs 290) 0.666 0.9 0.72 1.24 
HIF2B rs3848170 (CT+TTvsCC) 534 (110 vs 424) 0.956 I 0.72 1.41 
HIF2B rs4778791 (GA+AAvsGG) 534 (394 vs 140) 0.244 0.8 0.62 l.l3 
HIF2B rs8034535 (AG+GGvsAA) 534 (146 vs 388) 0.34 1.2 0.86 !.56 
HIF2B rs895442 (CT+TTvsCC) 534 (107 vs 427) 0.761 l.l 0.75 1.47 
HIF2B rs1037124 (GA+AAvsGG) 534 (153 VS 381) 0.791 0.71 1.29 
HIF2B rs1374213 (TC+CCvsTT) 533 (376 vs 166) 0.608 l.l 0.8 1.45 
HIF2B rs3901896 (CT+TTvsCC) 534 (351 VS 183) 0.431 0.9 0.68 1.18 
HIF2B rs2278709 (CT+TTvsCC) 534 (265 vs 269) 0.825 0.74 1.27 
HIF2B rs8028295 (CT+TTvsCC) 534 (371 vs 163) 0.576 0.9 0.69 1.23 
HIF2B rs4609803 (GA+AAvsGG) 534 (242 vs 292) 0.301 1.2 0.88 1.5 1 
HIF2B rs4778800 (TG+TTvsGG) 534 (211vs323) 0.553 0.9 0.7 1.21 
HIF2B rs7178902 (TC+CCvsTT) 534 (36lvsl73) 0.497 1.1 0.83 1.48 
HIF2B rs4238521 (GA+AAvsGG) 534 (154 vs 386) 0.458 1.1 0.84 1.49 
HIF2B rs4331301 (GA+AAvsGG) 534 (327 vs 207) 0.403 1.1 0.85 1.49 
HJF2B rs4778600 (TG+TTvsGG) 533 (143 vs 390) 0.387 0.9 0.64 l.l9 
HJF2B rs11856676 (CT+TTvsCC) 534 (372 vs 162) 0.441 1.1 0.83 1.51 
HIF2B rs4238522 (TC+CCvsTT) 534 (338 vs 196) 0.098 1.3 0.96 1.7 
H!F2B rs4074666 (CT+TTvsCC) 534 (388 vs 146) 0.805 0.71 1.3 
HJF2B rs11635554 (AG+GGvsAA) 534 (253 vs281) 0.888 0.75 1.29 
HIF2B rs4778818 (AG+GGvsAA) 534 (238 vs 296) 0.765 0.73 1.26 
HIF2B rs4778819 (CT+TTvsCC) 534 (261 vs 273) 0.97 1 0.77 1.32 
HIF2B rs7403706 (TC+CCvsTT) 478 (187 vs 347) 0.852 1 0.73 1.29 
HJF2B rs6495509 (GA+AAvsGG) 534 (204 vs 330) 0.686 0.9 0.7 1 1.25 
HIF2B rs8039725 (AG+GGvsAA) 534 (187 vs 347) 0.208 0.8 0.62 1.11 
HIF2B rs8033706 (TC+CCvsTT) 534 (338 vs 140) 0.02 0.7 0.52 0.95 
HJF2B rs4301984 (GA+AAvsGG) 534 (207 vs 327) 0.443 0.9 0.68 1.18 
HJF2B rs4459508 (GA+AAvsGG) 534 (256 vs 278) 0.303 0.9 0.66 1.14 
HIF3A rs2072491 (CT+TTvsCC) 534 (Ill vs 423) 0.092 0.7 0.51 1.05 
HIF3A rs757638 (GA+AAvsGG) 534 (147 vs 387) 0.408 0.9 0.65 1.19 
HIF3A rsl 2461322 (GA+AAvsGG) 534 (108 vs 426) 0.501 1.1 0.8 1.56 
H!F3A rs887946 (AG+GGvsAA) 534 (279 VS 255) 0.942 0.77 1.32 
HIF3A rs3764610 (CT+TTvsCC) 534 (160 vs 374) 0.22 1 1.2 0.9 1.6 
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HJF3A rsll665853 (AG+GGvsAA) 534 (105 VS 429) 0.979 0.71 1.4 
Sex (male vs female) 534 (328 vs 206) 0.01 1.5 1.1 1.96 
Histology 534 (61 VS 473) 0.778 0.9 0.61 1.45 (mucinous vs non-mucinous) 
Location (rectum vs colon) 534 (179 VS 355) 0.03 1.4 1.04 1.8 
Stage 534 <0.001 
Stage (II vs I) (206 vs 96) 0.258 1.3 0.82 2.11 
Stage (III vs I) (179 vs 96) 0.002 2.1 1.32 3.35 
Stage (IV vs I) (53 vs 96) <0.001 5.7 3.43 9.43 
Vascular invasion(+ vs -) 498 (171 vs324) 0.001 1.6 1.24 2.17 
Lymphatic invasion(+ vs -) 492 (179 vs 313) <0.001 1.5 1.16 2.02 
Familial risk (high/moderate vs low) 534 (280 vs 254) 0.302 1.2 0.88 1.51 
MSI-H status (Yes vs No) 512 (57 vs 455) 0.001 0.4 0.18 0.65 
BRAFmutation status(+ vs -) 484 (49 vs 435) 0.654 0.9 0.56 1.44 
Age 534 0.882 0.99 1.02 
Grade (poorly differentiated/ 0.483 0.81 0.453 1.454 
undifferentiated vs well/moderately 530 (38 vs 492) 
differentiated) 
(+ ): presence, (-) : absence, CI: Confidence Interval, HR: Hazard Ratio, MSI-H Microsatellite 
Instability-High, vs: versus. Values that are bolded are statistically significant (p value <0.05). 
Please note that the numbers might have been rounded to fit the table in this page. 
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Appendix 14: List of phase I and phase II SNPs that are identical or highly correlated 
phase I SNP investigated in 
phase I SNPs SNPs phase n that are highly r2 
analyzed in correlated with SNPs 
phase n in phase I 
LOX rs 1 0040971 rs3792802 0.831 
LOX rs2288393 rsl800449 0.944 
HIFJA rs2301106 rs2301106 
HIFJA rs2301111 rs12434438 I 
HIFJA rsll158358 rs2057482 0.929 
HIFJB rs2228099 rs2228099 
HIFJB rs11204737 rs11204737 
HJFJB rsl0847 rs 10847 
CXCLJ2 rs11592974 rs2839695 
HIF2A rs2121266 rs2121266 
HIF2A rs2346175 rs2346175 
HIF2A rs3768730 rs7594912 0.871 
HIF2A rs9679290 rs6758592 0.967 
HIF2A rs9973653 rs9973653 
HIF2A rs 10178633 rs 10178633 
HIF2A rs 11125070 rs4953342 0.913 
HIF2A rs12614710 rs 12614710 
HIF2A rsl3019414 rs7571218 0.933 
HIF2A rs 1562453 rs6756667 0.967 
HIF2A rs 1868087 rs 1868086 
HIF2A rs2044456 rs17034950 0.921 
HIF2A rs2346176 rs2346176 
HIF2A rs3768728 rs3768728 
HIF2A rs4953349 rsl868089 
HIF2A rs4953353 rs4953353 
HIF2A rs6706003 rs4953352 0.87 
HIF2A rs6712143 rs6712143 
HIF2A rs7583392 rs7557402 0.964 
SNPs that are in green are those SNPs that are common between phase I and II. SNPs that are in 
red are SNPs that are investigated in phase II and are highly correlated with corresponding SNPs 
in phase I. / values are the correlation coefficient between the corresponding SNPs. 
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Appendix 15: Pooled univariate analysis results for the polymorphisms that were 
common between phase I and phase II (overall survival) 
Number of 
95% CI for HR patients in p-Variables 
each value HR 
category Lower Upper 
HIFJA rs2301l06 (182 VS 624) 0.238 0.856 0.662 1.108 
HJFJB rs2228099 (463 VS 344) 0.944 0.992 0.803 1.226 
HIFJB rsll204737 (539 vs 267) 0.126 1.194 0.951 1.499 
HI FIB rs 10847 (365 VS 431) 0.484 0.927 0.749 1.146 
HIF2A rs2121266 (494 vs 291) 0.837 1.024 0.82 1.278 
HIF2A rs2346175 (502 vs 218) 0.534 1.084 0.84I 1.398 
HIF2A rs9973653 (389 vs 388) 0.975 I.003 0.809 I.245 
HIF2A rs I 0 I7863 3 (514 vs 261) 0.84 0.977 0.777 1.227 
HIF2A rs126147IO (553 VS 230) 0.779 1.034 0.8I7 1.31 
HIF2A rs2346l76 (475 VS 311) 0.726 1.04 0.835 1.295 
HIF2A rs3768728 (196vs590) 0.675 1.054 0.825 1.346 
HIF2A rs6712143 (359 VS 427) 0.99 0.999 0.806 1.237 
HIF2A rs4953353 (445 vs 341) 0.832 1.02 0.825 1.269 
Sex (male vs female) (479 vs 336) 0.015 1.309 1.054 1.626 
Age <.001 1.03 1.024 1.045 
Grade (poorly differentiated/ undifferentiated (80 VS 727) 0.002 1.65 1.195 2.263 
vs weiVmoderately differentiated) 
Histology (mucinous vs non-mucinous) (1 04 vs 711) 0.501 1.11 0.819 1.505 
Lymphatic invasion(+ vs -) (289 vs 384) <.001 2.1 1.663 2.652 
Location (rectum vs colon) (236 vs 579) 0.447 1.092 0.871 1.37 
Stage <.001 
Stage (II vs I) (300vs i5I) 0.06I 1.426 0.983 2.067 
Stage (III vs I) (255 vs 151) <.001 2.19 1.516 3.155 
Stage {IV vs I) ( I 00 vs 15I) <.001 9.61 6.528 14.136 
MSI-H status (Yes vs No) (92 VS 701) <.001 0.32 0.194 0.514 
(+ ) : presence, (-) : absence, CI: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite 
Instability-Highvs: versus. Values that are balded are statistically significant (p value <0. 05). 
Please note that the numbers might have been rounded to fit the table in this page. 
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Appendix 16: Pooled univariate analysis results for the polymorphisms that were 
common between phase I and phase II (disease free survival) 
Number of 95% CI for HR 
Variables patients in p-value HR 
each category Lower Upper 
HIFIA rs2301106 ( 182 VS 623) 0.766 0.965 0.761 1.223 
HIFIB rs2228099 (462 vs 344) 0.651 0.955 0.782 1. 166 
HJFJB rs ll 204737 (538 VS 267) 0.197 1.151 0.93 1.425 
HIFI B rs I 0847 (365 vs 430) 0.381 0.914 0.748 1.118 
HJF2A rs2 121266 (493 vs 291) 0.557 1.065 0.863 1.315 
HIF2A rs2346175 (501 vs 218) 0.539 1.077 0.849 1.367 
HJF2A rs9973653 (388 vs 388) 0.455 1.081 0.882 1.324 
HIF2A rsl0178633 (5 14 VS 260) 0.712 0.96 0.775 I.I9 
HIF2A rsl2614710 (552 VS 230) 0.587 1.064 0.85 1 1.329 
HIF2A rs2346176 (474 vs 311 ) 0.881 1.016 0.827 1.248 
HJF2A rs3768728 (196 VS 589) 0.992 1.001 0.793 1.264 
HIF2A rs67 12143 (359 VS 426) 0.863 0.982 0.803 1.202 
HIF2Ars4953353 (445 VS 340) 0.921 1.0 I 0.824 1.238 
Sex (male vs female) (478 vs 336) 0.027 1.26 1.027 1.544 
Age <.001 1.03 1.016 1.036 
Grade (poorly differentiated/ 
undifferentiated vs welVmoderately (80 vs 726) 0.016 1.465 1.074 1.999 
differentiated) 
Histology (104 vs 7 10) 0.587 1.083 0.81 1 1.447 (mucinous vs non-mucinous) 
Lymphatic invasion(+ vs -) (289 vs 383) <.001 1.918 1.54 2.388 
Location (rectum vs colon) (236 vs 578) 0.139 1.173 0.949 1.45 
Stage <.001 
Stage (II vs I) (300 vs 150) 0.036 1.446 1.024 2.043 
Stage {III vs I) (255 VS 150) <.001 2.253 1.601 3.169 
Stage (TV vs I) (100 vs 150) <.001 8.301 5.762 11.957 
MSI-H status (Yes vs No) (91 vs701) <.001 0.362 0.236 0.557 
(+):presence, (-): absence, Cl: Confidence Interval, HR: Hazard Ratio, MSI-H Microsatellite 
lnstability-Highn: number, vs: versus. Values that are balded are statistically significant (p value 
<0. 05). Please note that the numbers might have been rounded to fit the table in this page. 
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Appendix 17: Results of the multivariate analysis of the HIF2A rs4953342 
polymorphism with respect to the disease free survival in the replication cohort 
Number of 95%CI 
Variables n patients in p HR 
each value Lower Upper 
category 
HIF2A rs4953342 (AG+GG vs AA) 509 (25 1 VS 258) 0.094 1.267 0.96 1.672 
Age 0.5 1.005 0.99 1.021 
Grade (poorly differentiated vs (37 vs 472) 0.512 0.821 0.455 1.482 
well/moderately differentiated) 
Stage <.001 
Stage (II vs I) (196 vs 93) 0.136 1.447 0.89 2.352 
Stage (Ill vs I) (169 vs 93) 0.001 2.166 1.344 3.49 
Stage (IV vs I) (51 vs 93) <.001 5.894 3.491 9.951 
MSI-H status (Yes vs No) 0.01 0.428 0.223 0.819 
CJ: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite Instability-High, vs-: versus. 
Values that are balded are statistically significant (p <0. 05). Please note that the numbers might 
have been rounded to fit the table in this page. 
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Appendix 18: Pooled univariate analysis results for the polymorphisms that were 
investigated in phase I and were highly correlated with the other SNPs in phase II (overall 
survival) 
Number of 
patients in p- 95% CI forHR 
*Variables compared 
each value HR 
category Lower Upper 
LOJrrsl0040971orrs3792802 (238 vs 568) 0.596 1.063 0.848 1.334 
LOJr rs2288393 or rs 1800449 (246 vs 560) 0.623 1.058 0.845 1.324 
HJFJA rs2301111 or rs 12434438 (288 vs 519) 0.595 0.942 0.757 1. 173 
HJFJA rslll58358 orrs2057482 (206 vs 601) 0.14 0.83 0.648 1.063 
CJrCLI2 rs 11592974 or rs2839695 (293 vs 509) 0.235 0.875 0.701 1.091 
HIF2A rs3768730 or rs7594912 (548 VS 234) 0.496 1.086 0.857 1.376 
HIF2A rs9679290 or rs6758592 (543 vs 244) 0.839 0.976 0.776 1.229 
HIF2A rs 11 125070 or rs4953342 (390 VS 392) 0.151 0.854 0.689 1.059 
HIF2A rs 13019414 or rs7571218 (486 VS 300) 0.715 0.96 0.771 1.195 
HIF2A rs 1562453 or rs6756667 (571 VS 212) 0.978 1.003 0.789 1.275 
HIF2A rs 1868087 or rs 1868086 (277 vs 507) 0.865 0.981 0.783 1.228 
HIF2A rs2044456 or rs 17034950 (385 vs 389) 0.845 1.022 0.823 1.268 
HIF2A rs4953349 or rs 1868089 (57 1 vs209) 0.7 0.953 0.749 1.214 
HIF2A rs6706003 or rs4953352 (577 vs 208) 0.091 1.242 0.966 1.596 
HIF2A rs7583392 or rs7557402 (550 VS 236) 0.731 0.96 0.762 1.2 1 
Sex (male vs female) (479 vs 336) 0.015 1.31 1.054 1.626 
Age <.001 1.03 1.024 1.045 
Grade (poorly 
differentiated/undifferentiated vs (80 vs 727) 0.002 1.65 1.195 2.263 
well/moderately differentiated) 
Histology (mucinous vs non-mucinous) (104 vs 711 ) 0.501 1.11 0.819 1.505 
Lymphatic invasion(+ vs -) (289 vs 384) <.001 2.1 1.663 2.652 
Location (rectum vs colon) (236 vs 579) 0.447 1.092 0.87 1 1.37 
Stage <.001 
Stage (II vs I) (300 VS 151) 0.061 1.43 0.983 2.067 
Stage (III vs I) (255 VS 151) <.001 2.19 1.516 3.155 
Stage (IV vs I) (1 00 vs 151) <.001 9.61 6.528 14.14 
MSI-H status (Yes vs No) (92 VS 701) <.001 0.32 0.194 0.514 
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(+):presence, (-) : absence, CI: Confidence Interval, HR: Hazard Ratio, MSI-H: Microsatellite 
Instability-High, n: number. Values that are balded are statistically significant (p value <0. 05). 
*The first SNP is the SNP investigated in phase I and the second SNP is the highly correlated 
SNP investigated in phase-2. Please note that the numbers might have been rounded to fit the 
table in this page. 
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Appendix 19: Pooled univariate analysis results for the polymorphisms that were 
investigated in phase I and were highly correlated with the other SNPs in phase II 
(disease free survival) 
Number of 
patients in p- 95% CI for HR 
*Variables compared 
eacb value HR 
category Lower Upper 
LOX rs I 0040971 or rs3 792802 (238 VS 567) 0.544 1.068 0.863 1.323 
LOX rs2288393 or rs 1800449 (246 VS 559) 0.573 1.063 0.86 1.314 
HIFIA rs2301111 or rs 12434438 (287 VS 519) 0.765 1.032 0.841 1.266 
HIFIA rs11158358 or rs2057482 (206 VS 600) 0.555 0.934 0.744 1.172 
CXCL/2 rsll592974 or rs2839695 (293 VS 508) 0.444 0.922 0.75 1.135 
HIF2A rs3768730 or rs7594912 (547 VS 234) 0.84 1.023 0.82 1.276 
HIF2A rs9679290 or rs6758592 (542 VS 244) 0.768 0.968 0.779 1.202 
HIF2A rs 11125070 or rs4953342 (389 vs 392) 0.334 0.905 0.739 1.108 
HIF2A rs 13019414 or rs7571218 (485 VS 300) 0.506 0.933 0.759 1.146 
HIF2A rs 1562453 or rs6756667 (570 vs 212) 0.638 0.948 0.757 1.186 
HIF2A rs 1868087 or rs 1868086 (277 vs 506) 0.473 0.925 0.747 1.145 
HIF2A rs2044456 or rs 17034950 (384 vs 389) 0.487 1.075 0.877 1.318 
HIF2A rs4953349 or rsl868089 (570 vs 209) 0.855 0.979 0.779 1.23 
HIF2A rs6706003 or rs4953352 (576 vs 208) 0.058 1.258 0.992 1.596 
HIF2A rs7583392 or rs7557402 (549 vs 236) 0.301 0.892 0.719 1.107 
Sex (male vs female) (478 VS 336) 0.027 1.259 1.027 1.544 
Age <.001 1.026 1.016 1.036 
Grade (poorly 
differentiated/undifferentiated vs (80 vs 726) 0.016 1.465 1.074 1.999 
well/moderately differentiated) 
Histology (mucinous vs non-mucinous) (104 vs 710) 0.587 1.083 0.811 1.447 
Lymphatic invasion(+ vs -) (289 vs 383) <.001 1.918 1.54 2.388 
Location (rectum vs colon) (236 vs 578) 0.139 1.173 0.949 1.45 
Stage <.001 
Stage (II vs I) (300 vs 150) 0.036 1.446 1.024 2.043 
Stage (Ill vs I) (255vs 150) <.001 2.253 1.601 3.169 
Stage (IV vs I) (100 VS 150) <.001 8.301 5.762 11.957 
MSI-H status (Yes vs No) (91 vs 701) <.001 0.362 0.236 0.557 
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(+): presence, (-): absence, CI: Corifidence Interval, HR: Hazard Ratio, MSI-H Microsatellite 
Instability-High, vs: versus. Values that are balded are statistically significant (p value <0. 05). 
*The first SNP is the SNP investigated in phase I and the second SNP is the highly correlated 
SNP investigated in phase-2. Please note that the numbers might have been rounded to fit the 
table in this page. 
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